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ABSTRACT 
 
Photodynamic therapy (PDT) is an alternative cancer cure which involves the selective 
uptake and retention of a photosensitizer in a cancer tissue, followed by irradiation with 
light of a specific wavelength to kill tumour cells via the production of reactive oxygen 
species (ROS). Fractionation of the light administration is one of the protocol 
modifications in PDT based on the hypothesis of tissue reoxygenation during the one or 
more dark intervals between illuminations with a subsequent greater production of 
singlet oxygen and thus greater PDT effect. However we demonstrate in the present 
study that two-fold illumination scheme with equal light doses (3 or 6 J.cm-2) separated 
by a dark interval 1 or 6 h do not enhanced, even reduced hypericin-mediated 
photocytotoxic effect in HT-29 adenocarcinoma cells in vitro by illumination with 
unequal light doses (1 + 11 J.cm-2) separated with a longer dark pause (6 h). 
Fractionation with a longer dark pause increased cell number and cell survival in HT-29 
cells when compared with such treatment but with a 1 h dark pause or with a single light 
delivery (12 J.cm-2). Even proportion of cells in G1 and G2 phase of cell cycle were 
near to control. Longer dark pause also repressed cell death and enhanced clonogenic 
potential of HT-29 cells. Since longer dark interval after the irradiation by first sub-
lethal light dose (1 J.cm-2) makes cells resistant to the effect of the lethal light dose (11 
J.cm-2), we studied the events proceeded during a dark pause after sub-lethal dose (1 
J.cm-2) up to the second illumination. We show that pre-sensitization did not affect 
physiological elimination of hypericin however administration regime affected 
hypericin elimination after lethal dose. Inhibition of p38 MAPK did not improve 
photocytotoxic effect of light fractionation. Cell pre-sensitization induced ROS 
production, increased activity of redox-regulated nuclear transcription factor NF-κB and 
expression of proteins connected with a cell survival (NF-κB p50 and p65 subunits, 
IκB-α, Mcl-1, HSP70, GRP94, Clusterin-α). Although the role of heat shock proteins 
was generally established in response upon photo-induced stress, we uncovered that 
HSPs are not necessarily the “key” molecules in photo-resistance. Our findings indicate 
that timing of the second light dose before or after NF-κB activation could be crucial for 
the fate of cancer cell. We estimate successful application of hypericin in a high-dose 
multi-fraction PDT with dark intervals reduced bellow 1 h that might yield improved 
outcome.  
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1 INTRODUCTION 
 
Relatively new and promising anticancer modality is photodynamic therapy using 
two individually nontoxic components – photosensitizer and light. The research of new 
natural photosensitizers such as hypericin as well as a modification in the delivery of 
photo-radiation is a promising additional approach in this therapeutic method. Recently, 
modification in the light delivery regime has been introduced on the standard 
photodynamic protocol (single-dose photosensitizer, single-dose light) to maximize the 
therapeutic effect of PDT, for example fractionated light regime. We have observed, 
that fractionated light regime with a longer dark period resulted in a decrease of 
hypericin cytotoxicity in HT-29 adenocarcinoma cancer cells. Longer dark interval after 
the irradiation of cells by first light dose makes cells resistant to the effect of the second 
illumination. The serious problem in photodynamic anticancer therapy is photo-
resistance or photo-tolerance. However, molecular mechanism of photo-resistance is not 
unraveled till now. New information about this phenomenon should be useful in 
managing of cancer cells metabolism and improving of therapeutic effect. Inhibition of 
rescue metabolic pathways activated in photodynamic insulted cancer cells should be 
promising treatment tool in cancer therapy. Recent studies indicate that stimulation of 
the expression of the heat shock proteins upon photo-induced stress may be involved in 
this process. However, there is a variety of cancer cells responses to treatment resulted 
in a cell death or rescue pathways. Apart from the study of cell death, there is also 
important the research of the resistance development to cancer therapies. Therefore, this 
study is focused on the molecules and molecular pathways involved in a cancer cell 
survival probably playing role in a photo-resistance to fractionated light delivery 
regime. We investigated the impact of a sub-lethal light dose (1 J.cm-2) and length of a 
following dark pause (1 or 6 h) on the development of resistance to the effect of the 
second illumination (11 J.cm-2). We investigated the relationship between a dark 
interval and PDT response on HT-29 adenocarcinoma cancer cell line with respect to 
cellular and sub-cellular events after fractionated photodynamic therapy.   
  
1.1 Photodynamic therapy 
Photodynamic therapy (PDT) is a binary therapy in which two individually 
nontoxic components are combined to mediate cell and tissue death. The first 
component is the localization of a photosensitizing molecule in the target tissue, and the 
second component is the activation of the photosensitizer (PS) by light. In the light 
activation process, the photosensitizer acts as an energy transducer and transfers energy 
to molecular oxygen, resulting in the generation of a series of highly reactive oxygen 
species (ROS), particularly singlet oxygen. These ROS have been shown to cause 
oxidative damage to a number of molecules including lipids, proteins, and 
glycoproteins, and as a consequence damage to cellular membranes, organelles, and 
protein complexes (Dougherty et al. 1998). An efficacy of PDT is affected by many 
factors such as cell type, type of photosensitizer and its intracellular localization, light 
dose and its fluency rate, drug to light interval and photodynamic protocol (Blant et al. 
1996, Henderson et al. 2004, Noodt et al. 1999, Ris et al. 1993, Sackova et al. 2005, 
Wyld et al. 2001). Photodynamic therapy has come a long way since beginning up to 
the present. The research of new natural photosensitizers as well as synthesis of 
photosensitizers with desired characteristics contributed to increased efficiency of this 
therapy. The ideal photosensitizer should fulfil several requirements. One of them is 
low level of a dark toxicity as well as low incidence of allergic reactions of patients. 
The photosensitizer should absorb light in the red or far-red wavelengths to achieve the 
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higher efficiency of the tumour treatment as a consequence of deeper penetration of the 
light in treated tissue. The photosensitizer should be easy available, it means that its 
extraction or synthesis should be inexpensive. The stability, water solubility and rapid 
pharmacokinetic elimination of PS from the patients are other important characteristics 
of these drugs (Fritsch et al. 1998, Kalka et al. 2000). 
The therapeutic effect of photodynamic therapy is mediated by reactive oxygen 
species that can damage cellular components leading to cell death. Photochemical 
reaction creates reactive oxygen species and singlet oxygen with the lifetime not longer 
than 4 µs in aqueous solution (Redmond and Kochevar 2006). Since singlet oxygen 
movement is limited, the target of cell damage is expected at sub-cellular sites of PS 
localization. Therefore, predominant localization of PS in cell membranes leads to lipid 
oxidation and to formation of protein crosslinks (Shen et al. 1996, Spikes et al. 1999). 
 
1.1.1  Hypericin as a potential photosensitizer 
A natural substance with potent photosensitizing properties is hypericin, a 
naphthodianthrone derivative with a chemical structure 1, 3, 4, 6, 8, 13-hexahydroxy-
10, 11-dimethylphenanthro[1, 10, 9, 8-opqra]perylene-7, 14-dione (Fig. 1a) isolated in 
1939 as a secondary metabolite from Hypericum perforatum L. (St Johnˋs wort) 
displaying a potential as a photosensitizer for PDT (Brockmann et al. 1939) (Fig. 1b). 
Apart from hypericin, the other metabolites of St Johnˋs wort are investigated for their 
medical use. For example hyperforin is an acylphloroglucinol derivative with 
antibacterial activity (Gurevich et al. 1971) and antitumoral properties (Hostanska et al. 
2003, Schempp et al. 2002). Hyperforin is also known as a dual inhibitor of 5-LOX and 
COX-1 suggesting therapeutic potential in inflammatory and allergic diseases connected 
to eicosanoids (Albert et al. 2002). A promising approach in the treatment of cancer 
diseases seems to be a combination of hypericin and hyperforin (Hostanska et al. 2003). 
 
 
Figure 1. Hypericin. Chemical structure of hypericin (a), spectra of hypericin (b) (Mw=504.46) 
dissolved in ethanol (2.5 µg/ml) (excitation at 280 nm). Adapted from (Zeisser-Labouebe et al. 
2006). 
 
A potential application of hypericin in a photodynamic therapy in clinical 
oncology is an interesting research area for researchers as well as its using as a 
diagnostic tool in photodynamic diagnosis (PDD) of neoplastic lesions (Sim et al. 
2005). Apart from anticancer properties, hypericin displays an antidepressant activity 
(Perovic and  Muller 1995) and antiviral activity against a variety of viruses, in brief 
outline including influenza virus, herpes virus, leukemia virus, herpes simplex virus 
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type 1 in mice (Lavie et al. 1989, Tang et al. 1990) and anti-HIV activity (Holden 
1991). Hypericin seems to be an effective drug in an anticancer therapy due to its 
advantageous properties. Hypericin inhibits key steps of angiogenesis (Martinez-Poveda 
et al. 2005), has not genotoxic activity (Miadokova et al. 2009) and its antimetastatic 
activity in the dark was also described (Blank et al. 2004). It was reported that hypericin 
increased activity and expression of drug efflux transporters in HT-29 cells 
(Jendzelovsky et al. 2009). The other biological effects of HYP are an inhibition of 
epidermal growth factor receptor tyrosine kinase activity (de Witte et al. 1993), specific 
inhibition of protein kinase C (Takahashi et al. 1989) and inhibition of succinoxidase 
(Thomas et al. 1992). Photodynamic properties of HYP are mediated through 
peroxidation of membrane lipids. Photo-activated HYP increases superoxide dismutase 
activity, decreases cellular glutathione levels, impairs mitochondrial function (Hadjur et 
al. 1996, Chaloupka et al. 1999, Miccoli et al. 1998, Thomas et al 1992, Utsumi et al. 
1995, Vantieghem et al. 2001) and contributes to a drop of pH (Fehr et al. 1995). The 
HY is a source of high triplet quantum yield and superoxide anions (Ehrenberg et al. 
1998, Thomas et al 1992, Thomas and  Pardini 1992), therefore singlet oxygen (Type II 
mechanism) as well as reactive oxygen radicals (Type I mechanism) plays a major role 
in the photo-activity of hypericin in cells (Park et al. 1998). Hypericin seems to be very 
effective photosensitizer which has hydrophilic/lipophilic properties (Crnolatac et al. 
2005) and binds to low density lipoproteins (LDL) at the boundary between the lipidic 
and protein part of the particle (Kascakova et al. 2005). Due to its hydrophilic/lipophilic 
properties the preferential localization of hypericin is in lipid membranes in cytoplasmic 
membranes. This compound accumulates in membranes of endoplasmic reticulum and 
Golgi complex, but not in mitochondria (Ho et al. 2009, Thomas and Pardini 1992) 
however mitochondrial membranes are central trgets of hypericin photodynamic action 
(Agostinis et al. 2002). Accumulation of HY was shown also in a nuclear plasma 
membranes (Miskovsky et al. 1995, Sattler et al. 1997) and lysosomes (Buytaert et al. 
2006a). Hypericin uptake was shown to be higher in cells with elevated number of LDL 
receptors, however it seems that cellular uptake of hypericin is determined by diffusion 
and solubility and does neither require active transport nor specific receptors (Thomas 
and Pardini 1992). It seems that cellular localization of HY is a cell type dependent and 
its cellular targets are membranes (Hadjur et al. 1996, Chaloupka et al. 1999, Thomas 
and Pardini 1992). 
 
1.1.2 Mechanisms in photodynamic therapy 
The consequences of PDT on a cellular level vary according to activation of 
specific pathways, including apoptotic, autophagic, necrotic as well as pro-survival 
pathways. Apoptosis is programmed mechanism of cell death suitable for cancer 
therapies including PDT. Apoptosis contrary to necrosis is a type of cell death 
manifested by shrinking and blebbing of membrane, chromatin condensation and 
genomic DNA fragmentation. Cells forms membrane-enclosed vesicles called apoptotic 
bodies that are ingested by neighboring cells and phagocytes without involvement of 
immune system and without inflammatory reactions (Fiers et al. 1999, Kerr et al. 1972). 
Apoptosis may be activated by extrinsic pathway upon binding ligands the surface death 
receptors as TNF receptor 1, TRAIL receptor, or Fas receptor. Apoptotic program 
executes effector procaspase-3/7 cleaved by activated caspase-8/10 (Bellnier et al. 2003, 
Granville et al. 2001). A dominant role in PDT-induced apoptosis has intrinsic pathway 
mediated through mitochondria. PDT-mediated stress may cause loss of the 
mitochondrial transmembrane potential (∆Ψm) and the release of cytochrome c (Cyc) 
from the intermembrane space into the intracellular space (Granville et al. 1998). 
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Cytoplasmic Cyc associates with the apoptotic protease activating factor 1 (Apaf-1) and 
forms the heptameric apoptosome that integrates procaspase-9, leading to its cleavage 
and resultant activation. Caspase-9 hydrolyzes and activates caspases-3/7, reaching the 
same terminal path as the extrinsic pathway (Granville et al. 1997, Varnes et al. 1999). 
Apart from cytoplasmic Cyc other mitochondrial protein may enhance apoptotic 
response. One of them is Smac/DIABLO (Second mitochondria-derived activator of 
caspase/direct inhibitor of apoptosis-binding protein with low pI) is such a protein and 
its release depends on cell type and photosensitizing protocol (Usuda et al. 2002). 
Smac/DIABLO interferes with a family of proteins called inhibitor of apoptosis (IAP) 
on procaspase-9, thus making it available for activation in the apoptosome. Apoptosis-
inducing factor (AIF) is a mitochondrial protein that gets released during the initiation 
of apoptosis and translocates to the cell nucleus. There it degrades DNA independently 
of caspases (Furre et al. 2005). Other controlled cell death process occurred in PDT is 
autophagocytosis or autophagy (Buytaert et al 2006a, Buytaert et al. 2006b, Xue et al. 
2007). The cell components, including whole organelles are sequestered in membrane-
bound vesicles that fuse with lysosomes for degradation and reutilization of their 
components damaged by ROS (Klionsky 2005). In contrary to apoptosis, necrosis is 
a cell death characterized by cellular swelling, organelles alterations, rupture of plasma 
membrane, and finally cell lysis and leakage of the cellular components (Luo and 
Kessel 1997). Although cell death is expected and required response to PDT, in some 
cases, PDT induces signaling pathways associated with cell survival. Photodynamic 
treatment affects tumour cells directly as well as tumour vasculature and immune 
system. The PDT damages vasculature of tumors and can leads to tumour hypoxia 
(Agarwal et al. 1991), platelet aggregation, vessel constriction and vessel leakage 
(Evans et al. 1990, Schempp et al. 2001). These vascular events after PDT contribute to 
improved effect of the tumour treatment. Cytotoxic reactive oxygen species (ROS) 
induce vascular occlusion and may cause local inflammatory response mediated by 
complement activation cytokines (Korbelik et al. 2004, Korbelik 2006).  
 
1.2 Hormesis – adaptive cell response - resistance 
It is well known that cancer therapy is often complicated and could be attended by 
treatment failure. The response to cancer therapy can be significantly determined by 
stress response that depends on the stress conditions. Stress may activate increased 
production of reactive oxygen species (ROS) in the cells. When they are stimulated with 
ROS, cell signalling cascades are activated. It appears that the cellular redox potential is 
an important determinant of cell function and interruption of redox balance may it 
adversely affect. ROS damage cells by interactions with critical macromolecules 
including DNA, proteins, and lipids leading to cell death, mutation, and other toxicities 
(Martin and Barrett 2002). Apart from the involvement of ROS in apoptosis, ROS can 
also enhance mitogenesis in a number of cell types, including normal cells, initiated 
cells, and cancer cells. It is known that low levels of ROS may stimulate cell division 
and promote tumor growth, presumably through regulation of proliferative genes 
(Davies 1999, Dreher and Junod 1996). However, sub-toxic ROS production may affect 
cellular responses via alterations in cell signaling. It is well accepted that relatively low 
levels of ROS promote cellular proliferation rather that cause cell degeneration or death 
(Finkel 2000). This cellular response is related with the phenomenon called hormesis. 
Previously hormesis has been generally defined in terms of potential beneficial effects 
(Chapman 2002) and was used to describe the stimulatory effects on growth following 
single exposures to low doses of genotoxic agents which are toxic at high doses (Joiner 
et al. 1996). Nowadays, hormesis should be considered as an adaptive response 
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characterized by biphasic dose responses of generally similar quantitative features with 
respect to amplitude and range of the stimulatory response that are either directly 
induced or the result of compensatory biological processes following an initial 
disruption in homeostasis. Hormetic responses are characterized as biphasic dose-
response relationships exhibiting low-dose stimulation and high-dose inhibition 
(Calabrese and Baldwin 2002). The ability of the cells, tissues or organism to better 
resist stress damage by prior to a lesser amount of stress is known as adaptive response. 
Oliviery et al. (1984) have demonstrated that cells exposed to small doses become less 
susceptible to the genotoxic effect of a subsequent high dose it referred as adaptive cell 
response. We can tell that cells seem to be resistant to the influence of a high dose.  
There exist many definitions of resistance: the sum total of body mechanisms that 
interpose barriers to the invasion or multiplication of infectious agents, or to damage by 
their toxic products. Inherent resistance is an ability to resist disease independent of 
immunity or specifically developed tissue responses; it commonly resides in anatomic 
or physiologic characteristics of the host and may be genetic or acquired, permanent or 
temporary (http://www.doh.wa.gov/notify/other/glossary.htm).  
Another definition referred resistance as the ability of an organism to exclude or 
overcome, completely or in some degree, the effect of a pathogen or other damaging 
factor. Resistance is sometimes referred as a tolerance - the ability of an organism to 
sustain the effects of a disease without dying or suffering serious injury 
(http://ppathw3.cals.cornell.edu/glossary/Defs_R.htm). Different stress conditions can 
cause resistance in biological systems. There are some examples of stresses such as heat 
shock, radiation, drugs, chemicals and photodynamic action. 
 
1.2.1 Resistance to different stimuli 
 
Thermo-tolerance 
The response to heat shock provides probably the most spectacular example of 
the cellular capacity to react in an active manner to toxic stress. An exposure to mild 
heat shock induces the development of thermo-tolerance, a state of extreme resistance to 
severe heat shock (Gerner and Schneider 1975). The thermo-tolerance develops within a 
few hours after exposure to heat shock and lasts for 2–3 days. Its development is 
accompanied by the transcriptional activation and accumulation of a group of highly 
conserved proteins called heat shock proteins (HSPs) (Landry et al. 1982, Li and Werb 
1982, Subjeck et al. 1982). Until recently, the protective role of HSPs was confined to 
their chaperone function, it means, their capacity to bind heat-denatured proteins and 
prevent their irreversible aggregation (Lindquist 1986). However, recent findings reveal 
that HSPs can regulate both the signaling and the execution of major cell death 
pathways (Beere and Green 2001, Jaattela 1999). Consequently, HSPs play a primordial 
role in the resistance to a variety of toxic agents and situations that do not necessarily 
involve protein denaturation (Beere et al. 2000, Gabai et al. 2000, Mosser et al. 1997, 
Nylandsted et al. 2000, Pandey et al. 2000). This evolutionary conserved response is 
triggered at least in part by heat-induced accumulation of denatured proteins (Ananthan 
et al. 1986). At normal temperatures, HSP70, HSP40, and HSP90 are expressed at low 
basal level and maintain the heat shock transcriptional factor (HSF) in a repressed state. 
Relief of repression occurs via the titration of the HSPs by the stress-induced unfolding 
and denaturation of native proteins (Lindquist and Craig 1988, Morimoto 1993, Mosser 
et al. 1990, Zou et al. 1998). This results in the activation of HSF, the activation of hsp 
genes, and the accumulation of HSPs, which contributes in enhancing cell survival 
against subsequent protein-denaturing heat shock and in turning off HSF. HSPs 
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accumulation occurs in terms of hours. Another evolutionary conserved heat shock 
response develops in minutes and leads to the activation of the major signaling 
transduction pathways involving mitogen-activated protein kinases (MAPKs). The 
members of MAPK are extracellular lignal-regulated kinase (ERK), stress-activated 
protein kinase 1 (SAPK1)–c-Jun N-terminal kinase (JNK) (called here JNK), and 
SAPK2/p38 (called here p38) (Dorion et al. 1999, Guay et al. 1997). These signalling 
cascades play a central role in the regulation and determination of cell fate, such as 
growth, differentiation, or apoptosis in numerous physiological as well as stress 
conditions. The mechanisms of activation and the roles of these pathways during heat 
shock have been the subject of recent investigations.  
Activation of p38 and JNK early during heat shock is a mechanism of heat-
induced cell death and that the desensitization process may be a mechanism of thermo-
tolerance. Support for this idea has been obtained in the case of JNK, where blocking its 
activation was shown to be sufficient to protect cells against various stressors including 
heat shock (Gabai et al. 2000, Mosser et al. 2000, Park et al. 2001). Recent studies 
further proposed that regulation of JNK activity is a mechanism of HSP70-mediated 
protection. Overexpression of HSP70 can inhibit JNK activation by various stimuli, 
including heat shock, sorbitol, TNF, UV light, IL-1, and H2O2 (Gabai et al. 1997, 
Mosser et al. 1997). Mechanism of JNK inhibition involves the direct binding of HSP70 
to JNK (Park et al. 2001) or an HSP70-mediated protection of a JNK phosphatase from 
heat denaturation (Meriin et al. 1999). The inhibition of JNK activity could therefore be 
a factor of acquired thermo-tolerance. In contrast, the activation of the p38 pathway 
leads to the phosphorylation of one of the HSPs, HSP27 (Huot et al. 1995, Chretien and 
Landry 1988, Landry et al. 1991), an event that is generally assumed to be protective. 
The phosphorylation of HSP27 is catalyzed by MAPKAP kinase-2, a serine-protein 
kinase itself activated by phosphorylation by p38 (Huot et al 1995, Rouse et al. 1994). 
Upon phosphorylation, major changes are induced in the supramolecular organization of 
HSP27, changes that are thought to activate a homeostatic function of the protein 
(Lambert et al. 1999). One of the phosphorylation-modulated functions of HSP27 is the 
regulation of actin dynamics. HSP27 phosphorylation is involved in the stabilization of 
the actin filament during stress (particularly oxidative stress) and also in mediating 
rapid change in actin filament dynamics in response to stimuli that activate the p38 
pathway (Guay et al 1997, Landry and Huot 1999, Lavoie et al. 1995, Schafer et al. 
1999). HSP27 phosphorylation occurs not only after heat shock but also after 
stimulation by various types of agonists, including tyrosine kinase, serpentine, or 
cytokine receptor activators. Although it is essential in several physiological events 
requiring modulation of actin polymerization, this activity of HSP27 can also mediate 
inappropriate actin polymerization activity and lead to extensive cell blebbing and 
apoptosis. This was shown to occur when an incorrect balance is generated between the 
activity of p38 and ERK, as for example, during treatment with toxic agents such as 
cisplatin (Deschesnes et al. 2001, Huot et al. 1998). Toxic effects resulting from 
excessive or badly timed actin polymerization activities may also occur upon stress, 
when the concentration of HSP27 is very high (Deschesnes et al. 2001). It is thus 
possible that p38 desensitization is protective during thermo-tolerance, preventing an 
overload in the homeostatic response and stringently circumscribing the induced 
stimulatory effects in a given time frame. This restriction in the duration of activation of 
the signaling pathway may be important to ensure that an adequate response is 
generated (Dorion et al. 1999). 
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Chemo-resistance 
       The failure of cancer cells, viruses, or bacteria to respond to a drug used to kill or 
weaken them is termed as drug resistance. The cells, viruses, or bacteria may be 
resistant to the drug at the beginning of treatment, or may become resistant after being 
exposed to the drug (http://www.nci.nih.gov/dictionary/?CdrID=416100). Resistance to 
chemotherapeutic drugs is a principal problem in the treatment of cancer. Because of 
the serious problem of clinical drug resistance, much effort has been expended to 
advance understanding of the mechanisms of drug resistance in cancer cells. The 
molecular mechanisms of drug resistance, however, are not fully understood (Tsuruo et 
al. 2003). Resistance to a broad spectrum of chemotherapeutic agents in cancer cell 
lines and human tumors has been called multidrug-resistance (MDR) (Tsuruo 1988). In 
chemo-resistance and chemo-sensitivity of tumor cells play important roles membrane 
transporters mediating this phenomenon. ATP binding cassette (ABC) transporters, such 
as ABCB1/MDR1, ABCC1/MRP1 and ABCG2/BCRP, are frequently associated with 
decreased cellular accumulation of anticancer drugs and multidrug resistance of tumors. 
Solute carrier transporters, such as folate, nucleoside, and amino acid transporters, 
commonly increase chemo-sensitivity by mediating the cellular uptake of hydrophilic 
drugs. Ion channels and pumps variably affect sensitivity to anticancer therapy by 
modulating viability of tumor cells (Huang and Sadee 2006). In particular, ABC 
transporters, such as the multiple drug resistance transporter MDR1 (multidrug 
resistance 1, ABCB1 or P-glycoprotein), mediate energy-dependent drug efflux and 
play a main role in chemo-resistance (Gottesman et al. 2002). Multiple types of 
membrane transporters contribute to chemo-sensitivity and chemo-resistance of tumor 
cells. Water-soluble drugs, such as cisplatin, nucleoside analogues and antifolates, 
cannot cross the plasma membrane unless they ‘piggy-back’ onto membrane 
transporters, or enter through hydrophilic channels in the membrane. Resistance may 
result from decreased activity of the uptake transporters, or alternatively, enhanced 
efflux. For hydrophobic drugs, such as the natural product vinblastine, doxorubicin, and 
paclitaxel, entry occurs largely by diffusion across the membrane, although this process 
can be critically enhanced by transport proteins. Cellular resistance to these drugs 
commonly results from increased drug efflux mediated by energy-dependent 
transporters. Indirect mechanisms may also modulate chemo-sensitivity. For example, 
transporters and channels can affect chemo-sensitivity by providing nutrients to cancer 
cells or modulating the electrochemical gradient across membranes, thereby, modifying 
apoptosis pathways or the efficiency of drug diffusion along electrochemical gradients 
into cells. Transporters can be classified into passive and active transporters. The latter 
are further classified as primary- (ABC transporters) or secondary-active transporters 
according to the mechanism of energy coupling (Huang and Sadee 2006). 
 
Radiation resistance 
The adaptive response is a phenomenon in which the resistance to high-dose 
ionizing radiation is acquired by prior exposure to low-dose radiation. Olivieri et al. 
(1984) first identified this type of adaptive response using human lymphocytes in vitro, 
and others later confirmed it in many studies showing, for example, resistance to the 
induction of mutations (Ueno et al. 1996), chromosomal aberrations (Wolff 1996) and 
apoptosis (Sasaki et al. 2002). Evidence of an adaptive response during embryogenesis 
has also been reported in chicken embryos (Tempel and Schleifer 1995) and in limb 
buds (Wang et al. 1998). Its molecular mechanisms are largely unknown. The optimum 
dose of prior low-dose radiation required for observation of the radiation adaptive 
response is below 10 cGy in mammalian cells (Sasaki 1995). However, in studies 
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carried out in vivo, the priming whole-body doses 1.0 Gy (Mitchel et al. 1999), 30 cGy 
(Wang et al. 1998), 15–60 cGy (Takahashi et al. 2003) to which mice were exposed 
were higher than those given in the in vitro studies. The radiation adaptive response was 
observed in cultured mouse cells in the 1-h interval between the priming and challenge 
radiation exposures, reaching its peak level at 4–9 h after the priming dose (Sasaki 
1995). Radiation-sensitivity is quite high during organogenesis (Russell and Russell 
1954). In the adaptive response during embryogenesis of mice, 2 cGy g rays may be a 
large enough primary conditioning dose to suppress radiation-induced teratogenesis, 
and that the period of gestation when fetuses are exposed to radiation might be 
important (Okazaki et al. 2005). 
 
1.2.2 Resistance to photodynamic therapy 
Relatively new approach in photodynamic therapy is modification in the 
delivery of photo-radiation (Gibson et al. 1990). Recently, new modifications in light 
delivery regime have been introduced on the standard photodynamic protocol (single-
dose photosensitizer, single-dose light) to maximize the therapeutic effect of PDT. For 
example by reducing the fluency rate to improve oxygenation (Henderson et al. 2004, 
Hua et al. 1995, Pogue and Hasan 1997, Robinson et al. 1998, Sitnik et al. 1998, Thong 
et al. 2006), enabling re-oxygenation in treated tissue (Curnow et al. 1999, Takahashi 
and Ohnishi 2009) or by fractionated drug administration (Cavarga et al. 2005, Dolmans 
et al. 2002, Webber et al. 2005). It has been hypothesized that splitting the light dose 
into fractions by interrupting illumination for a certain time allows the treatment site to 
be re-oxygenated, which results in increased generation of singlet oxygen and thus a 
greater PDT effect (Hua et al. 1995, Pogue et al. 2001, Robinson et al. 2000). 
Fractionated light regime uses light disrupted at a particular point for a period of 
darkness to increase the efficacy of photodynamic therapy {Ascencio et al. 2008, 
Babilas et al. 2003, Curnow et al. 2000, Curnow et al. 1999, de Bruijn et al. 2007, de 
Bruijn et al. 2006, de Bruijn et al. 1999, Gibson et al. 1990, Huygens et al. 2005, Iinuma 
et al. 1999, Messmann et al. 1995, Paba et al. 2001, Pogue et al. 2008, Sackova et al. 
2005, Togashi et al. 2006, Varriale et al. 2002, Xiao et al. 2007). In contrast to in vivo 
studies, in which enhanced or no effect of fractionated irradiation was shown, the so far 
known in vitro works report either on photo-resistance/photo-tolerance (Paba et al. 
2001, Varriale et al. 2002) or on decreased production of reactive oxygen species and 
cytotoxicity via regeneration of glutathione (Oberdanner et al. 2005). In the last decade, 
an application of light fractionation in PDT achieved increased attention of researchers 
and led to the comparison of continuous and fractionated light regimes (Ascencio et al. 
2008, Curnow et al. 2000, de Bruijn et al. 1999, Sackova et al 2005, Xiao et al. 2007). 
Indeed, improved efficiency of fractionated light delivery was demonstrated on various 
models in vivo (Ascencio et al 2008, Curnow et al 2000, de Bruijn et al 1999, Pogue et 
al. 2008, Takahashi and Ohnishi 2009, Xiao et al 2007). However, the outcome of 
fractionated light regime is still limited by some parameters such as distribution of 
photosensitizers in tissue (de Bruijn et al. 2007), dark intervals between light doses (de 
Bruijn et al. 1999, de Bruijn et al. 2006, Sackova et al. 2005, Togashi et al. 2006, 
Uehara et al. 1999) or oxygen depletion (Huygens et al. 2005). It was shown that 
fractionated light regime with a longer dark period resulted in a decrease of hypericin 
cytotoxicity. Longer dark interval after the irradiation of cells by first light dose makes 
cells resistant to the effect of the second illumination. These findings confirm that the 
light application scheme together with other photodynamic protocol components is 
crucial for the photocytotoxicity of hypericin (Sackova et al. 2005). The photo-
activation of hypericin with low doses of light-induced apparent photo-resistance in 
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human histiocytic lymphoma U937 cells (Paba et al. 2001) and HT-29 cells (Sackova et 
al. 2005). Pre-sensitized U937 cells with hypericin appear to be fully resistant to light 
doses that normally determine massive cellular apoptosis in experimental photodynamic 
therapy. Pre-sensitization renders cells insensitive to higher light doses. Photo-
resistance was manifested by changes in levels of expression of pro- and antiapoptotic 
proteins, PARP fragmentation and cell viability (Paba et al. 2001).  
Also, low-energy pre-sensitization caused enhanced photo-tolerance of 
hypericin-loaded HEC1-B cells (Varriale et al. 2002). Fractionated illumination did not 
enhance the efficacy of PDT using methyl 5-aminolevulinate but it did in case of ALA 
application (de Bruijn et al. 2007). Singh and his co-workers (2001) examined 
mechanism(s) of action for PDT via the generation of PDT-resistant cell lines. In this 
study they used three human cell lines, namely, human colon adenocarcinoma (HT-29), 
human bladder carcinoma and human neuroblastoma. The three photosensitizers used 
were Photofrin, Nile Blue A and aluminum phthalocyanine tetrasulfonate. The protocol 
for inducing resistance consisted of repeated in vitro photodynamic treatments with a 
photosensitizer to the 1–10%-survival level followed by regrowth of single surviving 
colonies. Varying degrees of resistance were observed. They determined that the 
mechanisms and pathways of cellular death are sensitizer specific. For the HT-29 cell 
line they were able to create resistant variants for all three photosensitizers. It is not 
apparent from either the initial clonogenic survival curves or any properties intrinsic to 
this cell line why resistance was possible here and not in the other two cell lines. The 
cells HT-29 was significantly more resistant to Nile Blue A–mediated PDT but 
displayed intermediate sensitivity to the other sensitizers. As such, they were unable to 
identify any characteristics of the three cell lines that were predictive of their ability to 
generate resistant variants upon repeated PDT action (Singh et al. 2001). 
In PDT, the photo-tolerance, as any type of unexpected resistance should be 
regarded as a potential adverse process. The present data do not unravel the molecular 
mechanism underlying the appearance of photo-resistance. However, the observed 
stimulation of the expression of the HSP70 protein upon photo-induced stress, may 
suggest its involvement in this process (Paba et al. 2001). There is strong evidence that 
HSP induction coincides with acquisition of tolerance to stress which otherwise may 
kill the cell. For example, heat-shocked cells are more resistant to environmental stress 
and death (Jaattela et al. 1992, Lindquist and Craig 1988). Similarly, apoptosis induced 
by various stresses is inhibited in heat-shocked cells suggesting that HSPs play a role in 
resistance mechanisms (Mosser and Martin 1992). Finally, it was demonstrated that 
mild pre-sensitization endows cells with an unexpected high degree of photo-tolerance, 
enhances HSP70 synthesis, sequentially promotes the expression of specific apoptosis-
related proteins and causes cell cycle arrest (Varriale et al. 2002). Photofrin-mediated 
PDT can also induce expression of mitochondrial heat shock protein HSP60 in colon 
cancer cell line HT-29 and its PDT-induced resistant variant HT-29-P14 as well as the 
radiation-induced fibrosarcoma cells RIF-1 and its PDT-resistant variant, RIF-8A 
(Hanlon et al. 2001). Photodynamic therapy-mediated hypoxia may induce also 
expression of hypoxia-inducible factor-1α (HIF-1α) and plays the role in resistance to 
apoptosis in ALA-mediated PDT (Ji et al. 2006). However in normoxic condition is 
induction of HIF-1α is mediated by the prostaglandin pathway (Mitra et al. 2006).  
The role of extracellular signal-regulated kinases (ERKs) in the cell survival 
after PDT is less clear. However sustained ERK1/2 activation protects cells from 
Photofrin-mediated phototoxicity and duration of ERK1/2 activation is regulated by 
mitogen-activated protein kinase phosphatase MKP-1. Blocking of the sustained ERK 
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activity with inhibitor of mitogen-activated protein/ERK kinase significantly decreased 
cell survival of PDT-resistant LFS087 cells (Tong et al. 2002).   
In photodynamic therapy, with the phthalocyanine photosensitizer Pc 4 
[HOSiPcOSi(CH3)2(CH2)3N(CH3)2] was an oxidative stress associated with induced 
activation of sphingomyelinase, ceramide generation and subsequent induction of 
apoptosis in various cell types. Although ceramide was elevated in normal lymphoblast 
after PDT, accumulation of ceramide in Niemann–Pick human lymphoblasts (NPD) was 
significantly suppressed. Resistance of NPD cells seems to be associated with the loss 
of acid sphingomyelinase function (Separovic et al. 1999). This result agrees with the 
similar defects observed in NPD cells in response to ionizing radiation (Santana et al. 
1996). 
Resistance to cancer therapies is a serious problem. Each of information which 
contributes to better understanding of events underlying resistance development can 
improve therapeutic outcome. Therefore it is important to pay attention to phenomenon 
of resistance. 
 
1.3 Molecules playing role in resistance to cancer therapies 
 
1.3.1 Heat shock proteins 
All living organisms respond at a cellular level to unfavourable conditions such 
as heat shock, or other stressful situations of many different origins. Reactions of 
stressed cells are characterized by an expression of a small number of specific genes 
(heat shock genes). Consequently, the products of this genes – heat shock proteins or 
stress proteins – are also present under normal conditions but in lesser amounts.       
Cellular stress can engage two fundamental responses: apoptosis, a cell death 
mechanism that eliminates irreparably damaged cells, and stress response. In stress 
response the heat shock proteins (HSPs) function to sustain survival by limiting cellular 
damage and accelerating recovery. Evidence indicates that the coordinated interaction 
between these two functionally opposing pathways, apoptosis and the stress response, 
may determine cellular susceptibility to damaging stresses. The HSPs are a large family 
of highly conserved proteins broadly categorized according to their size. Some are 
constitutively expressed and associated with specific intracellular organelles, and others 
are rapidly induced in response to cellular stress. HSPs function collectively to protect 
cells from the potentially fatal consequences of adverse environmental, physical, or 
chemical stresses by their ability to prevent protein aggregation and to promote the 
refolding of denatured proteins (Parsell and Lindquist 1993). The protective function of 
the HSPs may be extended to include an antiapoptotic role for several members of the 
HSP family, including HSP70, HSP90 and HSP27 (Beere and Green 2001). 
 
HSP70 
 HSP70 and its cochaperones, especially the Bcl-2–associated athanogene family 
proteins, are well-recognized antiapoptotic factors. The mechanisms by which they 
exert their effects, however, are just beginning to be understood in detail. It was shown 
that HSP70 in vitro (Beere et al. 2000) and in whole cells (Saleh et al. 2000) blocks the 
assembly of a multiprotein complex termed the apoptosome. This complex is essential 
for activating the cascade of cysteine-aspartyl proteases known as caspases that are 
responsible for executing the apoptotic program. Enforced overexpression of HSP70 in 
stably transfected cells provides protection from stress induced apoptosis at the levels of 
both cytochrome c release and initiator caspase activation. Furthermore, it has been 
shown that the actual chaperoning function of HSP70 is required for this protection 
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(Mosser et al 2000). Conversely, antisense-mediated inhibition of HSP70 expression 
has been shown to cause massive death in multiple breast cancer cell lines, whereas 
nontumorigenic breast epithelial cells are not affected (Nylandsted et al. 2000). The first 
study to demonstrate a correlation between the antiapoptotic effects of HSP70 and an 
inhibition of caspase activity provided no specific mechanism except to suggest that the 
point of HSP70 intervention was upstream of caspase-3 activation (Mosser et al. 1997). 
Subsequently, it has been demonstrated that HSP70 is able to directly inhibit caspase 
processing by interacting with Apaf-1 to prevent the recruitment of procaspase-9 to the 
apoptosome (Beere et al. 2000, Saleh et al. 2000). HSP90 and HSP27 are also 
reportedly able to inhibit the formation of a functionally competent apoptosome, HSP90 
by directly associating with Apaf-1 to prevent its oligomerization (Pandey et al 2000), 
and HSP27 by binding and sequestering cytosolic cytochrome c away from its target 
Apaf-1 (Bruey et al. 2000). Although it is unlikely that the disruption of apoptosome 
assembly is the only point of intervention by the HSPs, it represents a likely target for 
HSPs with the potential for a significant effect on cell survival (Beere and Green 2001). 
 
HSP90 
 In vertebrates, two distinct genes encode constitutive and inducible isoforms of 
the protein (HSP90h and HSP90a, respectively), but functional differences between 
these isoforms are poorly understood. Homologues of HSP90 are also found in the 
endoplasmic reticulum (GRP94) and mitochondrion (TRAP1). Recently, HSP90 variant 
(HSP90N) has been identified (Grammatikakis et al. 2002) that seems to be primarily 
membrane associated as a result of its unique hydrophobic NH2-terminal domain. 
Limited information exists on its precise cellular functions. HSP90 resides primarily in 
the cytoplasm, where it exists predominantly as a homodimer. Each homodimer is made 
up of monomers consisting of three main functional domains that display important 
functional interactions. The NH2-terminal domain contains an adenine nucleotide 
binding pocket of the GHKL superfamily (Dutta and Inouye 2000). Structural 
alterations driven by the hydrolysis of ATP to ADP in this pocket are thought to play an 
essential role in the chaperoning activity of the protein. This pocket is also the binding 
site of the structurally unrelated natural products geldanamycin and radicicol as well as 
the growing number of semisynthetic derivatives and synthetic compounds. These drugs 
bind with higher affinity than nucleotides do, and they lock the domain in its ADP-
bound conformation. These drugs thus alter many if not all of the normal functions of 
the chaperone (Roe et al. 1999). 
Endoplasmic reticulum and Golgi apparatus are folding sites of newly synthesized 
proteins. This chaperone is pivotal for stability and function of a large group of client 
proteins including ser/thr quinces, tyrosine quinces, mutated p53, cyclin D-associated 
Cdk4 (Helmbrecht et al. 2000) and Cdk6, and wild-type Plk (Simizu and Osada 2000). 
Replication mechanisms in cells that lose HSP90-protective function are severely 
compromised, disabling cell progression through the cell cycle (Piper 2001). Indeed, 
HSP90 modulators such as geldanamycin or radicicol, which interact with the ATP 
binding pocket of HSP90, exhibit potent anticancer effects (Neckers 2002). 
In photodynamic therapy used photosensitizer hypericin is localized to 
endoplasmic reticulum and Golgi apparatus (Uzdensky et al. 2001) which are folding 
sites of newly synthesized proteins as mentioned before. Hypericin can cause reduction 
in intracellular pH by proton transfer to surrounding molecules (Sureau et al., 1996) 
leading to pH-dependent structural changes in proteins (Tcherkasskaya and Uversky 
2001). The broad range of activities may, thus, result from hypericin targeting 
chaperone networks. Hypericin inactivates the chaperone activity via ubiquitinylation. 
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This effect appears to be exclusive to HSP90 and not to affect HSP70 chaperones 
(Blank et al. 2003). HSP90 and its cochaperones are also reported to modulate tumor 
cell apoptosis. Much of this activity seems to be mediated through effects on AKT 
(Basso et al. 2002), tumor necrosis factor receptors (Vanden Berghe et al. 2003), and 
nuclear factor-κB function (Chen et al. 2002). However, HSP90 may also play a more 
global role in facilitating neoplastic transformation than just inhibiting apoptosis. 
Among the heat shock proteins, HSP90 is unique because it is not required for the 
biogenesis of most polypeptides (Nathan et al. 1997). This finding has led to the 
suggestion that HSP90 inhibitors may prove of unique therapeutic benefit (Bagatell and 
Whitesell 2004). 
GRP94 is a glucose-regulated protein of 94 kDa, also known as gp96 or 
endoplasmin, the ER paralog of HSP90 and is found only in higher eukaryotes. GRP94 
is essential for proper assembly and maturation of numerous client proteins (Melnick et 
al. 1992, Nigam et al. 1994, Randow and Seed 2001). Wassenberg at al. (2000) 
described bis-ANS and heat shock induction of GRP94 multimerisation. A tertiary 
conformational change is accompanied by a marked elevation of chaperone and peptide 
binding activity. In this conformation, GRP94 can undergo, in a concentration-
dependent manner, homotypic oligomerization. Exposure to heat shock caused a 
relatively rapid formation of tetramers, hexamers and octamers of GRP94 with high 
molecular weights (Wassenberg et al. 2000).  
 
HSP27 
 Elevated levels of HSP27 are observed in many tumor types and are often 
correlated with a drug-resistant phenotype. When overexpressed in vitro, HSP27 
confers enhanced cellular survival in response to a variety of proapoptotic stimuli. 
Exposure of cells to stresses such as heat shock, IL-1, TNF-α, and chemotherapeutic 
agents induces the transcription-dependent accumulation and rapid phosphorylation of 
HSP27 (Rouse et al. 1994). This p38-dependent, MAPK-activated protein kinase-2-
mediated phosphorylation of HSP27 is essential for its survival-promoting effects 
(Lavoie et al. 1995). The protective capacity of HSP27 is likely due to its unique ability 
to modulate the dynamics of microfilament reorganization so as to maintain stability of 
the cytoskeleton under conditions of cellular stress (Guay et al 1997, Huot et al. 1996). 
Aldrian et al. (2002) demonstrated that HSP27 overexpression decreased invasion of 
melanoma cells (Aldrian et al. 2002). In contrast, others have shown that HSP27 
increases cell migration in both breast and smooth muscle cells (Hansen et al. 2001, 
Hedges et al. 1999).  
 
Clusterin 
 Clusterin/apolipoprotein J is an enigmatic protein which has chaperone-like 
activity similar to that of small heat shock proteins and may play role in cytoprotection 
(Humphreys et al. 1999). In human cells are two isoforms of clusterin generated by an 
alternative splicing. The main product of the clusterin gene is a ~60 kDa pre-secretory 
form (pre-sCLU), which is targeted to the endoplasmic reticulum by an initial leader 
peptide and could be glycosylated and cleaved into ~40 kDa α- and β-subunits which 
held together by disulphide bonds. The mature form ~80 kDa of sCLU is secreted to 
extracellular space (Burkey et al. 1991, Wong et al. 1993). Intracellular pre-nuclear 
isoform (pre-nCLU) is 50-55 kDa is localized in the cytoplasm and not exerts apoptotic 
effect whereas activated pre-nCLU (n-CLU) translocates to nucleus and contributes to 
cell death (Leskov et al. 2003). At low doses of irradiation, secretory clusterin (sCLU) 
production provides a cytoprotective molecular chaperone defence mechanism in 
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clearing cell debris from traumatised tissue. At higher doses, the pre-nCLU becomes 
activated. Activated nuclear clusterin (nCLU), a prodeath mature 55 kDa protein that 
causes apoptosis, is formed (Araki et al. 2005). Increased ROS and lipid peroxidation 
levels, while not affecting cell viability, elicit a significant and concomitant increase in 
levels of clusterin mRNA and protein (Strocchi et al. 2006). It was described that 
decreased expression of clusterin is involved in rheumatoid arthritis and high levels of 
extracellular CLU and low expression of intracellular CLU may enhance NF-κB 
activation and survival of the synoviocytes (Devauchelle et al. 2006). Disruption of the 
clusterin gene promotes NF-κB activation (Devauchelle et al. 2006, Santilli et al. 2003). 
Attenuation of NF-κB activation after heat shock is both dose- and time-dependent 
(Schell et al. 2005). 
 
1.3.2 Nuclear transcription factor-kappaB 
Apoptosis is negatively regulated by the activities of “survival factors” such as 
insulin-like growth factor-1 (IGF-1), nerve growth factor (NGF), and platelet-derived 
growth factor (PDGF). These factors mediate their survival-promoting effects at least 
partly by activation of the phosphatidylinositol 3-kinase (PI3K) to serine-threonine 
proteine kinase B or Akt (PKB/Akt) signaling cascade (Datta et al. 1999). Activation of 
PKB/Akt occurs at the plasma membrane and has been shown in several studies to be 
followed by its translocation to both the cytosol and nucleus (Borgatti et al. 2000, 
Filippa et al. 2000). Many of the substrates of PKB/Akt are proteins that function in the 
nucleus. PKB/Akt may promote cell survival by directly phosphorylating transcription 
factors that control the expression of pro- and anti-apoptotic genes. PKB/Akt appears to 
both negatively regulate factors that promote the expression of death genes and 
positively regulate factors that induce survival genes (Nicholson and Anderson 2002). 
Akt-mediated phosphorylation of the proapoptotic Bcl-2 family protein Bad at Ser136 
induces its dissociation from Bcl-XL (to which Bad is constitutively bound), to promote 
the sequestration of BAD by 14-3-3 proteins in the cytosol. Thus prevents BAD from 
interacting with Bcl-2 or Bcl-XL at the mitochondrial membrane (Zha et al. 1996). Akt-
mediated phosphorylation and functional inactivation of caspase-9 may also contribute 
to the antiapoptotic activity of Akt (Cardone et al. 1998). The scope of Akt survival-
promoting activity broadens further with its ability to regulate the activity of 
transcription factors such as forkhead (FKHRL1) (Brunet et al. 1999) and nuclear factor 
κB (NF-κB) (Romashkova and Makarov 1999). PKB/Akt has been shown to interact 
with and activate IKKa. Data suggest that PKB/Akt phosphorylates IKKa directly but 
more importantly PKB/Akt is believed to be essential for IKK-mediated destruction of 
I-κB and activation of NF-κB (Romashkova and Makarov 1999). 
CREB is transcription factor which bind to certain sequences called cAMP 
responses elements (CREs) in DNA and thereby increase or decrease the transcription 
of certain genes. CREB is also a direct target for phosphorylation by PKB/Akt (Du and 
Montminy 1998) and this phosphorylation occurs on site that increases binding of 
CREB to accessory proteins necessary for induction of genes containing CREs in their 
promoter regions. CREB has also been shown to mediate PKB/Akt-induced expression 
of anti-apoptotic gene mcl-1 (Wang et al. 1999).   
Transcription factor NF-κB is undoubtly one of the major regulators of the 
inflammatory response initiated in the context of numerous pathologic and 
nonpathologic events. NF-κB is playing a key role in tumor demise by eliciting the 
onset of the immune defense against the tumor. Yet, NF-κB also modulates the 
expression of anti-apoptotic genes which may, in turn, favour tumor cell survival in 
response to pro-apoptotic therapeutics (Matroule et al. 2006). Akt can increase NF-κB 
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activity by accelerating the degradation of inhibitor of κB (IκB), which associates with 
and retains NF-κB in the cytosol (Kane et al. 1999). NF-κB is then available to regulate 
the expression of genes, which include the antiapoptotic Bcl-2 family member A1 
(Zong et al. 1999) and the caspase inhibitors c-IAP1 (You et al. 1997) and c-IAP2 (Chu 
et al. 1997). NF-κB is likely involved in tumor recurrence phenomena by upregulating 
COX-2 and MMPs that are primary actors in tumor cells proliferation and angiogenesis 
(Lee et al. 2006). NF-κB is also sensitive to the cellular oxidative status. Since then, the 
key role of ROS as second messengers in NF-κB activation has been investigated in the 
context of multiple stimuli (TNF-α, IL-1β, UVs, calcium ionophore, LPS) 
(Schoonbroodt and Piette 2000). NF-κB is involved in the regulation of cell 
proliferation, apoptosis, and survival by a wide range of cytokines and growth factors 
and also it is critical in tumourigenesis (Baldwin 2001). Its survival-promoting activity 
is mediated through its ability to induce prosurvival genes such as c-IAP-1 and c-IAP-2. 
NF-κB is regulated through its association with an inhibitory cofactor I-κB, which 
sequesters NF-κB in the cytoplasm. Phosphorylation of I-κB by upstream kinases, 
known as IKKs, promotes its degradation allowing NF-κB to translocate to the nucleus 
and induce target genes (Romashkova and Makarov 1999). Low level of ROS may 
function as second messengers activating pathways that protect cells against apoptotic 
stimuli (Chandra et al. 2000). Reactive oxygen intermediates (ROI) serve as messengers 
mediating directly or indirectly the release of the inhibitory subunit IκB from 
transcription factor NF-κB (Schreck et al. 1991). NF-κB is often considered to be a 
ROS-responsive transcription factor (Chandra et al 2000, Janssen-Heininger et al. 2000) 
also shown to be implicated in a cancer cell responses to photodynamic therapy 
(Legrand-Poels et al. 1995). Phosphorylation and degradation of IκB is an important 
step for NF-κB releasing from complex with IκB, translocation from cytoplasm to 
nucleus and binding to DNA. Human colonic epithelial cells HT-29 have altered 
regulation of IκB-α degradation and activation of NF-κB activity can occur 
independently of IκB degradation (Jobin et al. 1997, Wang et al. 2000). 
 
1.3.3 Mitogen activated protein kinases 
The MAPKs are group of serine/threonine protein kinases that are activated in 
response to a variety of extracellular stimuli and mediate signal transduction from the 
cell surface to the nucleus. Together with several others signaling pathways, they can 
alter fosforylation status of numerous proteins, including transcription factors, 
cytoskeletal proteins, kinases and other enzymes, and influence gene expression, 
metabolism, cell morphology, cell division and cell survival. There are four major 
groups of MAPKs in mammalian cells – the ERKs, p38 MAPKs, JNKs and ERK5 or 
BMK cascades (Wada and Penninger 2004). Mitogen-activated protein kinases 
(MAPKs) are activated in a cascade of phosphorylation reactions in which individual 
MAP kinases are phosphorylated. In general, each group of MAP kinases is activated by 
a specific MAPK kinase (Fanger et al. 1997). Upstream signaling molecules involve 
kinases, adaptors, and receptors or sensors, which connect the pathway to specific 
stimuli (Chang and Karin 2001, Widmann et al. 1999). 
 The p38 (also known as CSBP, mHOG1, RK, and SAPK2) is the member of the 
MAPK-related pathway in mammalian cells (Han et al. 1994, Lee et al. 1994) and 
consists of the four known p38 isoforms (α, β, γ and δ) (Kyriakis and  Avruch 1990). In 
mammalian cells, the p38 isoforms are strongly activated by environmental stresses, 
inflammatory cytokines and VEGF but not appreciably by mitogenic stimuli. Most 
stimuli that activate p38 also activate JNK (Lee et al. 1994). The p38 pathway consists 
of membrane receptors or sensors that are connected through adapter proteins to GTP-
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ases that are upstream of MAPK kinase, (MKK), and the MAPK itself (Brancho et al. 
2003). The p38 also regulates the immune response by stabilizing specific cellular 
mRNAs involved in this process (Ono and Han 2000). While the exact mechanisms 
involved in p38 immune functions are starting to emerge, activated p38 has been shown 
to phosphorylate several cellular targets, including cytosolic phospholipase A2, the 
microtubule-associated protein Tau, and the transcription factors ATF1 and ATF2, 
MEF2A, Sap-1, Elk-1, NF-B, Ets-1, and p53 (Kyriakis and  Avruch 1990). It was 
previously shown that p38 MAP kinase is necessary for the regulation of TGFβ-
mediated increases in cell adhesion and invasion (Hayes et al. 2003) and also, inhibition 
of p38 MAP kinase blocks HSP27 phosphorylation, and decreases invasion in smooth 
muscle cells (Hedges et al. 1999). Hypericin mediated PDT of human cancer cells leads 
to up-regulation of the inducible cyclooxygenase-2 enzyme and the subsequent release 
of PGE2. COX-2 protein levels are up-regulated in cancer cells by hypericin-mediated 
PDT in a time- and dose-dependent fashion. This COX-2 expression is remarkably 
dependent on the PDT stress. Inhibition of p38a MAPK resulted in suppression of the 
PDT-induced COX-2 expression, PGE2 and VEGF release, and tumor-induced 
endothelial cell migration. The p38 MAPK α and β mediate COX-2 up-regulation at the 
protein and messenger levels. The half-life of the COX-2 messenger was drastically 
shortened by p38 MAPK inhibition in transcriptionally arrested cells, suggesting that 
p38 MAPK mainly acts by stabilizing the COX-2 transcript, however transcriptional 
regulation by nuclear factor NF-κB was not involved in COX-2 up-regulation by PDT. 
Although p38 MAPK activation by PDT is required to up-regulate COX-2, this enzyme 
is not likely the direct downstream mediator of the p38 MAPK anti-apoptotic response. 
This indicates that p38 MAPK is a common target of hypericin-based PDT and a 
general mediator of COX-2 up-regulation in photo-damaged cancer cells (Hendrickx et 
al. 2003). 
 Many stresses that engage apoptosis simultaneously induce the activation of c-
Jun NH2-terminal kinase (JNK). However, the precise role of JNK signaling in 
apoptosis remains controversial. Although several studies favor a proapoptotic role for 
JNK signaling, equally valid are a number of observations indicating an enhancement of 
cellular survival by the JNK pathway (Davis 2000, Chen and Tan 2000). Many of the 
stresses that cause the elevation of JNK activity also increase the expression of HSPs. 
Several studies have shown that HSP70 can inhibit JNK activation induced by a number 
of stresses, including heat shock (Gabai et al. 1997, Mosser et al 1997), ethanol (Gabai 
et al. 1997), proteasome inhibitors (Meriin et al 1999), and ultraviolet (UV) irradiation 
(Park et al. 2001). The precise mechanism for HSP70-mediated suppression of JNK 
activity is unclear. Two different models have been proposed to explain how HSP70 
inhibits JNK activation. Based on the observation that elevated JNK activity following 
stimuli (such as heat shock, ethanol, arsenite, and oxidative stress) is a consequence of 
inhibition of JNK dephosphorylation. Meriin et al. (1999) suggested that HSP70 
modulates JNK activity by inhibiting this stress-induced suppression of 
dephosphorylation. Alternatively, HSP70 may function to inhibit UV-induced JNK 
activation by directly interacting with JNK to suppress its association with, and 
phosphorylation by, SEK1. This effect requires the COOH-terminal peptide-binding 
domain of HSP70 (Park et al. 2001), which is entirely consistent with earlier 
observations that HSP70-mediated suppression of JNK activation is independent of its 
ATPase domain (Mosser et al 1997, Volloch et al. 1999). Importantly, both of these 
models and their supporting data indicate that HSP70 can suppress JNK activation 
independently of its capacity as a chaperone protein. This is in contrast to HSP70-
mediated suppression of heat shock-induced apoptosis and cytochrome c release, which 
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require both the peptide-binding and ATPase domains (Mosser et al 1997, Volloch et al 
1999). The conflicting pro- and antiapoptotic roles of JNK signaling are suggested to 
reflect the duration of JNK activation such that a transient elevation of JNK activity 
selectively engages a survival pathway (Chen and Tan 2000). Perhaps a careful 
examination of the kinetics of JNK signaling and HSP70 expression would reveal a 
relationship consistent with the idea that simultaneous induction of HSP70 and JNK 
tempers the magnitude and duration of JNK activation and, in doing so, favors the 
engagement of cellular survival (Beere and  Green 2001). 
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2 AIMS OF THE STUDY 
 
Photodynamic therapy is an attractive, emerging therapeutic procedure suitable for 
the treatment of a variety of tumor and non-malignant disorders. The efforts to improve 
therapeutic outcome of PDT led to modification of standard photodynamic protocol by 
light fractionation.  
The first aim of the study was to compare continuous and fractionated light regime 
in which a total light dose was delivered in two equal or unequal light fractions 
separated by a dark interval 1 or 6 h. The purpose was to identify photodynamic 
protocol suitable to enhance (or for enhancing) hypericin-mediated photocytotoxic 
effects on HT-29 adenocarcinoma cells. Since MTT assay preliminary experiments 
revealed no or minor photocytotoxic effects in response to various fractionated light 
delivery regimes as compared to standard protocol, we were promoted to investigate the 
reasons of the observed failure of fractionated administration of PDT.  
The second aim of the study was addressed to unravel the reasons of this decrease 
of photo-cytotoxicity caused by a fractionated light delivery regime when a sub-lethal 
light dose (1 J.cm-2) was followed by a lethal light dose (11 J.cm-2) 1h or 6 h later. In 
such regard, we have described the various effects caused by continuous and 
fractionated illumination schedules in some details. We analyzed cell viability 
modifications, cell cycle alterations, cell death induction (by dual staining Annexin 
V/PI) and colony-forming activity. All together, these data resulted particularly useful 
in identifying cellular and sub-cellular events determined by different light delivery 
regimes. 
As we observed significant alterations in all cellular parameters studied depending 
upon the extension of the dark phase between two unequal exposures to light, the third 
aim of our study was clarifying the events that take place during the dark pause. For this 
reason we analyzed the production of reactive oxygen species, the fluctuations of 
hypericin content, the activation of redox-regulated nuclear transcription factor NF-κB 
(by luciferase activity assay), the changes in the expression of proteins connected with a 
cell survival, namely NF-κB p50 and p65 subunits, IκB-α, Mcl-1, HSP70, GRP94, 
Clusterin-α (by Western Blotting) and role of p38 MAPK inhibition in cell survival. In 
whole these information have given some insight into molecules processes and 
mechanisms which are involved in the development of resistance to PDT.  
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3 MATERIAL AND METHODS 
 
3.1 Cell culture 
Human adenocarcinoma cell line HT-29 was purchased from American Tissue 
Culture Collection (ATCC, Rockville, MD, USA). Cells were cultured in RPMI-1640 
medium (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal 
calf serum (FCS; PAA Laboratories GmbH, Linz, Austria) and antibiotics (penicillin 
100 U/ml, streptomycin 100 µg/ml and amphotericin 25 µg/ml; Invitrogen Corp., 
Carlsbad, CA, USA). Cells were maintained at 37 °C in a humidified 5% CO2 
atmosphere and constantly kept under dark conditions. 
 
3.2 Hypericin activation 
The cells were irradiated in hypericin-free medium by placing cultivation dishes 
(TPP, Trasadingen, Switzerland) on a plastic diffuser sheet above a set of eleven 
L18W/30 lamps (Osram, Berlin, Germany) with maximum emission between 530 and 
620 nm (the absorption peak of hypericin is ~ 600 nm) (Fig. 2). Uniform fluency rate at 
the surface of the diffuser was 3.15 mW.cm-2 and the temperature did not exceed 37 ˚C. 
Light dose was calculated as multiplication of fluency rate by time. 
 
 
 
Figure 2. Irradiation device. Eleven L18W/30 lamps with maximum emissium in the range of 
530-620 nm are located under plastic diffuser sheet (Photo: L. Grada Kuliková). 
 
3.3 Experimental design 
HT-29 cells (2×104/cm2) were seeded and cultivated 24 h in a complete medium 
with 10% FCS. Hypericin ((4,5,7,4´,5´,7´-hexahydroxy-2,2´-dimethylnaphtodiantron, 
HPLC grade), AppliChem GmbH, Darmstadt, Germany) at final concentration 60 nM 
was added and then incubated 16 h with cells in dark conditions. Prior to light 
application, the medium was replaced with a fresh one, free of hypericin (Fig. 2A). The 
hypericin was photoactivated with a sub-lethal or lethal single light dose (1 or 12 J.cm-2) 
or fractionated light doses (1 + 11 J.cm-2) with a dark interval 1 or 6 h. The cells 
photoactivated with a sub-lethal light dose were analyzed 1 or 6 h after PDT. The 
effects of single or fractionated light regime deliveries were analyzed up to 24 h after 
PDT (Fig. 2B) and cell viability, cell number and cell cycle were analyzed 24 or 48 h 
after PDT. 
 
3.4 Quantification of cell viability and cell number 
Cells were treated according to the standard protocol (Fig. 3A) and at defined 
incubation times after hypericin photoactivation (24 or 48 h) eosin vital dye (0.15 %) 
exclusion assay was used to determine both cell viability and cell number 
(microscopically). The viability was expressed as the percentage of live cells out of the 
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total number of cells. Cell number was assessed by counting live cells in a Bürker 
chamber. 
 
 
 
Figure 3. Experimental design. (A) Time schedule of experiments - HT-29 cells were seeded 
(point -40 h in time schedule of experiments) and cultivated 24 h in a complete medium and 
then hypericin was supplemented (point -16 h). Medium with hypericin was removed from cells 
16 h later and replaced for hypericin free medium with subsequent activation of intracellular 
hypericin (point 0 h). Analyses were performed up to 6 h or up to 24 h after PDT (point +6 h or 
+24 h). (B) Schedule of hypericin activation - hypericin loaded HT-29 cells were illuminated 
with a single light dose (sub-lethal 1 J.cm-2 or lethal 12 J.cm-2 light dose) or two unequal light 
dose (1+11 J.cm-2) separated with 1 h or 6 h dark pause. (S) single light delivery 12 J.cm-2, 
fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) dark pause between the two 
light doses.  
           
3.5 MTT assay 
Cells were seeded into 96 wells plates in amount 2×104 cells per well and then 
were treated according to standard protocol (Fig. 3A). Analyses were performed: a) 24 h 
after photodynamic treatment with a range of single light doses 0, 1, 2, 4, 8 or 12 J.cm-2 
(Fig. 4); b) 24 and 48 h after photodynamic treatment with single (S) or  fractionated 
light delivery regimes (FR1, FR6) (Fig. 6); c) inhibitor of GRP94 and HSP90 proteins 
geldanamycin (AXXORA, Nottingham, UK) was added 1 h prior to hypericin treatment 
(Fig. 18); d) inhibitor of p38 MAPK, SB202190 (Sigma-Aldrich Corporation, St. Louis, 
MO, USA),  was added 2 h prior photoactiovation of hypericin (Fig. 19) and then in 
both cases MTT assay was performed 24 h after photodynamic treatment with a single 
or fractionated light delivery. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (Sigma-Aldrich) assay was performed to evaluate the survival of 
cultured cells as previously reported (Mosmann 1983). The amount of dye extracted 
was quantified by absorbance measurements at 584 nm using FLUOstar Optima (BMG 
Labtechnologies GmbH, Offenburg, Germany) and expressed as a percentage of the dye 
extracted from untreated control. 
 
3.6 Cell cycle analysis 
For the DNA content determination, cells treated according to the standard 
protocol (Fig. 3A) were harvested 24 or 48 h after PDT and washed with phosphate-
buffered saline (PBS) and fixed with 70% ice cold ethanol at -20 ºC. Fixed cells were 
centrifuged, washed with PBS and stained with staining solution (5 mg/mL propidium 
iodide, 10 mg/mL RNase A and 10% Triton X-100 in PBS). Then samples were kept in 
dark conditions for 30 min and measured on a flow cytometer (FACS Calibur, Becton 
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Dickinson, San Diego, CA, USA). For each sample, 15 000 cells were evaluated and the 
sample flow rate during analysis did not exceed 200–300 cells per second. The data 
obtained were analyzed using the Cell Quest Pro software (Becton Dickinson). 
 
3.7 Colony-forming assay 
Cells were treated according to the standard protocol (Fig. 3A), then harvested 24 
h after single or fractionated light delivery and counted microscopically using a Bürker 
chamber. Equal cell numbers (500 cells per 60 mm Petri dish (TPP)) were seeded and 
cultivated under standard conditions for 7 days. Colonies were stained using coloured 
solution (40 mg methyl blue diluted in 50 ml 78% ethanol).  
 
3.8 Detection of phosphatidylserine externalization and cell membrane 
permeability 
 For a phosphatidylserine externalization and cell viability analysis, an annexin V-
FITC and propidium iodide (PI) double-staining kit (Bender MedSystems, Vienna, 
Austria) was used according to the manufacturer’s instructions. The cells were treated 
according to the standard protocol (Fig. 3), then adherent and floating cells were 
harvested together 0.5, 3 and 24 h after PDT and stained with annexin V-FITC in 
binding buffer for 10 min, washed, stained with PI for 5 min and analyzed using the 
FACSCalibur flow cytometer. Results were analyzed with CellQuest Pro software. The 
cell populations were differentiated as living (annexin V–/PI–), apoptotic (annexin 
V+/PI–), secondary necrotic (annexin V+/PI+) or necrotic (annexin V–/PI+) cells. The 
results are presented as a mean ± SD of three independent experiments. 
 
3.9 Production of ROS 
The cells were treated according to the standard protocol (Fig. 3), then harvested 
0.25, 0.5, 1, 6 h after a sub-lethal light dose or 0.5, 3, 24 h after single or fractionated 
light delivery, washed twice in phosphate-balanced salt solution (PBS), and 
resuspended in Hank's balanced salt solution (HBSS). Dihydrorhodamine-123 (DHR-
123, Fluka, Buchs, Switzerland) was added at a final concentration of 0.2 µM, samples 
were then incubated for 15 min at 37 °C in 5% CO2 atmosphere and subsequently kept 
on ice during analysis. Fluorescence was analyzed using a FACSCalibur flow cytometer 
in the FL-1channel. Forward and side scatters were used to gate the viable populations 
of cells. CellQuestPro software (Becton Dickinson) was used to quantify the intensity of 
DHR-123 fluorescence in the cells expressed as the ratio of DHR-123 fluorescence in 
the treated cells compared to fluorescence of untreated control cells. 
 
3.10 Hypericin content analysis 
The cells were treated according to the standard protocol (Fig. 3), then harvested 
0.25, 0.5, 1, 6 h after a sub-lethal light dose or 0.5, 3, 24 h after single or fractionated 
light delivery, washed twice in PBS, and resuspended in HBSS. Fluorescence of 
hypericin was analyzed using the FACSCalibur flow cytometer in the FL-2 channel (1 x 
104 cells per sample). CellQuestPro software was again used to quantify the intensity of 
hypericin fluorescence in the cells, expressed as the ratio of hypericin fluorescence in 
treated cells compared to the fluorescence of untreated control cells.  
 
3.11 Luciferase activity assay 
Luciferase reporter construct and stable cell transfection were executed as 
described previously (Hyzd'alova et al. 2008). Stable transfected HT-29 cells were 
treated according to the standard protocol (Fig. 3). Cells were rinsed with PBS 0, 0.5, 1, 
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3, 6 h after hypericin photo-activation with a sub-lethal light dose, and lysed with 400 µl 
of reagent (Luciferase Assay System; Promega Corp., Madison, WI, USA). Protein 
concentrations of the cell extracts were determined using detergent-compatible protein 
assay (BioRad Laboratories Inc., Hercules, CA, USA). One sample at a time was 
diluted in equal amount of proteins and 50 µl of extract was mixed with 50 µl of 
luciferase substrate and luminescence was measured immediately using the FLUOstar 
Optima. The luminescent signal of each sample was measured for the same period. 
 
3.12 Western blot analysis 
The cells were treated according to the standard protocol (Fig. 3), then harvested 1 
and 6 h after low light dose, 24 h after single or fractionated light delivery (Fig. 16) or 
24 h after light doses 0, 1, 2, 4, 8, or 12 J.cm-2. The cells were then washed twice in cold 
PBS and lysed in lysis buffer (100 mM Tris-HCl, pH 7.4, 1% SDS, 10% glycerol and 
protease inhibitor cocktail P2714 (Sigma-Aldrich Corporation, St. Louis, MO) for 10 
min on ice. The cell lysates were sonicated and centrifuged. Protein concentration was 
determined using detergent-compatible protein assay (BioRad Laboratories Inc.). 
Samples were diluted in equal amounts (30 - 50 µg proteins) with 0.01 % bromphenol 
blue and 1% 2-mercaptoethanol, then separated with SDS-polyacrylamide gel and 
transferred onto nitrocellulose membrane (Advantec, Tokyo, Japan) or PVDF 
membrane (Millipore, Bedford, MA, USA) in a transfer buffer containing 192 mM 
glycine, 25 mM Tris and 10 % methanol. The membrane was blocked in 5 % non-fat 
milk (or 5 % BSA) in TBS (20 mM Tris-HCl, pH=7.6; 150 mM NaCl; 0.05 % TWEEN 
20, pH=7.4) for 1 h at first and then the membrane blots were incubated 2 h at RT or 
overnight at 4 °C (depending on the particular antibody) with primary antibody: anti-
NF-κB p65 (sc-372), anti-NF-κB p50 and p105 (sc-8414), anti-IκB-α (sc-203), anti-
GRP94 (sc-1794), anti-clusterin (sc-6420), all from Santa Cruz Biotechnology, anti-
Mcl-1 (#4572 Cell Signalling), anti-HSP70 (MA3-006, Affinity BioReagents). After 30 
min washing in wash buffer, membranes were incubated with appropriate horseradish-
conjugated secondary antibody for 1 h at RT (AntiMouse IgG-HRP, NA931 (1:3000), 
AntiGoat IgG-HRP (1:20 000), AntiRabbit IgG-HRP (1:20 000) (Amersham 
Biosciences, Buckinghamshire, UK). Detection of antibody reactivity was performed 
using a chemiluminescence detection kit ECL+ (Amersham Biosciences) and visualized 
on X-ray films (Foma Slovakia, Skycov, Slovakia). Equal sample loading was verified 
by immunodetection of β-actin (A5441, Sigma-Aldrich).  
 
3.13   Statistical analysis 
Data were processed with GraphPadPrism (GraphPad Software Inc., San Diego, 
CA) and statistically analyzed using one-way ANOVA with Tukey’s multiple 
comparison test and are expressed as mean ± standard deviation (S. D.). Significance 
was evaluated at three levels; p < 0.05, p < 0.01 and p < 0.001. 
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4 RESULTS AND DISCUSSION 
 
The efficiency of PDT may be improved by modification of standard photodynamic 
protocol through light dose fractionating to several illuminations with dark pauses 
between light fractions (Ascencio et al. 2008, Babilas et al. 2003, de Bruijn et al. 1999, 
Pogue et al. 2008, Takahashi and Ohnishi 2009, Xiao et al. 2007). As it was mentioned 
before light fractionation is based on the premise of reoxygenation at the treated side 
during a dark pause and therefore higher ROS production improves the outcome of PDT 
(Curnow et al. 1999, Takahashi and Ohnishi 2009). Even though, such treatment 
doesn’t avoid troubles. Light fractionation may lead to resistance development under 
specific circumstances (Paba et al. 2001, Sackova et al. 2005, Varriale et. al 2002). The 
molecular mechanisms underlying resistance development to PDT with hypericin are 
not completely understood. We therefore would like to contribute to better 
understanding of these events at a cellular and sub-cellular level.    
    
4.1 Fractionated photodynamic treatment with hypericin doesn’t improve the 
outcome as compared with to single irradiation scheme. 
On the bases of our screening experiments provided by MTT assay were selected 
light doses as well as hypericin concentrations for further analysis. The most interesting 
results are depicted in Figure 4. Although MTT assay is considered to be a rapid 
colorimetric assay for cellular growth and survival suitable as an application to 
proliferation and cytotoxicity assay (Mosmann 1983). However we and others observed 
apparently increased proliferation over the control specifically in the case of analysis 
performed shortly after PDT (1 h); this increase has been interpreted as the consequence 
of enhanced mitochondrial metabolic activity rather than in cell proliferation or survival 
(Figure 4). A high light-dose mediated oxidative stress probably stimulated 
mitochondria oxidative metabolism that resulted in increased reduction of MTT to 
formazan by mitochondrial succinate dehydrogenase. MTT assay provides reliable 
information about cytotoxic effects of light doses over an extended timespan. The 
results revealed that a fluence rate of 1 J.cm-2 had no effect on cell survival. In this 
work, 
 
Figure 4. MTT assay of HT-29 cells 1, 6 and 24 h after hypericin (60 nM) mediated 
photodynamic treatment with single light doses 1, 2, 4, 8 and 12 J.cm-2. Results are expressed as 
percentage of/over the control. The results are the mean ± SD of three independent experiments 
presented as percentage of untreated control. Statistical significance is expressed as follows: 
light dose versus untreated control in a given time of analysis (+) on the significance level 
p<0.05 (+); p<0.001 (+ + +). (C) control cells. 
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work, this dose is thereafter considered as the “sub-lethal” dose, while, in opposition the 
fluence rate of 12 J.cm-2 is considered the fully lethal dose. Light doses between 2 and 4 
J.cm-2 are borderline and are considered as the threshold of an explicit photodynamic 
cytotoxic effect.  
When this research was initiated, our expectations were foreseeing an 
improvement of PDT upon fractionated irradiation. On the contrary, our preliminary 
results revealed non-significant or minor cytotoxic effects of various light irradiation 
schemes as compared to standard photodynamic protocol. The results (Table 1) indicate 
not only different cytotoxic effects of photodynamic treatment at the various light 
irradiation schemes but also the relevance of a dark-interval duration within a light 
fractionation. According to Robinson et al. (2003) a two-fold illumination with a 2 h 
dark interval using two equal doses (50 J.cm-2) delivered after topical ALA application 
on hairless mouse skin resulted in an increase in PDT response over that observed 
following a single illumination with 100 J.cm-2. 
 
Table 1. Cytotoxicity of hypericin after various light-irradiation schemes 
 
                                                                     Cytotoxicity (MTT assay 
Light dose (J.cm-2)      Dark pause (h)            evaluated 24 h after PDT) 
 
3 + 3 vs 6   1   NS* 
    6   NS   
6 + 6 vs 12   1   NS 
    6   NS 
1 + 11 vs 12   1   NS 
    6   P < 0.001 
1 vs 0 (control)  1   NS** 
 6                 NS*** 
* NS – not significant 
** 1 h after PDT 
*** 6 h after PDT 
 
However in our case, two equal light doses (3 + 3 J.cm-2) or (6 + 6 J.cm-2) 
separated with 1 or 6 h dark interval did not improve PDT response. They have also 
reported that if the first fraction was reduced to 5 J.cm-2 and if 95 J.cm-2 was delivered 
in the second fraction, the PDT response was significantly greater then when the two 
fractions are equal (Robinson et al 2003). However, when a light fractionation scheme 1 
+ 11 J.cm-2 was applied, we could not confirm such findings in our system. Moreover 
we observed even a decreased cytotoxic effect. Our present findings therefore agree 
more strictly with previous in vitro studies with hypericin on HEC1-B cells and U937 
cells, which reported that pre-sensitized cells become fully resistant to light doses that 
normally determine massive cellular apoptosis in experimental photodynamic therapy 
(Paba et al. 2001, Varriale et al. 2002). Relative to our results presented in Table 1, we 
have selected light irradiation scheme for further study in which the selected total dose  
(12 J.cm-2) was divided in two unequal doses, i.e. 1 J.cm-2 (sub-lethal) followed by 1 or 
6 hours later by the dose of 11 J.cm-2  (close to the fully lethal). This scheme (1 + 11 
J.cm-2) applied to HT-29 adenocarcinoma cells model in vitro, has been chosen as 
reference scheme in our experimental model for the study of events that promote 
resistance development to PDT. Therefore we compared the effects of single and 
fractionated light delivery regimes and continued with the study concerning the effects 
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of a sub-lethal light dose as well as the importance of dark-interval duration within a 
light fractionation and their participation on the resistance outcome. Although in vivo 
and in vitro experimental models are not easy to compare because the different order of 
complexity that determines sometimes totally different responses to PDT, we consider 
the knowledge of intracellular mechanisms of photo-resistance as a standpoint for 
further study aimed to the improvement of its use in cancer therapy.  
The comparison of the effects of hypericin treatment on tumour cell number (Fig. 
5) and metabolic activity evaluated by MTT assay (Fig. 6) after a single light-dose (12 
J.cm-2) with those obtained after fractionated light delivery (1 + 11 J.cm-2) revealed,  
except for viability, measurable differences when the irradiation was interrupted for 6 
aaaaa 
 
Figure 5. HT-29 cell numbers 24 h (a) and 48 h (b) after hypericin-mediated photodynamic 
treatment with both single (12 J.cm-2) or fractionated (1 + 11 J.cm-2) light delivery regime. 
Results are expressed as relative cell numbers related to untreated control groups. The results 
are the mean ± SD of three independent experiments. Statistical significance is expressed as 
follows: experimental groups versus control (+) and fractionated light delivery versus single 
light delivery (●) on the significance level p<0.05 (+ or ●); p<0.01 (++ or ●●); p<0.001 (+++ or 
●●●). (C) control cells, (S) single light dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with 
a 1 h (FR1) or 6 h (FR6) dark pause between the two light doses. 
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but not 1 hours. While fractionation with a shorter dark period induced the same 
cytotoxic effect in HT-29 tumor cells as a single-dose application, the effect of 
hypericin activated with light fractions separated by a dark interval of 6 h was reversed. 
Increased cell number (Fig. 5) and rise in metabolic activity evaluated by MTT assay 
indicate a sustained proliferation and mitochondrial function. This means that the 
behavior of cells was similar to that of the control. In contrast to earlier analysis (Fig. 
6a), the only significant change was observed in the metabolic activity of cells receiving 
60nM hypericin evaluated 48 h after light sensitization (Fig. 6b), which was 
significantly les as compared to that of the control. 
 
 
Figure 6. MTT assay of HT-29 cells 24 h (a) and 48 h (b) after hypericin-mediated 
photodynamic treatment with both single (12 J.cm-2) or fractionated (1 + 11 J.cm-2) light 
delivery regime. Results are expressed as percentage of control. The results are the mean ± SD 
of four independent experiments. Statistical significance is expressed as follows: experimental 
groups versus untreated control (+) and fractionated light delivery versus single light delivery 
(●) on the significance level p<0.05 (+ or ●); p<0.001 (+++ or ●●●). (C) control cells, (S) 
single light dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) 
dark pause between the two light doses. 
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4.2 Fractionated photodynamic treatment with a longer dark pause does not 
alter the original cell cycle regulation 
The results mentioned formerly were in agreement with cell cycle analysis 
outcome. Fractionation with a longer dark pause (FR6) induced increased proportion of 
cells in the G1 phase of cell cycle (Fig. 7) and a significant decrease in the percentage 
of G2 phase cells (to the control level) (Fig. 8a, b). Our results therefore indicate 
sustained proliferation and preservation of original cell cycle regulation. On the other 
hand, the percentage of cells in the G2 phase of cell cycle increased when cells were 
treated with hypericin photoactivated by single (S) or fractionated irradiation with a 
shorter dark pause (FR1). These findings are in line with those reporting interconnection 
of hypericin-induced photocytotoxicity with G2/M arrest in HT-29 (Sackova et al. 
2006). However, in contrast to our findings Varriale et al. (2002) reported that longer 
dark interval (20 h) between the first (2 J.cm-2) and the second (5 J.cm-2) exposure to 
light, resulted in accumulation of HEC1-B cells in G2/M phase. These differences in 
cell sensitivity and cell cycle regulation observed upon double irradiation cannot be 
easily understood. However, it is possible that different p53 status of HT-29 and HEC1-
B cells may be implicated. Considering reduced p21 and p53 expression at longer dark 
pause in HEC1-B cells exposed to light twice (Varriale et al. 2002) as well as mutation 
in p53 of the colon adenocarcinoma cell line HT-29 (Barberi-Heyob et al. 2004, Zacal 
et al. 2005). Mutations of p53 generally results in thei inactivation of its tumour-
suppressor functions and is known to be linked to p53 overexpression, probably due to 
the production of a more stable form (Rodrigues et al. 1990) and its consequent 
accumulation may play a key role in the photo-sensitivity of HT-29 in PDT with 
hypericin (Mikes et al. 2007). There is also different ratio between first and second light 
dose in our experiment (1:11 vs. 2:5), which might be, together with different time 
schedule of light delivery, responsible for the differences. 
 
 
 
Figure 7. Proportion of HT-29 cells in G1 phase 48 h after hypericin-mediated photodynamic 
treatment with both single (12 J.cm-2) and fractionated (1 + 11 J.cm-2) light delivery regime. The 
results are the mean ± SD of two independent experiments. Statistical significance is expressed 
as follows: experimental groups versus untreated control (+) and fractionated light delivery 
versus single light delivery (●) on the significance level p<0.01 (++ or ●●). (C) control cells, 
(S) single light dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) 
dark pause between the two light doses. 
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Figure 8. Proportion of HT-29 cells in G2 phase 24 h (a) and 48 h (b) after hypericin-
mediated photodynamic treatment with both single (12 J.cm-2) and fractionated (1 + 11 
J.cm-2) light delivery regime. The results are the mean ± SD of two independent 
experiments. Statistical significance is expressed as follows: experimental groups versus 
untreated control (+) and fractionated light delivery versus single light delivery (●) on 
the significance level p<0.05 (+ or ●); p<0.01 (++); p<0.001 (+++ or ●●●). (C) control 
cells, (S) single light dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h 
(FR1) or 6 h (FR6) dark pause between the two light doses. 
 
4.3 Longer dark pause between two unequal light doses repressed cell death in 
HT-29 cell after hypericin-mediated PDT 
Only one concentration of hypericin (60 nM) was selected for further analysis 
aimed to better understanding of processes underlying reduced photocytotoxic effect of 
overextended fractionated regime. When the phosphatidylserine externalization and cell 
permeability analysis were performed, we obtained results in agreement with all the 
above findings. In summary, light fractionation with a longer dark pause between two 
unequal light doses (FR6) reduced hypericin-mediated photocytotoxic effect on HT-29 
adenocarcinoma cells in vitro (Sackova et al. 2005). In contrary to earlier analysis (Fig. 
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9a), significantly higher survival of FR6 group was accompanied by regress in ratio of 
apoptotic and secondary necrotic cells that appeared 24 h after PDT (Fig. 9b). As it 
might be noticed, PDT effects of single and fractionated light delivery when the dark 
pause is short are very similar. So far all reported results on the changes in cellular 
parameters were concerned with the effects of three different light delivery regimes. We 
have demonstrated increased viability and cell metabolic activity. Such changes were 
accompanied to increased cell proportion in G1 and decrease in G2 cell cycle phase 
while 
 
Figure 9. Detection of phosphatidilserine externalization and membrane permeability of HT-29 
cells by dual annexin V/PI staining 3 h (a) and 24 h (b) after single (12 J. cm-2) or fractionated 
(1 + 11 J.cm-2) light dose. Cells were harvested and evaluated 3 or 24 h after PDT. The results 
are the mean ± SD of three independent experiments presented as a percentage to control. 
Statistical significance is expressed as follows: experimental groups versus untreated control 
(+); fractionated light delivery versus single light delivery (●); fractionated light delivery with a 
6 h versus 1 h dark pause () on the significance level p<0.05 (+ or ● or ); p<0.01 (++ or 
●●); p<0.001 (+++). (C) control cells, (D) hypericin under dark conditions, (S) single light dose 
12 J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) dark pause between 
the two light doses. 
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while death in HT-29 cells, irradiated twice with a longer dark pause between two 
unequal light doses, was repressed. It appears that cell pre-sensitization and extension of 
the dark pause play an important role in the photo-resistance. While we have 
demonstrated significant reduction in PDT efficacy of fractionation along with 
prolonged dark pause, the adverse effect has been observed in the skin of the hairless 
mouse. In this case the dark interval cannot be reduced below 2 h without a significant 
reduction in Protoporphyrin IX-PDT efficacy (de Bruijn et al. 1999). These 
discrepancies still await explanation. On the other hand there are numerous reports in 
the literature of successful light fractionation regimes, varying the photosensitizer and 
with single or multiple breaks in illumination that can last from a few seconds to days 
(Anholt and Moan 1992, Hua et al. 1995, Mlkvy et al. 1996, Pe et al. 1994, van der 
Veen et al. 1994). However only very few researchers have explored the biological 
processes that are activated during the dark interval (Babilas et al. 2003, Huygens et al. 
2005, Varriale et al. 2002) therefore we focused our attention to events occurring after 
sub-lethal light dose and before the second exposure to light.    
 
4.4 Longer dark pause between two unequal light doses enhanced clonogenic 
potential of HT-29 cells after PDT with hypericin  
We examined impact of a sub-lethal light dose and duration of a dark pause on 
HT-29 cells proliferation. In comparison with both controls, the effect all of three 
different photodynamic irradiation schedules resulted in reduced colony-forming 
activity. As is depicted in Figure 10, single (S) or fractionated light delivery (FR1) with 
1 h dark pause, demonstrated very low colony-forming activity. Longer pause 
continuing for 6 h (FR6) proved much higher ability to create visible colonies, even 
when compared to FR1 group. As might be seen, hypericin under dark conditions (D) 
did not affect clonogenic potential of HT-29 cells. Sub-lethal light dose resulted not 
only in increased amount of viable cells, but resistance manifested also by increased 
clonogenic activity when prolonged dark pause was applied. These findings rose a 
query what events underlie resistance to protracted fractionated light delivery regime.     
Low intensity of stress in general may accelerate stress-inducible pathways and cell 
signaling that result in defence mechanisms in terms of survival. Since low-dose cell 
survival is described mainly in context of radiation- or heat-induced adaptive cell 
response (Shadley et al. 1987, Yoshida et al. 1993), we presume that even sub-lethal 
light dose in PDT may trigger similar biological events as well. When we look for the 
answers in the reports discussing adaptive response to ionizing radiation, we can find 
connections. For example similarly as in our case augmentation of colony-forming 
ability of myeloid leukemia cells was observed in vitro after low-dose irradiation and 
showed thermo-resistance 1 h after low-dose pre-irradiation and also showed radiation-
reistance 4 h after irradiation. Induction of heat shock protein HSP70 was not detectable 
by Western blot therefore it seems that some proteins other than HSP70 were concerned 
with the augmentation of colony-forming ability and thermo- and radiation-resistance 
(Ibuki et al. 1998). Takahashi and Ohnishi (2009) have shown that NO radicals are an 
initiator of radiation- and heat-resistance induced by low dose pre-irradiation. They 
have also demonstarted association with p53 functioning (Takahashi and Ohnishi 2009). 
Other authors reported that conditioning doses (0.25 Gy or 0.5 Gy) and subsequent 
exposure to 8 Gy caused significant increase in the survival of mice compared to 
irradiated control (Tiku and Kale 2004). Adaptive response to ionizing radiation 
involves DNA repair mechanisms and induced proteins may enhance this repair (Wolff 
1996). However according to Wouters and Skarsgard (1997) the radiation-induced 
increase in radiation-resistance observed in HT-29 cell line is distinct from the adaptive 
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response. Concidering that hypericin not show genotoxicity (Diwu and  Lown 1994, 
Miadokova et al. 2009) and cell killing mechanism after PDT is not at the chromosom 
level (Halkiotis et al. 1999), therefore resistance to hypericin mediated-PDT involves 
other mechanisms then resistance to radiation, for example antioxidant adaptive 
response. Activation of antioxidant adaptive response to ALA-mediated PDT was 
demonstrated in lymphocytes (Casas et al. 2002).  
 
 
 
Figure 10. Colony-forming assay of HT-29 cells. Cells were harvested 24 h after hypericin 
photoactivation. The results are presented as a representative photo of three independent 
experiments. (C) control cells, (D) hypericin under dark conditions, (S) single light dose 12 
J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) dark pause between the 
two light doses. 
 
4.5 Duration of a dark pause affects PDT-mediated ROS level induced by second 
light dose 
Detection of intracellular levels of ROS revealed shortly after the first 
illumination steady remission within first hour, although 6 h after PDT, the ROS level 
was found to be raised significantly. Dark conditions did not affect ROS level 
significantly when compared to untreated control (Fig. 11). The second elevation of 
ROS level observed 6 h after the first illumination might be secondary consequence of 
the ROS induced by PDT, a phenomenon known as “(ROS-induced)-ROS release” 
(RIRR). This fact demonstrated in mitochondria of cardiac myocytes resulted from 
MPT induction was considered as a general mechanism independent of the signaling 
ROS source (Zorov et al. 2000). The study of oxidative metabolism changes after 
different light delivery regimes revealed that resistant group (FR6) kept shortly after 
PDT, steady ROS level achieved already tightly before the lethal dose application, 
whereas further delivery regimes (S, FR1) resulted in markedly elevated ROS 
production (Fig. 12). We have observed that illumination of cells at the time of a basal 
ROS concentration (Fig. 11; 1 J.cm-2 1 h) resulted in its significant increasing (Fig. 12; 
FR1 0.5 h) whereas the upraised ROS level shortly before the second illumination (Fig. 
11; 1 J.cm-2 6 h) did not rose dramatically after PDT (Fig. 12; FR6 0.5 h). Decreased 
ROS production and cytotoxicity after fractionated PDT was observed also by 
Oberdanner et al. (2005). They suggested that the dark intervals during irradiation 
allowed the glutathione reductase to regenerate reduced glutathione (GSH), thereby 
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cells were less susceptible to ROS produced by PDT compared with continuous 
irradiation. Although we did not analyze glutathione involvement, we predict that it 
might play a role in management of ROS level in cells irradiated by second light dose 
after 6 h long dark pause. Taking into concideration that glutathione reductase was 
found to recycle GSH within 1 minute of dark interval (Oberdanner et al 2005), it could 
be difficult to explain increase of ROS 6 h after sub-lethal PDT if glutathione reductase 
is implicated. Though, later analyses (3 or 24 h) showed barely induced levels in all 
studied experimental groups (Fig. 12). It follows that pre-sensitization and the timing of 
a second 
 
 
Figure 11. The effect of a sub-lethal dose 1 J.cm-2 on ROS production in HT-29 cells. Cells 
were harvested and evaluated 0.25, 0.5, 1 and 6 h after hypericin photoactivation. The results 
are the mean ± SD of three independent experiments presented as a ratio to untreated control. 
Statistical significance is expressed as follows: photoactivated (1 J.cm-2) versus not 
photoactivated (D) (+) on the significance level p<0.01 (++); p<0.001 (+++). (D) hypericin 
under dark conditions. 
 
 
 
Figure 12. The effect of a single (12 J. cm-2) and fractionated (1 + 11 J.cm-2) light delivery on 
ROS production in HT-29 cells. Cells were harvested and evaluated 0.5, 3 and 24 h after 
hypericin-mediated photodynamic treatment.  The results are the mean ± SD of three 
independent experiments presented as a ratio to control. Statistical significance is expressed as 
follows: experimental groups versus untreated control (+); fractionated light delivery versus 
single light delivery (●); fractionated light delivery with a 6 h versus 1 h dark pause () on the 
significance level p<0.05 (●); p<0.01 (++); p<0.001 (+++ or ●●● or ). (D) hypericin under 
dark conditions, (S) single light dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h 
(FR1) or 6 h (FR6) dark pause between the two light doses.  
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a second illumination could decrease photocytotoxic effect of PDT mediated through 
restricted ROS production. According to Huygens et al. (2005), acutely induced oxygen 
depletion rather than a lack of photosensitizer rendered tumour cells less sensitive to the 
photodynamic action of hypericin. They have reported that failure in hypericin-
mediated PDT with spheroids can only by overcome with hyperoxygenation (Huygens 
et al 2005). However, sub-lethal light dose is not able to induce extensive hypoxia, 
further 6 h dark pause is sufficient for re-oxygenation of treated cells. Therefore, we 
assume that restricted ROS production is not due to oxygen depletion mediated by a 
sub-lethal light dose during a dark pause. Loss of the intracellular hypericin during a 
dark pause could be another factor contributing to decreased PDT effect of protracted 
fractionated light delivery. 
 
4.6 Pre-sensitization did not affect physiological elimination of hypericin, 
however light administration regime affects hypericin elimination after lethal 
dose 
Another possible explanation of decreased ROS production could be reduction in 
intracellular concentration of hypericin during a dark interval. Detection of hypericin 
intracellular levels after first sub-lethal light dose (Fig. 13) proved that there was a 
steady decrease, which was found to be significant 6 h after PDT. This drop was in 
compliance with a physiological elimination of hypericin, similar to hypericin-treated 
cells under dark conditions (D). Although, extended time of a dark interval reduced 
hypericin content, indeed 80% of hypericin content measured at 1 h dark pause was 
available and susceptible to second photoactivation. Decreased hypericin content to 
90% of the original value during 3 h dark pause was reported by Paba et al. (2001) in 
human histiocytic lymphoma U937 cells and 20 h-dark interval reduced hypericin 
content to less than 75% of the hypericin present at 3 h in human endometrial carcinoma 
HEC1-B cells (Varriale et al. 2002). Resistance to second light dose occurred in all 
cases, although hypericin content was relatively high at time of the second illumination. 
Therefore in our opinion reduced hypericin content could result in decreased ROS 
production and thus partially contribute to decreased photocytotoxic effect of 
fractionated PDT. 
 
 
Figure 13. Determination of hypericin intracellular levels in HT-29 cells within a dark pause 
after first sub-lethal dose 1 J.cm-2. Cells were harvested and evaluated 0.25, 0.5, 1 and 6 h after 
hypericin photoactivation. The results are the means ± SD of three independent experiments 
presented as a ratio to control. Statistical significance is expressed as follows: photoactivated (1 
J.cm-2) or not photoactivated (D) hypericin (0.5, 1 and 6 h) versus (0.25 h) (+); (6 h) versus (1 h) 
(●) on the significance level p<0.01 (●●); p<0.001 (+++). (D) hypericin under dark conditions. 
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Though, administration of single lethal light dose decelerated hypericin 
elimination by cells significantly when applied without pre-sensitization (Fig. 14; S) on 
the other hand, this effect was partially or completely abolished in pre-sensitized groups 
drug transport function might increase hypericin content in HT-29 cells. Hypericin was 
also found to increase activity and expression of drug efflux transporters in HT-29 cells 
when applied by itself, without light activation. It is therefore liable that lethal light 
dose induced massive destruction and inhibited efflux pumps alongs, thus slowed down 
rate of hypericin efflux from the cells and prolonged retention of hypericin in the cells 
in contrary with not photoactivated hypericin. Hypericin is more photostable than most 
sensitizers used in PDT, including mTHPC and Photofrin, the photobleaching seems to 
be not oxygen dependent, and singlet oxygen probably plays insignificant role 
(Uzdensky et al. 2002). These findings together with prolonged retention of 
photosensitized hypericin in the treated tissue may predetermine hypericin as a suitable 
photosensitizer for a multiple high-dose fractionation with short dark intervals between 
light fractions. In summary, a drop of intracellular hypericin content is influenced by a 
length of a dark pause and photodynamic light regime. Even though, changes of 
hypericin content before second light dose application (Fig. 13) may partially contribute 
to lower ROS production and thus decreased photocytotoxic effect of fractionated PDT. 
On the bases of following findings, it seems that different molecular events participate 
on resistance development in HT-29 cells in vitro.  
 
 
 
Figure 14. Determination of hypericin intracellular levels in HT-29 cells illuminated with a 
single (12 J. cm-2) and fractionated (1 + 11 J.cm-2) light delivery. Cells were harvested and 
evaluated 0.5, 3 and 24 h after PDT. The results are the means ± SD of three independent 
experiments presented as a ratio to control. Statistical significance is expressed as follows: 
single or fractionated light delivery versus not photoactivated (D) hypericin (+); not 
photoactivated hypericin (3 h or 24 h) versus ( 0.5 h) () on the significance level p<0.05 (+); 
p<0.01 (++); p<0.001 (). (PDT) photodynamic treatment, (D) hypericin under dark 
conditions, (S) single light dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) 
or 6 h (FR6) dark pause between the two light doses. 
 
4.7 Sub-lethal photodynamic treatment induced NF-κB activity 
It is well known that low levels of ROS may function as second messengers 
activating pathways that protect cells against apoptotic stimuli (Chandra et al. 2000). 
Since NF-κB is often considered to be a ROS-responsive transcription factor (Chandra 
et al. 2000, Janssen-Heininger et al. 2000) also shown to be implicated in a cancer cell 
responses to photodynamic therapy (Legrand-Poels et al. 1995), we employed HT-29 
cells transfected with a nuclear transcription factor (NF-κB) luciferase reporter 
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construct in our experiments. Induction of NF-κB activity after sub-lethal dose of 1 
J.cm-2 was verified in stably transfected HT-29 cells (clone #3 and clone #93) by 
luciferase reporter activity executed 0, 0.5, 1, 3 and 6 h after PDT (Fig. 15a, b). Both 
tested clones indicated insignificant changes within first hour, however later on, the NF-
κB activity was identically induced 3 and 6 h after PDT in both models. Significantly 
increased luciferase activity in a later time after sub-lethal dose indicate that pre-
sensitized cells prepared themselves during a longer dark period by provoking NF-κB 
activity and timing of the second light dose before or after NF-κB activation could be 
crucial for the fate of cancer cell. Since NF-κB is known as redox-regulated protein 
coupled with cell proliferation, transformation, and tumour development (Legrand-
Poels et al. 1995), our results indicate that pre-sensitized cells activated NF-κB 
transcription activity that resulted in resistance. Independently of us the same finding 
has been reported by Chen et al. (2009) who have demonstrated that low level laser 
therapy (LLLT) not only enhanced mitochondrial respiration, but also activated the 
redox-sensitive 
 
Figure 15. NF-κB binding activity (expressed as a relative luciferase activity) of two HT-29 
clones #3 (a) and #93 (b) with pBIIX-LUC construct after treatment with  sub-lethal dose 1 
J.cm-2. Cells were lysed 0, 0.25, 0.5, 1, 3 and 6 h after PDT. The results are the mean ± SD of 
three independent experiments presented as a ratio to untreated control. Statistical significance 
is expressed as follows: sub-lethal light dose versus untreated control (+) on the significance 
level p<0.01 (++). (C) control cells. 
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redox-sensitive transcription factor NF-κB by generating ROS as signalling molecules 
in embryonic fibroblasts of transgenic NF-κB luciferase reporter mice. Even significant 
activation of NF-κB has been observed for fluencies higher than 0.003 J.cm-2 (Chen et 
al. 2009). Although low-dose photodynamic effect differs from photobiomodulatory 
effect of low level laser therapy by the using of photosensitizing drug, both approaches 
lead to low-level ROS-mediated activation of NF-κB, eventually influencing long-term 
cell behaviour such as proliferation and survival. Taking into consideration published 
reports we have demonstrated for the first time possible implication of NF-κB in photo-
resistance to fractionated PDT. Although the biological effects of low doses were 
described mainly in context of radiation- or heat-induced adaptive cell response 
(Shadley et al. 1987, Yoshida et al. 1993), we have shown that even low light doses 
make cells less sensitive to second light exposure. It was suggested that other stress 
stimuli may induce NF-κB activity through the ROS signalling. For example induction 
of NF-κB was shown after low-dose ionizing radiation that involved a reactive oxygen 
intermediate signalling pathway (Mohan and Meltz 1994). Lower doses of ionizing 
radiation, 0.25-2.0 Gy, were capable of inducing expression of NF-κB in human 
lymphoblastoid cells (Prasad et al. 1994). It follows that pro-survival pathway initiated 
by NF-κB seems to be responsible not only for the radiation-adaptive response in cells 
but also photo-adaptive cells response that resulted in resistance to second light 
exposure. Therefore it is liable that any exposure of treated site to light prior to regular 
treatment could affect efficiency of photodynamic therapy and targeted inhibition of 
NF-κB pathway may prevent resistance to therapy. 
 
4.8 Even sub-lethal light dose increased whole protein expression that altered the 
timing of a second photodynamic treatment  
Expressions of NF-κB p65, p50 and p105, Mcl-1, IκB-α, HSP70, GRP94 and 
clusterin-α (Fig. 16) were detected 1 and 6 h after the first sub-lethal light dose (SLD; 1 
J.cm-2) or 24 h after administration of a single lethal light dose (S, 12 J.cm-2) and two 
unequal doses (1+11 J.cm-2) separated by 1 or 6 h of a dark pause (FR1 or FR6). Apart 
from activation of NF-κB transcription activity our hypothesis concerning implication 
of NF-κB is also supported by increased levels of proteins whose genes are under its 
transcription control (increased level of NF-κB subunits p65, p50 and a precursor form 
of p50; p150, IκB-α and anti-apoptotic Mcl-1 protein detected 6 h after sub-lethal light 
dose). Even though phosphorylation and degradation of IκB is an important step for NF-
κB releasing from complex with IκB, translocation from cytoplasm to nucleus and 
binding to DNA (Jobin et al. 1997, Wang et al. 2000), in our experimental model NF-
κB activation has occurred without degradation of IκB. Therefore our results are in 
agreement with a study reporting altered regulation of IκB-α degradation and activation 
of NF-κB activity which can occur independently of IκB degradation in human colonic 
epithelial cells HT-29 (Jobin et al. 1997, Wang et al. 2000).  
Similarly, induction of heat shock protein HSP70, occurrence of GRP94 
multimers and elevation of clusterin-α already 1 h after hypericin activation confirmed 
onset of oxidative stress response in pre-sensitized cells. Analysis 24 h after lethal light 
doses (S, FR1, FR6) revealed interesting differences in levels of HSP70 and especially 
in GRP94 multimerization and clusterin-α expression (Fig. 16). Whereas single lethal 
light dose administration (S) and FR1 group demonstrated similar pattern, the 
fractionated administration separated by a 6 h dark pause showed significantly 
abolished clusterin-α level as well as suppressed occurrence of HSP70 and GRP94 
multimers and slightly elevated IκB-α together with p50 and p65 subunits of NF-κB. 
We have also shown dose dependent increased expression of GRP94 accompanied with 
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a dose dependent formation of high molecular GRP94 multimers. Although, homotypic 
oligomerization of GPR94 protein as well as formation of high molecular multimers 
were described in a connection with bis-ANS and heat shock induced stress 
(Wassenberg et al. 2000), we presume that photodynamic therapy with hypericin may 
have a similar effect to GRP94 in a light dose- and photodynamic protocol-dependent 
manner. Our assumption supports also gradually increased amount of GRP94 multimers 
induced by the scale of light doses from 1 to 12 J.cm-2 as well as marked expression of 
clusterin-α and HSP70 (Fig. 17). These results are in conformity with MTT assay (Fig. 
4) where 4 J.cm-2 could be regarded as threshold light dose that cause oxidative stress. 
This resulted in decreased metabolic activity and increased production of GRP94 
multimers and clusterin-α. Since GRP94 protein is localized exclusively in endoplasmic 
reticulum, it indicates the role of ER in stress response to hypericin-mediated PDT. Our 
work describes for the first time multimerisation of GRP94 in a connection with PDT-
mediated stress response.  
Another protein related to ER is clusterin-α. Oxidative stress induced by sub-
lethal light dose increased level of ~40 kDa clusterin subunit whereas a lethal light dose 
(Fig. 16; S, FR1) significantly altered expression of clusterin towards higher molecular 
forms of clusterin-α indicating the involvement of clusterin in extensive defence stress 
response, evidently reduced in resistant group. In summary, we have shown altered 
expression of proteins in a light dose dependent manner and depending on the light 
delivery regime of photodynamic protocol.  
 
 
 
Figure 16. Western blot analysis of Mcl-1, NF-κB p65, p50 and p105, IκB-α, HSP70, GRP94, 
clusterin-α and β-actin proteins 1 or 6 h after hypericin photoactivation with a sub-lethal dose (1 
J.cm-2) or 24 h after single (12 J. cm-2) and fractionated (1 + 11 J.cm-2) light deliveries 
application. The results are presented as a representative photo of three independent 
experiments. (C) control cells, (D) hypericin under dark conditions, (SLD) sub-lethal light dose 
1 J.cm-2 (S) single light delivery 12 J.cm-2, fractionated light delivery 1+11 J.cm-2 with a 1 h 
(FR1) or 6 h (FR6) dark pause between the two light doses. 
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Figure 17. Western blot analysis of GRP94, HSP70, clusterin-α and β-actin proteins 24 h after 
hypericin photoactivation with 1, 2, 4, 8 or 12 J.cm-2. The results are presented as a 
representative photo of three independent experiments. (C) control cells, (D) hypericin under 
dark conditions. 
 
The inhibition of HSP90 protein family as well as its member GRP94 did not 
confirme any important role in the resistance to fractionated light delivery with 6 h-dark 
pause between the two unequal light doses even though higher concentration of 
geldanamycin was applied (Fig. 18). The results of Western blot analysis (Fig. 16) and 
of HSP90 inhibition complement one another. Similarly as in the case of dark 
conditions, geldanamycin demonstrated the same effect on resistant group (FR6) (Fig. 
18). However, the implication of HSP90 proteins manifested both single (S) and 
fractionated light delivery regime with a 1 h dark pause (FR1) when higher 
concentration of geldanamycin was applied. It follows that although HSP90 proteins as 
f4 
 
 
Figure 18. The effect of GRP94 and HSP90 proteins inhibition by geldanamycin on survival of 
HT-29 cells 24 h after hypericin mediated photodynamic treatment with a single (12 J. cm-2) and 
fractionated (1 + 11 J.cm-2) light deliveries. The results are the mean ± SD of three independent 
experiments presented as percentage of untreated control. Statistical significance is expressed as 
follows: monotherapies versus untreated control (+); combination therapy versus monotherapy 
with geldanamycin (*); combination therapy versus monotherapy with hypericin (○) on the 
significance level p<0.05 (+ or * or ○); p<0.01 (++ or **); p<0.001 (+++ or *** or ○○○). (H) 
hypericin, (G) geldanamycin, (C) control cells, (D) hypericin under dark conditions, (S) single 
light dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) dark 
pause between the two light doses.  
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well as GRP94 assist to overcome overscaled stress conditions and the absence of 
HSP90 or GRP94 functions intensified cell damage, doesn’t play role in resistance to 
fractionated PDT. 
 
4.9 Inhibition of p38 MAPK did not enhanced effect of hypericin-mediated PDT   
Inhibition of p38 mitogen-activated protein kinases (MAPK) slightly decreased 
survival of cells irradiated with single or fractionated light deliveries, however not 
significantly in comparison with monotherapies with hypericin (Fig. 19). We noticed 
that changes in cell survival of inhibited cells were manifested by cytotoxic effect of 
hypericin itself. Inhibition of p38 MAPK did not abolished resistance of pre-sensitized 
cells to the second lethal light dose and p38 MAPK inhibition remained the same trend 
of hypericin-mediated photocytotoxic effect for all light delivery regimes. Contrary to 
our results Chan et al. (2009) have reported enhanced cell death induced with hypericin-
mediated PDT by the chemical inhibition of p38 MAPKs in HK-1 nasopharyngeal 
carcinoma (NPC) cells. It was also shown that PDT activated p38 MAPKs through the 
production of singlet oxygen (Chan et al. 2009). Other authors reported that hypericin-
mediated PDT of cancer cells also promoted a sustained activation of the p38 MAPK 
cascade, which resulted in the stabilization of the cyclooxygenase-2 (COX-2) transcript 
and in a rapid increase in COX-2 protein expression levels (Hendrickx et al. 2003). In 
spite of the evidences about p38 MAPK activation with PDT, inhibition of p38 MAPK 
did not enhanced hypericin-mediated photodynamic effect in our experimental model. 
On the other side, since pretreatment of HT-29 cells with rofecoxib and SC-560, 
selective inhibitors of COX-2 and COX-1, attenuated the impact of hypericin-mediated 
PDT in a time-dependent manner (Kleban et al. 2006) it could indicate that p38 MAPK 
– COX-2 is not crucial survival pathway for HT-29 cells. 
 
 
 
Figure 19. The effect of p38 MAPK inhibitor SB202190 on survival of HT-29 cells 24 h after 
hypericin mediated photodynamic treatment with a single (12 J.cm-2) or fractionated (1 + 11 
J.cm-2) light deliveries. The results are the mean ± SD of three independent experiments 
presented as percentage of untreated control. Statistical significance is expressed as follows: 
monotherapy versus untreated control (+); combined therapy versus monotherapy with 
SB202190 (*); on the significance level p<0.05 (+); p<0.01 (**); p<0.001 (+++ or ***). (H) 
hypericin, (SB) p38 MAPK inhibitor SB202190, (C) control cells, (D) hypericin under dark 
conditions, (S) single light dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) 
or 6 h (FR6) dark pause between the two light doses. 
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5 CONCLUSIONS 
 
Our research focused on the study of different effects of single and fractionated light 
delivery regimes in photodynamic therapy with hypericin on HT-29 adenocarcinoma 
cells in vitro revealed following findings: 
 
- two-fold illumination scheme with equal or unequal light doses doesn’t enhance 
cytotoxic effect of photodynamic therapy with hypericin in HT-29 adenocarcinoma 
cells 
 
- hypericn-mediated photocytotoxic effect on HT-29 cells is reduced by light 
fractionation with a longer dark pause between two unequal light doses and is light 
dose- and photodynamic protocol-dependent 
 
- a sub-lethal light dose alters ROS levels, protein expression and makes cells 
resistant to the effect of second illumination depending on its timing 
 
- duration of a dark pause significantly decreases hypericin content that may result in 
decreased ROS production after second illumination and thus partially contribute to 
decreased cytotoxic effect of fractionated PDT 
 
- possible implication of NF-κB in photo-resistance of HT-29 adenocarcinoma cells 
to fractionated delivery with a longer dark pause between two unequal light doses 
 
- the role of p38 MAPK in resistance to fractionated PDT with hypericin is 
insignificant in our experimental model 
 
- since any exposure of cancer cells to light prior to proper therapy could make them 
less sensitive to photodynamic treatment with hypericin, this finding could be useful 
in practice and together with targeted inhibition of NF-κB pathway could prevent 
resistance to photodynamic therapy 
 
- although two-fold light fractionation with hypericin is not suitable therapeutic 
approach we assume that a high photo-stability and prolonged retention of hypericin 
in the light-treated cells may indicate its successful application in a high-dose multi-
fraction PDT with dark intervals reduced bellow 1 h 
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ABSTRACT
The present study demonstrates the in vitro effect of hypericin-
mediated PDT with fractionated light delivery. Cells were
photosensitized with unequal light fractions separated by dark
intervals (1 or 6 h). We compared the changes in viability, cell
number, survival, apoptosis and cell cycle on HT-29 cells
irradiated with a single light dose (12 J/cm2) to the fractionated
light delivery (1 1 11 J/cm2) 24 and 48 h after photodynamic
treatment. We found that a fractionated light regime with
a longer dark period resulted in a decrease of hypericin
cytotoxicity. Both cell number and survival were higher after
light sensitization with a 6-h dark interval. DNA fragmentation
occurred after a single light-dose application, but in contrast
no apoptotic DNA formation was detected with a 6-h dark
pause. After fractionation the percentage of cells in the G1
phase of the cell cycle was increased, while the proportion of
cells in the G2 phase decreased as compared to a single light-
dose application, i.e. both percentage of cells in the G1 and G2
phase of the cell cycle were near control levels. We presume
that the longer dark interval after the irradiation of cells by
first light dose makes them resistant to the effect of the second
illumination. These findings confirm that the light application
scheme together with other photodynamic protocol compo-
nents is crucial for the photocytotoxicity of hypericin.
INTRODUCTION
Photodynamic therapy (PDT) is a cancer treatment mode based on
the light activation of a photosensitizer preferentially localized in
tumor tissue with subsequent reactive oxygen species production
that causes photochemically induced cell death. The antitumoral
effect of PDT depends on the photodynamic protocol used.
Responses to photodynamic treatment depend on the photosensi-
tizer used, the illumination conditions, the oxygenation status of
the tissue and the type of cells involved (1).
Recently, modiﬁcations in light illumination scheme have been
introduced on the standard photodynamic protocol (single-dose
photosensitizer, single-dose light) to maximize the therapeutic
effect of PDT, for example by reducing the ﬂuence rate to improve
oxygenation (2–4) or by fractionated drug administration (5–7).
Light fractionation is a relatively new approach to light delivery
in which the photosensitizer is exposed to light disrupted at
a particular point for a period of darkness to increase the efﬁcacy of
photodynamic therapy in tumor destruction (8–10). A number of
animal studies have demonstrated that the response to PDT after
systemic ALA administration can be improved by the use of light
fractionation with either a short-term (2, 3, 9) or a long-term
interval (11). Enhanced photodynamic effects on tumor cell killing
using fractionated laser light have been described (12). A
fractionated illumination scheme in which a cumulative ﬂuence
of 100 J/cm2 was delivered in two equal light fractions separated
by a dark interval of 2 h considerably increased the efﬁcacy of
5-aminolevulinic acid (ALA)-PDT (13). It has been hypothesized
that splitting the light dose into fractions by interrupting
illumination for a certain time allows the treatment site to be
reoxygenated, which results in increased generation of singlet
oxygen and thus a greater PDT effect (14–16). In contrast, less or
no effect was achieved by dividing the illumination in photody-
namic therapy with mTHPC on a normal colon and a transplantable
tumor in rats (17). Babilas et al. (18) found fractionated PDT with
ALA to be unsuccessful in clinical PDT.
Photoactivation of hypericin with low doses of light-induced
apparent photoresistance in human histiocytic lymphoma U937
cells (19). Low-energy pre-sensitization caused enhanced photo-
tolerance of hypericin-loaded HEC1-B cells (20). Photodynamic
treatment with fractionated light led to decreased production of
reactive oxygen species and cytotoxicity in vitro via regeneration
of glutathione (21).
In the present study, we demonstrate the in vitro effect of
hypericin-mediated photodynamic therapy (PDT) with fractionated
light delivery. We compared the effects of hypericin treatment on
tumor cell viability, cell number, survival, apoptosis and cell cycle
in a HT-29 cell line irradiated with a single light dose (12 J/cm2)
with its effects after fractionated light delivery (1þ11 J/cm2 with 1
or 6-h dark interval).
MATERIALS AND METHODS
Cell culture. A human colon adenocarcinoma cell line HT-29 (ATCC,
Rockville, MD) was cultured in RPMI-1640 medium supplemented with
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TBE, Tris-Borat-EDTA.
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10% fetal calf serum (FCS) and antibiotics (penicillin 100 U/mL,
streptomycin 100 lg/mL and amphotericin 25 lg/mL; Invitrogen Co.,
Carlsbad, CA). For determination of survival, 2 3 104 cells/well were
seeded into 96 wells, and for evaluation of hypericin content, tumor cell
viability, cell number, apoptosis and cell cycle, 6 3 105 cells/well were
seeded into 6 well microplates. Cells were maintained at 378C in
a humidiﬁed 5% CO2 atmosphere and protected from light constantly after
hypericin treatment.
Hypericin treatment. Cells were incubated 16 h with different
concentrations (2 3 108 M, 4 3 108 M, 6 3 108 M) of HPLC-grade
hypericin (AppliChem, Darmstadt, Germany) in dark conditions, following
irradiation with a single light dose (12 J/cm2) or fractionated light doses
(1 þ 11 J/cm2). The dark intervals between the two light fraction deli-
veries were 1 or 6 h. The control group received a medium with serum
without hypericin. Before light application, the medium was replaced
with fresh medium with 10% FCS.
Cell photosensitization. The cells were irradiated in hypericin-free
medium by placing the microplates on a plastic diffuser sheet above a set of
nine L18W/30 lamps (Osram, Berlin, Germany) with maximum emission
between 530 and 620 nm (the absorption peak of hypericin is 595 nm). At
the surface of the diffuser, the uniform ﬂuence rate was 4.4 mW/cm2.s and
the temperature did not exceed 378C. Light dose (12 J/cm2, 11 J/cm2 and
1 J/cm2) was calculated by multiplying the ﬂuence rate by the time.
Quantification of cell viability and cell number. At deﬁned incubation
times after hypericin photoactivation (24 and 48 h) eosin vital dye (0.15%)
exclusion assay was used to determine both cell viability and cell number
(microscopically). The viability was expressed as the percentage of live
cells out of the total number of cells. Cell number was assessed by counting
live cells in a Bu¨rker chamber.
MTT assay. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (Sigma Chemicals Co., St. Louis, MO) assay was performed to
evaluate the survival of cultured cells as previously reported (22). The
amount of dye extracted was quantiﬁed by absorbance measurements at
584 nm (FLUOstar Optima, BMG Labtechnologies GmbH, Offenburg,
Germany) and expressed as a percentage of the dye extracted from
untreated control cells ([OD value of treated cells/mean OD value of control
cells]3 100%).
DNA fragmentation analysis. For DNA preparation 106–107 cells were
harvested, pelleted and incubated with cold lysis buffer (10 mM TRIS pH
7.5; 1 mM EDTA pH 8; 0.2% Triton X-100) for 30 min on ice. Then,
RNase A (10 mg/mL) and proteinase K (25 mg/mL, Amresco Inc., Solon,
OH) were added and incubated for 30 min at 378C. The DNA was
precipitated with isopropanol and 5 M NaCl at 208C overnight,
centrifuged and resuspended in TE buffer (10 mM TRIS pH 7.5; 1 mM
EDTA pH 8). DNA was analyzed by electrophoresis on 1% TBE agarose
gel stained with ethidium bromide (25 lg) and visualized by UV light.
Morphological analysis by fluorescent microscopy. Adherent and
ﬂoating cells were stained together by dual Hoechst 33342/propidium
iodide viable staining. Native slides were evaluated by ﬂuorescent
microscope (Nikon, Eclipse 400, Japan) as a percentage of apoptotic cells
from total number of minimum 300 cells.
Cell cycle analysis. For the DNA content determination, cells were
harvested, washed with phosphate-buffered saline (PBS) and ﬁxed with
70% ice cold ethanol at 208C. Fixed cells were centrifuged, washed
with PBS and stained with staining solution (5 mg/mL propidium
iodide, 10 mg/mL RNase A and 10% Triton X-100 in PBS). Then
samples were kept in dark conditions for 30 min and measured on a ﬂow
cytometer (FACS Calibur, Becton Dickinson, San Diego, CA). For each
sample, 15 000 cells were evaluated and the sample ﬂow rate during
analysis did not exceed 200–300 cells per s. The data obtained were
analyzed using the Cell Quest Pro software. Cells characterized by
a smaller ﬂuorescence than the G1 peak were considered as apoptotic
cells (sub-G1 population).
Hypericin fluorescence. Cell extracts were prepared as described
previously (1). Intracellular hypericin content was quantiﬁed by measuring
ﬂuorescence emission in FLUOstar Optima before the second irradiation
and expressed as percentage of the ﬂuorescence at time 0 (before
irradiation) (Fig. 6).
Statistical analysis. Data were processed by GraphPadPrism (GraphPad
Software Inc., San Diego, CA) and statistically analyzed using one-way
ANOVA followed by Tukey’s multiple comparison test.
RESULTS
Our preliminary studies together with the results presented here
(Table 1) showed the different cytotoxic effect (MTT assay) of
photodynamic treatment using the various light irradiation schemes
and the importance of dark interval duration within a light
fractionation scheme on the photocytotoxicity of hypericin. Based
on this screening, in later experiments, we compared the effects of
hypericin treatment on tumor cell viability, cell number, survival,
apoptosis and cell cycle in a HT-29 cell line irradiated with a single
light dose (12 J/cm2) with its effects after fractionated light
delivery (1þ 11 J/cm2 ) separated by dark intervals 1 or 6 h.
Cell viability and cell number
Single light delivery (12 J/cm2) vs control. The activation of
hypericin (6 3 108 M) by a single light dose caused a non-
signiﬁcant decrease of cell viability (about 12%) compared with
the untreated control. Treatments with lower drug concentrations
resulted in cell viability similar to control (difference of 3%, data
not shown). In contrast, cell number was reduced to 60% of control
value after treatment with 4 3 108 M hypericin and to 40% of
control value after 63 108 M hypericin treatment (Fig. 1a,b).
Fractionated light delivery (1 + 11 J/cm2) vs control. Only
minimal nonsigniﬁcant decrease of cell viability was observed after
treatment with 6 3 108 M hypericin when fractionated light
delivery with 1 or 6-h dark interval between light fractions was
applied, compared with that of control cells (data not shown). The
number of cells treated with 43 108 M or 63 108 M hypericin
was reduced from 60% to 35% (at 48 h post-treatment) of the
control group when the light regime of 1 þ 11 J/cm2 illumination
was separated by a 1 h dark period. A dark period of 6 h in the
fractionated illumination scheme reduced cell number not
signiﬁcantly (Fig. 1a,b).
Fractionated light delivery (1+11 J/cm2) vs single light delivery
(12 J/cm2). The cell viability slightly decreased when a fractionated
light regime with a 1 h break between the 2 doses was used,
whereas a slight increase was found with a 6-h break (data not
shown). A 1-h dark pause between fractionated light deliveries
induced the same effect as from single irradiation (decline to 30–
40% of control). However, hypericin (63 108 M) activation with
2 light fractions separated by a dark interval of 6 h caused only
slight decline of cell number (90% of control), i.e. by 50% more
than after a single light dose after 24 h (Fig. 1a,b).
Table 1. Cytotoxicity of hypericin after various light-irradiation schemes
Light dose (J/cm) Dark pause (h)
Cytotoxicity (MTT assay
evaluated 24 h after PDT)
3 þ 3 vs 6 1 NS*
6 NS
6 þ 6 vs 12 1 NS
6 NS
1 þ 11 vs 12 1 NS
6 P , 0.001
1 vs 0 (control) 1 NS**
6 NS***
* NS—not signiﬁcantly.
** 1 h after PDT.
*** 6 h after PDT.
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MTT assay
Single light delivery (12 J/cm2) vs control. Treatment of HT-29
cells with all of the tested hypericin concentrations reduced
survival to 85–55% of control cells (Fig. 2a,b).
Fractionated light delivery (1+11 J/cm2) vs control. Survival of
cells irradiated with a second light dose after a pause of 1 h
decreased about 15–45% in comparison with control cells. In
contrast, hypericin photosensitization by 2 unequal light fractions
interrupted with 6-h dark period resulted in only slight decline in
cell survival after 24 h (Fig. 2a,b).
Fractionated light delivery (1+11 J/cm2) vs single light delivery
(12 J/cm2). Cell survival was about 15–25% higher in group
hypericin-treated cells irradiated with the 1þ 11 J/cm2 regime with
a 6-h dark pause compared with cells for which single irradiation
was used for hypericin activation. Survival of cells irradiated with
a second light dose after a pause of 1 h was found to be similar to
the effect of a single light dose, where a 15–45% drop in
comparison with control cells was observed (Fig. 2a,b).
Determination of apoptosis
Fractionated light delivery (1 + 11 J/cm2) vs single light delivery
(12 J/cm2). Both single-dose photosensitization and fractionated
photosensitization with a 1-h dark pause between 2 light doses
induced apoptotic DNA fragmentation in all hypericin-loaded cells
(63 108 M). No apoptotic DNA fragment formation was found in
cells after fractionated light delivery with the longer 6-h dark
interval between the 2 light doses (Fig. 3a). The same apoptotic
Figure 1. HT-29 cell numbers 24 h (a) and 48 h (b) after hypericin-
mediated photodynamic treatment with both single light-dose and
fractionated irradiation scheme. Results are expressed as relative cell
numbers related to control groups. The results are the means 6 SEM of
three independent experiments. Single light delivery vs control (8),
fractionated light delivery vs control (þ) and fractionated light delivery vs
single light delivery (*) were statistically compared (þ or 8P , 0.05, 88 or
**P , 0.01, þþþ or 888P , 0.001). (C) control, (S) single light dose,
(F) fractionated light dose.
Figure 2. Survival of HT-29 cells 24 h (a) and 48 h (b) after hypericin-
mediated photodynamic treatment with both single light dose and
fractionated irradiation scheme. The results are the means 6 SEM of
four independent experiments. Single light delivery vs control (8),
fractionated light delivery vs control (þ) and fractionated light delivery vs
single light delivery (*) were statistically compared (þ or 8 or *P , 0.05,
þþþ or 888 or ***P , 0.001). (C) control, (S) single light dose, (F) frac-
tionated light dose.
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effect was conﬁrmed by 2 other methods: morphological analysis
and sub-G1 evaluation of the nuclear fragmentation (Fig. 3b).
Cell cycle analysis
Single light delivery (12 J/cm2) vs control. Changes in G1 phase of
the cell cycle were not signiﬁcant at 24 h post-treatment (data not
shown). The percentage of cells in the G2 phase of the cell cycle
signiﬁcantly increased when cells were incubated with 63 108 M
hypericin. Simultaneously, the percentage of cells in the G1 phase
loaded with the same drug dose decreased (Figs. 4a,b and 5).
Fractionated light delivery (1+11 J/cm2) vs control. Changes in
cell cycle after light fractionation with a 1-h dark period before the
second light dose were found to be different compared with control
cells when the proportion of cells in the G2 phase increased and
that of G1 phase cells decreased. In contrast, a 6-h dark pause
between fractionated light deliveries resulted in no changes (Figs.
4a,b and 5).
Fractionated light delivery (1+11 J/cm2) vs single light delivery
(12 J/cm2). The effect of a 1-h break between light deliveries was
Figure 3. Determination of apoptosis in HT-29 cells 24 h after hypericin-
mediated photodynamic treatment with both single light dose and
fractionated irradiation scheme. (a) 1—control, 2—single light dose, 3—
63 108M/F/1h, 4—63 108M/F/6h, 5—1 kb DNA ladder (Amresco Inc.,
Solon, OH). (b) The results are the means 6 SEM of four independent
experiments. Single light delivery vs control (8), fractionated light delivery
vs control (þ) and fractionated light delivery vs single light delivery (*)
were statistically compared (þþ or 88 or **P , 0.01, þþþ or 888 or ***P ,
0.001). (C) control, (S) single light dose, (F) fractionated light dose.
Figure 4. Proportion of HT-29 cells in the G2 phase 24 h (a) and 48 h (b)
after hypericin-mediated photodynamic treatment with both single light-
dose and fractionated irradiation scheme. The results are the means 6 SEM
of two independent experiments. Single light delivery vs control (8),
fractionated light delivery vs control (þ) and fractionated light delivery vs
single light delivery (*) were statistically compared (þ or *P , 0.05, þþ or
88P , 0.01, 888 or ***P , 0.001). (C) control, (S) single light dose,
(F) fractionated light dose.
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almost the same as the single light-dose effect. Irradiation of
hypericin-treated cells by 1 þ 11 J/cm2 with a 6-h dark pause
induced a signiﬁcant decrease in the percentage of G2 phase cells
(to the control level) and a rise in the percentage of G1 phase cells
compared with cells treated with hypericin photoactivated by
single irradiation (to the control level) (Figs. 4a,b and 5).
Measurement of intracellular hypericin content conﬁrmed that
the ﬂuorescence of hypericin remains unchanged before the second
light-dose delivery (Fig. 6), therefore, reduced photocytotoxicity
following fractionated irradiation with 6-h dark pause is not a result
of photobleaching of hypericin.
DISCUSSION
Using fractionated light exposure to activate a photosensitive drug
is a relatively new mode of light application as part of
photodynamic treatment. So far there are several works reporting
on comparison of single light doses with fractionated light regimes
in vivo, producing contradictory results (9, 13, 17–18). It has been
shown that the level of tissue oxygen at the treatment site is
affected differently when the light dose is fractionated compared
with the effect when a single light dose is employed (23). It is
probable that the enhanced photodynamic effect of light fraction-
ation is associated with reoxygenation of the treatment site during
the dark period between the two light fractions, and that it is also
dependent on the timing of the dark interval (3, 15–17).
Enhancement of PDT by fractionation could be achieved by less
rapid oxygen consumption. At lower ﬂuence rates, the oxygen
consumption rate is not fast enough to be improved by
fractionation (17). It is difﬁcult to compare individual studies be-
cause the animal model used, the photosensitive drug doses and the
illumination methods are all different.
The in vivo and in vitro effects of light fractionation are
completely incomparable. In contrast to in vivo studies, in which
enhanced or no effect of fractionated irradiation was shown, the so
far known in vitro works report either on photoresistance/photo-
tolerance (19, 20) or on decreased production of reactive oxygen
species and cytotoxicity via regeneration of glutathione (21).
Our preliminary studies together with the results presented here
(Table 1) show the different cytotoxic effects of photodynamic
treatment using the various light irradiation schemes and the
importance of dark-interval duration within a light fractionation
scheme as part of photodynamic treatment for its outcome related
to the cytotoxic effect of hypericin on an HT-29 cell line.
Comparison of the effects of hypericin treatment on tumor cell
viability, cell number, cell survival, apoptosis and cell cycle after
a single light-dose application (12 J/cm2) with those after
fractionated light delivery (1 þ 11 J/cm2) revealed a marked
difference in all studied cellular parameters (except for viability)
when the irradiation was interrupted with a longer dark period of
6 h. While fractionation with a shorter dark period induced the
same cytotoxic effect on tumor cells as single-dose application, the
effect of hypericin activated with light fractions separated by a dark
interval of 6 h was reversed. Increased cell number and rise in
metabolic activity along with an increased proportion of cells in the
G1 phase of cell cycle together indicate maintained proliferation
and mitochondrial function. On the other hand, the percentage of
cells in the G2 phase of cell cycle decreased and no apoptotic
fragmentation occurred, which is in contrast to the effects of both
single-dose and fractionated light regimes. This means that the
behavior of cells was similar to that of the control. The only
signiﬁcant change was observed in the survival of cells receiving
63108 M hypericin evaluated 48 h after light sensitization, which
decreased compared to that of the control. Because the ﬂuorescence
of hypericin remains unchanged before the second light-dose
delivery (Fig. 6), reduced photocytotoxicity following fractionated
irradiation is not a result of photobleaching or sensitizer loss from
cells after the ﬁrst light fraction. Our results indicate that irradiation
of cells with the ﬁrst light dose followed by a subsequent dark
period of 6 h makes cells to resistant to the cytotoxic effect of
second light dose (11 J). These ﬁndings relating to decreased
cytotoxicity are in agreement with the results of the in vitro studies
mentioned above, but the fact that different cell lines as well as
Figure 5. Proportion of HT-29 cells in the G1 phase 48 h after hypericin-
mediated photodynamic treatment with both single light-dose and
fractionated irradiation scheme. The results are the means 6 SEM of two
independent experiments. Single light delivery vs control (8), fractionated
light delivery vs control (þ) and fractionated light delivery vs single light
delivery (*) were statistically compared (þþ or 88 or **P , 0.01). (C)
control, (S) single light dose, (F) fractionated light dose.
Figure 6. Fluorescence of hypericin before 1 J/cm2 and 11 J/cm2
irradiation. The results are the means 6 SEM of two independent
experiments expressed as percentages of ﬂuorescence at time 0. (0) before
irradiation and delivery of the ﬁrst light dose. (6) 6 h after irradiation and
before delivery of the second light dose.
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photodynamic protocols were used makes further comparison of
results impossible.
Mechanisms that make cells resistant to treatment when
hypericin is activated by two unequal light doses with a longer
dark pause between them are the subject of our next investigation.
For this time, the most probable hypothesis is that when the ﬁrst
light dose is sufﬁciently low not to induce nonreversible changes in
cells, and it is followed by a longer dark period before the next
light dose cells become resistant to the possible cytotoxicity of
hypericin after the second light-dose application.
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ABSTRACT 
 
This study follows up an earlier one in which hypericin-mediated photocytotoxic 
effects on HT-29 adenocarcinoma cells by light fractionation with a longer dark pause 
between two unequal light doses were described [Sackova, A. (2005) Photochem Photobiol, 
81, 1411-1416]. In the present study we investigated the impact of sub-lethal light dose (1 
J.cm-2) and length of a following dark pause (1 or 6 h) on development of resistance to the 
effect of the second illumination (11 J.cm-2). The use of HT-29 cells transfected with a 
nuclear transcription factor (NF-B) luciferase reporter construct revealed significantly 
increased activity of NF-B during a longer dark pause after 1 J.cm-2 as well as (ROS-
induced)-ROS release, decrease in hypericin content and elevated levels of NF-B, IB- and 
Mcl-1 proteins. We demonstrated that a fractionated light regime (1+11 J.cm-2) with a 6 h but 
not 1 h dark period resulted in an increase in cell proliferation activity, decrease in ROS 
production, hypericin content, cell membrane permeability, phosphatidilserine externalization 
and altered expression of HSP70, GRP94, clusterin, NF-B, IB-, Mcl-1. We assume that 
activation of the NF-B pathway suggests its involvement in development of photoresistance 
to hypericin-mediated fractionated photodynamic therapy in HT-29 cells in vitro. 
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INTRODUCTION 
 
The cytotoxic effect of photodynamic therapy (PDT) is mediated by highly toxic reactive 
oxygen species (ROS) formed in tissue treated with a photosensitizing drug activated with 
light of appropriate wavelength in the presence of oxygen. The efficacy of PDT and 
subsequent mode of cell death is affected by many factors such as cell type, type of 
photosensitizer and its intracellular localization, light dose and its fluency rate, drug to light 
interval and photodynamic protocol (1-6). 
Hypericin, a natural substance displaying potential as a photosensitizer for PDT, is a 
secondary metabolite present in Hypericum perforatum L. (St John’s wort) (7). It is devoid of 
toxicity in the dark (8, 9) and genotoxic effects in vitro or in vivo (10, 11). However exhibits 
potent photosensitizing properties with a high singlet oxygen quantum yield (12, 13). 
Efforts to improve the therapeutic effect of PDT have led to alternative approaches 
based on fractionationated dosing of photosensitizer (14-16) or multiple light illuminations 
separated with dark pauses (5, 17-29), enabling re-oxygenation in treated tissue (20, 30). In 
the last decade, application of light fractionation in PDT has gained increased attention from 
researchers and has led to the comparison of continuous and fractionated light regimes (5, 17, 
19, 23, 29). Indeed, improved efficiency of fractionated light delivery has been demonstrated 
in various models in vivo (17, 19, 23, 26, 29, 30). However, the outcome of fractionated light 
regimes is still limited by some parameters such as distribution of photosensitizers in tissue 
(21), dark intervals between light doses (5, 22, 23, 27, 31) or oxygen depletion (24). In 
general, maintaining the tumor tissue oxygen level is crucial for PDT efficacy, and low 
fluency rate has also been found to improve the therapeutic outcome (2, 32, 33). Treatments 
such as fractionated PDT do not therefore necessarily avoid all problems. For example 
fractionated illumination did not enhance the efficacy of PDT using methyl 5-
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aminolevulinate, but it did in the case of ALA application (21). Similarly, photo-activation of 
hypericin with a low light dose promoted apparent photo-resistance in U937 cells (25), just 
low-energy pre-sensitization of hypericin-loaded HEC1-B cells enhanced photo-tolerance 
(28). Increased expression of heat shock proteins (HSPs) is considered to be the basis of 
photo-resistance (25, 28).  
Previously, we have reported hypericin-mediated photocytotoxic effects on HT-29 
adenocarcinoma cells reduced by light fractionation with a longer dark pause between two 
unequal light doses (5). We have proceeded to investigate the relationship between dark 
interval and PDT response. Further study of mechanisms behind this resistance invoked by 
pre-sensitization with a sub-lethal light dose PDT is presented here. ROS at low levels may 
function as second messengers activating pathways that protect cells against apoptotic stimuli 
(34). Protein complex often considered to be a ROS-responsive transcription factor is NF-B 
(34, 35) also shown to be implicated in cancer cell responses to photodynamic therapy (36). 
 Analyses of ROS production, hypericin content, activity of nuclear transcription factor-B 
(NF-B), expression of selected proteins (HSP70, GRP94, clusterin, NF-B, IB-, Mcl-1), 
changes in cell membrane permeability and externalization of phosphatidilserine have been 
done with aim of approaching the mechanisms behind the PDT-induced resistance. We 
outline the possible implication of NF-B and describe other possible factors negatively 
affecting the photocytotoxic effect of fractionated light delivery with a longer dark pause. 
 
MATERIALS AND METHODS 
 
Cell culture. Human adenocarcinoma cell line HT-29 was purchased from American Tissue 
Culture Collection (ATCC, Rockville, MD). Cells were cultured in RPMI-1640 medium 
(Gibco, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum (FCS; 
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PAA Laboratories GmbH, Linz, Austria) and antibiotics (penicillin 100 U/ml, streptomycin 
100 g/ml and amphotericin 25 g/ml; Invitrogen Corp., Carlsbad, CA). Cells were 
maintained at 37 °C in a humidified 5% CO2 atmosphere and constantly kept under dark 
conditions. 
 
Experimental design. HT-29 cells (2 ×104/cm2) were seeded and cultivated 24 h in a complete 
medium with 10% FCS. Hypericin ((4,5,7,4´,5´,7´-hexahydroxy-2,2´-
dimethylnaphtodiantron), HPLC grade; AppliChem GmbH, Darmstadt, Germany) of final 
concentration 60 nM was added and then incubated 16 h with cells in dark conditions. Prior to 
light application, the medium was replaced with a fresh one, free of hypericin (see Scheme 
1A). The hypericin was photoactivated with a sub-lethal or lethal single light dose (1 or 12 
J.cm-2) or fractionated light doses (1 + 11 J.cm-2) with a dark interval 1 or 6 h. The cells 
photoactivated with a sub-lethal light dose were analyzed 1 or 6 h after PDT. The effects of 
single or fractionated light regime deliveries were analyzed up to 24 h after PDT (see Scheme 
1B). (SLD) sub-lethal light dose 1 J.cm-2 (S) single light dose 12 J.cm-2, fractionated light 
dose 1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) dark pause between the two light doses. 
 
<Scheme 1> 
 
Hypericin activation. The cells were irradiated in hypericin-free medium by placing 
cultivation dishes (TPP, Trasadingen, Switzerland) on a plastic diffuser sheet above a set of 
eleven L18W/30 lamps (Osram, Berlin, Germany) with maximum emission between 530 and 
620 nm (the absorption peak of hypericin is ~ 600 nm). Uniform fluency rate at the surface of 
the diffuser was 3.15 mW.cm-2 and the temperature did not exceed 37˚C. Light dose was 
calculated as multiplication of fluency rate by time. 
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Colony forming assay. Cells were treated according to the standard protocol (Scheme 1), then 
harvested 24 h after single or fractionated light delivery and counted microscopically using 
a Bürker chamber. Equal cell numbers (500 cells per 60 mm Petri dish (TPP)) were seeded 
and cultivated under standard conditions for 7 days. Colonies were stained using coloured 
solution (40 mg methyl blue diluted in 50 ml 78% ethanol). 
 
Detection of phosphatidilserine externalization and cell membrane permeability. For 
phosphatidylserine externalization and cell viability analysis an annexin V-FITC and 
propidium iodide (PI) double-staining kit (Bender MedSystems, Vienna, Austria) was used 
according to the manufacturer’s instructions. The cells were treated according to the standard 
protocol (Scheme 1), then adherent and floating cells were harvested together 0.5, 3 and 24 h 
after PDT and stained with annexin V-FITC in binding buffer for 10 min, washed, stained 
with PI for 5 min and analyzed using the FACSCalibur flow cytometer. Results were 
analyzed with CellQuest Pro software. The cell populations were differentiated as living 
(annexin V–/PI–), apoptotic (annexin V+/PI–), secondary necrotic (annexin V+/PI+) or necrotic 
(annexin V–/PI+) cells. The results are presented as means ± SD of three independent 
experiments. 
 
Production of ROS. The cells were treated according to the standard protocol (Scheme 1), 
then harvested 0.25, 0.5, 1, 6 h after a sub-lethal light dose or 0.5, 3, 24 h after single or 
fractionated light delivery, washed twice in phosphate-balanced salt solution (PBS), and 
resuspended in Hank's balanced salt solution (HBSS). Dihydrorhodamine-123 (DHR-123, 
Fluka, Buchs, Switzerland) was added at a final concentration of 0.2 M, samples were then 
incubated for 15 min at 37 °C in 5% CO2 atmosphere and subsequently kept on ice during 
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analysis. Fluorescence was analyzed using a FACSCalibur flow cytometer (Becton 
Dickinson, San Jose, CA) in the FL-1channel. Forward and side scatters were used to gate the 
viable populations of cells. CellQuestPro software (Becton Dickinson) was used to quantify 
the intensity of DHR-123 fluorescence in the cells, expressed as the ratio of DHR-123 
fluorescence in treated cells compared to the fluorescence of untreated control cells. 
 
Hypericin content analysis. The cells were treated according to the standard protocol (Scheme 
1), then harvested 0.25, 0.5, 1, 6 h after a sub-lethal light dose or 0.5, 3, 24 h after single or 
fractionated light delivery, washed twice in PBS, and resuspended in HBSS. Fluorescence of 
hypericin was analyzed using the FACSCalibur flow cytometer in the FL-2 channel (1 x 104 
cells per sample). CellQuestPro software was again used to quantify the intensity of hypericin 
fluorescence in the cells, expressed as the ratio of hypericin fluorescence in treated cells 
compared to the fluorescence of untreated control cells. 
 
Luciferase activity assay. Luciferase reporter construct and stable cell transfection were 
executed as described previously (37). Stable transfected HT-29 cells were treated according 
to the standard protocol (Scheme 1). Cells were rinsed with PBS 0, 0.5, 1, 3, 6 h after 
hypericin photoactivation with a sub-lethal light dose, and lysed with 400 l of reagent 
(Luciferase Assay System; Promega Corp., Madison, WI). Protein concentrations of the cell 
extracts were determined using detergent-compatible protein assay (BioRad Laboratories Inc., 
Hercules, CA). One sample at a time was diluted in equal amount of proteins and 50 l of 
extract was mixed with 50 l of luciferase substrate and luminescence was measured 
immediately using the FLUOstar Optima (BMG Labtechnologies GmbH, Offenburg, 
Germany). The luminescent signal of each sample was measured for the same period. 
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Western blot analysis. The cells were treated according to the standard protocol (Scheme 1), 
then harvested 1and 6 h after low light dose or 24 h after single or fractionated light delivery, 
then washed twice in cold PBS and lysed in lysis buffer (100 mM Tris-HCl, pH 7.4, 1 % SDS, 
10 % glycerol and protease inhibitor cocktail P2714 (Sigma-Aldrich Corporation, St. Louis, 
MO) for 10 min on ice. The cell lysates were sonicated and centrifuged. Protein concentration 
was determined using detergent-compatible protein assay (BioRad Laboratories Inc.,). 
Samples were diluted in equal amounts (30 - 50 g proteins) with 0.01 % bromphenol blue 
and 1% 2-mercaptoethanol, then separated with SDS-polyacrylamide gel and transferred onto 
nitrocellulose membrane (Advantec, Tokyo, Japan) or PVDF membrane (Millipore, Bedford, 
MA) in a transfer buffer containing 192 mM glycine, 25 mM Tris and 10 % methanol. The 
membrane was blocked in 5 % non-fat milk (or 5 % BSA) in TBS (20 mM Tris-HCl, pH=7.6; 
150 mM NaCl; 0.05 % TWEEN 20, pH=7.4) for 1 h at first, and then the membrane blots 
were incubated 2 h at RT or overnight at 4 °C (depending on the particular antibody) with 
primary antibody: anti-NF-B p65 (sc-372), anti-NF-B p50 and p105 (sc-8414), anti-IB- 
(sc-203), anti-GRP94 (sc-1794), anti-clusterin (sc-6420), all from Santa Cruz Biotechnology, 
anti-Mcl-1 (#4572 Cell Signalling), anti-HSP70 (MA3-006, Affinity BioReagents). After 30 
min washing in wash buffer, membranes were incubated with appropriate horseradish-
conjugated secondary antibody for 1 h at RT (AntiMouse IgG-HRP, NA931 (1:3000), 
AntiGoat IgG-HRP (1:20 000), AntiRabbit IgG-HRP (1:20 000) (Amersham Biosciences, 
Buckinghamshire, UK). Detection of antibody reactivity was performed using a 
chemiluminescence detection kit ECL+ (Amersham Biosciences) and visualized on X-ray 
films (Foma Slovakia, Skycov, Slovakia). Equal sample loading was verified by 
immunodetection of -actin (A5441, Sigma-Aldrich). 
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Statistical analysis. Data were processed with GraphPadPrism (GraphPad Software Inc., San 
Diego, CA) and statistically analyzed using one-way ANOVA with Tukey’s multiple 
comparison test, and are expressed as means ± standard deviation (S. D.). Significance was 
evaluated at three levels; p < 0.05, p < 0.01 and p < 0.001. 
 
RESULTS 
 
The scheme of the presented experiment was chosen based on our previous study (5). The 
light dose of 1 J.cm-2 was considered as sub-lethal on the basis of our initial preliminary data 
(not shown) according which the light dose did not affect cell viability/survival in comparison 
with untreated control or hypericin treated cells. The presented data concern two aspects; 
cellular and subcellular events induced by sub-lethal dose of 1 J.cm-2 (Figures 3, 5, 7 and 8) 
and its consequences studied after a second lethal dose of 11 J.cm-2 separated by a dark pause 
of 1 or 6 h (Figures 1, 2, 4, 6 and 8). All the present experiments involved untreated controls 
as well as controls treated with hypericin and kept under dark conditions through the 
experiments. 
 
Longer dark pause between two unequal light doses enhanced clonogenic potential of 
HT-29 cells after PDT with hypericin 
 
Verification of resistance induced by a longer dark pause between two unequal light doses 
using colony-forming assay proved that pre-sensitization of HT-29 cells with a sub-lethal 
light dose is time-dependent. As demonstrated in Figure 1, even 1 h dark pause (FR1) shows 
higher clonogenic ability when compared to single lethal light dose (S). A longer pause 
continuing for 6 h (FR6) demonstrated much higher ability to create visible colonies, even 
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when compared to the FR1 group. As can be seen, hypericin under dark conditions (D) did 
not affect the clonogenic potential of HT-29 cells. 
 
<Figure 1> 
 
Longer dark pause between two unequal light doses repressed cell death in HT-29 cells 
after PDT with hypericin 
 
Further analysis of phosphatidylserine externalization and cell viability (Fig. 2) in cells treated 
with single lethal light dose (S) or pre-sensitized with sub-lethal light dose separated by 1 h 
(FR1) or 6 h (FR6) dark pause, supported previous findings. In contrast to earlier analysis 
(Fig. 2a), significantly higher survival of the FR6 group accompanied by regress in the ratio 
of apoptotic and secondary necrotic cells showed 24 h after PDT (Fig. 2b). 
 
<Figure 2> 
 
Durations of a dark pause affects PDT-mediated ROS level induced by second light-dose 
 
Detection of intracellular levels of reactive oxygen species (ROS) shortly after sub-lethal light 
dose revealed steady remission within the first hour, although 6 h after PDT, the ROS level 
was found to be raised significantly. Dark conditions did not affect ROS level significantly 
when compared to untreated control (Fig. 3). However, detection of ROS 30 min after second 
lethal light dose revealed significantly lower levels in both pre-sensitized groups in reciprocal 
proportion with time of dark pause (Fig. 4). Later analyses (3 or 24 h) showed barely induced 
levels. 
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<Figure 3> 
 
<Figure 4> 
 
Pre-sensitization did not affect physiological elimination of hypericin, however 
administration regime affects hypericin elimination after lethal dose. 
 
Detection of hypericin intracellular levels within the first 6 h after the first sub-lethal light 
dose (Fig. 5) proved that there was a steady decrease, which was found to be significant 6 h 
after PDT. However this was in compliance with the physiological elimination of hypericin, 
similar to hypericin-treated cells under dark conditions (D). Although, administration of a 
single lethal light dose decelerated hypericin elimination by cells significantly when applied 
without pre-sensitization (Fig. 6, S), on the other hand, this effect was partially or completely 
abolished in pre-sensitized groups with 1 or 6 h dark pause (Fig. 6, FR1 or FR6). 
 
<Figure 5> 
<Figure 6> 
 
 
Luciferase activity assay-Sub-lethal light dose induced NF-B 
 
Induction of NF-B activity after a sub-lethal dose of 1 J.cm-2 was verified in stably 
transfected HT-29 cells (clone #3 and clone #93) by luciferase reporter activity executed 0, 
0.5, 1, 3 and 6 h after PDT (Fig. 7a, b). Both tested clones indicated insignificant changes 
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within the first hour, later on however, the NF-B activity was identically induced 3 and 6 h 
after PDT in both models. 
 
<Figure 7> 
 
Light delivery regime altered expression of heat-shock proteins and NF-B 
 
Expressions of NF-B p65, p50 and p105, Mcl-1, IB-, HSP70, GRP94 and clusterin- (Fig. 
8) were detected 1 and 6 h after the first sub-lethal light dose (SLD; 1 J.cm-2) or 24 h after 
administration of a single lethal light dose (S, 12 J.cm-2) and two unequal doses (1+11 J.cm-2) 
separated by 1 or 6 h of dark pause (FR1 or FR6). Induction of NF-B subunits p65, p50 and 
a precursor form of p50; p150, correlated with IB- and anti-apoptotic Mcl-1 detected 6 h 
after the sub-lethal dose. Similarly, induction of heat shock protein HSP70, occurrence of 
GRP94 multimers and elevation of clusterin- even 1 h after hypericin activation confirmed 
the onset of oxidative stress response in pre-sensitized cells. 
Analysis 24 h after lethal light doses (S, FR1, FR6) revealed interesting differences in 
HSP70, especially GRP94 multimerization and clusterin- expression. Whereas single lethal 
light dose administration (S) and FR1 group demonstrated similar pattern, the fractionated 
administration separated by a 6 h dark pause showed significantly reduced clusterin- levels 
as well as suppressed occurrence of HSP70 and GRP94 multimers and slightly elevated IB- 
together with p50 and p65 subunits of NF-B. 
<Figure 8> 
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DISCUSSION 
 
As previously reported by us (5), light dose fractionation with a longer dark pause 
between two unequal light doses reduced hypericin-mediated photocytotoxic effects on HT-
29 adenocarcinoma cells. Similar findings have been described for hypericin pre-incubated 
U937 and HEC1-B cells (25, 28). Although the biological effects of low doses were described 
mainly in the context of radiation- or heat-induced adaptive cell response (38, 39), we 
presume that a low sub-lethal light dose may have the same consequences in a time-dependent 
manner in PDT as well. We therefore examined the consequences of a sub-lethal light dose (1 
J.cm-2) and length of the following dark pause for photoresistance induced by fractionated 
light delivery, resulting in significant changes in all analyzed parameters. 
Since the intracellular content of the photosensitizer is a limiting factor for ROS 
production and thus also PDT efficiency, a drop in hypericin content during a longer dark 
pause, due to its ability to increase activity and expression of drug efflux transporters in HT-
29 cells (40) could contribute partially to decreased photocytotoxic effect of fractionated 
PDT. Our results indicate that increased ROS production can be induced even by sub-lethal 
light dose with a subsequent “(ROS-induced)-ROS release” (RIRR). This phenomenon has 
also been demonstrated in the mitochondria of cardiac myocytes resulting from MPT 
induction, and it is considered as a general mechanism independent of the signaling ROS 
source (34). 
Considering that low level of ROS may activate pathways that protect cells against 
apoptotic stimuli (41) such as NF-B, which is known as a redox-regulated protein linked 
with cell proliferation, transformation or tumour development (36), we therefore employed 
HT-29 cells transfected with a nuclear transcription factor (NF-B) luciferase reporter 
construct in our experiments. Significantly increased luciferase activity at a later time after 
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sub-lethal dose indicates that pre-sensitized cells prepared themselves during the longer dark 
period by provoking NF-B activity, and the timing of the second light dose before or after 
NF-B activation could be crucial for the fate of cancer cells. Apart from stimulation of NF-
B transcription activity, this theory also supports increased levels of proteins whose genes 
are under its transcription control (increased level of NF-B subunits p65, p50 and a precursor 
form of p50; p150, IB- and anti-apoptotic Mcl-1 protein detected 6 h after sub-lethal light 
dose as well as 24 h after second lethal dose application (apart from Mcl-1)). Even though 
phosphorylation and degradation of IB is an important step for NF-B release from the 
complex with IB, translocation from cytoplasm to nucleus and binding to DNA occurred in 
our experimental model NF-B activation has occurred without degradation of IB. Our 
results are thus in agreement with a study reporting altered regulation of IB- degradation 
and activation of NF-B activity which can occur independently of IB degradation in human 
colonic epithelial HT-29 cells (42, 43). 
Since the sub-lethal light dose did not affect cell viability in the long term when 
compared to control or hypericin in dark conditions (data not shown), we probed the impact 
of second lethal light dose timing on the resultant ability of the cells to form colonies. Apart 
from increased number of viable cells, resistance manifested itself also through increased 
clonogenic activity when a prolonged dark pause was applied. 
The study of oxidative metabolism changes revealed that resistant group (FR6) kept 
shortly after PDT, steady ROS level was achieved already just before the lethal dose 
application, whereas further delivery regimes (S, FR1) resulted in markedly elevated ROS 
production. The results indicate that pre-sensitization and the timing of a second illumination 
could decrease the photocytotoxic effect of PDT mediated through restricted ROS production. 
Although the timing of the photodynamic protocol could contribute to reduced hypericin 
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content, on the basis of our findings it seems that different molecular events participate in 
resistance development in HT-29 cells in vitro. 
Taking into consideration that the induction of HSPs is believed to be the basis of 
photo-tolerance/resistance (25, 28), we were interested in the expression of proteins playing a 
role in cell response to stress. Analyses revealed altered expression of proteins in a light dose 
dependent manner and depending on the light delivery regime of the photodynamic protocol. 
The expression of 94 kDa a glucose-regulated protein (GRP94), the endoplasmic reticulum 
paralog of HSP90 essential for proper assembly and maturation of numerous client proteins 
(44-46), was accompanied by proportional formation of high molecular GRP94 multimers. 
Although, the explanation of an unexpected band detected by GPR94 antibody was not a goal 
of this work, it could explain the findings of Wassenberg et all (2000). They described bis-
ANS and heat shock induction of GRP94 multimerisation accompanied by a marked elevation 
of chaperone and peptide binding activity. In this conformation and in a concentration-
dependent manner, GRP94 can undergo homotypic oligomerization leading to formation of 
multimers of GRP94 with high molecular weights (47). We therefore presume that 
photodynamic therapy with hypericin-induced oxidative stress may have a similar effect on 
GRP94 like heat shock, in a light dose- and photodynamic protocol-dependent manner. 
In cytoprotection a role may be played by clusterin, a molecule with a chaperon-like 
activity, whose secretory form contributes to clearing cell debris from traumatized tissue (48, 
49). The pre-secretory form of clusterin (~60 kDa) could be glycosylated and cloven into ~40 
kDa - and -subunits which held together by disulphide bonds (50). In our case, oxidative 
stress induced by a sub-lethal light dose increased the level of ~40 kDa clusterin subunit, 
whereas a lethal light dose (S, FR1) significantly altered clusterin expression towards higher 
molecular forms of clusterin-, which indicate involvement of clusterin in extensive defense 
stress response, not observed in the resistant group. 
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CONCLUSION 
 
In summary, changes in ROS production, increased transcription activity of NF-B, increased 
levels of NF-B and Mcl-1 proteins at the moment of second light dose application support 
our hypothesis that the cells prepare themselves for the lethal consequences of second 
illumination by development of resistance. We presume that, although at the moment of 
second light dose administration (1 or 6 h after the sub-lethal light dose) increased level HSPs 
were detected, it seems that HSPs themselves are not sufficient to develop resistance in such a 
photodynamic protocol whereas resistance occurred when NF-B activation was implicated. 
We assume therefore that activation of the NF-B pathway may suggest its involvement in 
photoresistance development to a fractionated light delivery regime. Our findings do not 
explain the mechanism of resistance development to fractionated hypericin photoactivation in 
HT-29 cells in vitro; they do however point out another aspect of resistance in two-fold 
photodynamic therapy with hypericin. 
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FIGURE LEGENDS 
 
Scheme 1. Experimental design. (A) Time schedule of experiments – HT-29 cells were 
seeded (point -40 h in the experimental time schedule) and cultivated 24 h in a complete 
medium and then hypericin was added (point -16 h). The medium with hypericin was 
removed from cells 16 h later and replaced with hypericin-free medium with subsequent 
activation of intracellular hypericin (point 0 h). Analyses were performed up to 6 h or up to 24 
h after PDT (point +6 h or +24 h). 
(B) Schedule of hypericin activation - hypericin-loaded HT-29 cells were illuminated with a 
single light dose (sub-lethal 1 J.cm-2 or lethal 12 J.cm-2 light dose) or two unequal light doses 
(1+11 J.cm-2) separated by 1 h or 6 h dark pause. (S) single light delivery 12 J.cm-2, 
fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) dark pause between the two 
light doses. 
 
Figure 1. Clonogenic assay of HT-29 cells. Cells were harvested 24 h after hypericin 
photoactivation. The results are presented as a representative photo of three independent 
experiments. (C) control cells, (D) hypericin under dark conditions, (S) single light dose 12 
J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) dark pause between 
the two light doses. 
 
Figure 2. Detection of phosphatidilserine externalization and membrane permeability of HT-
29 cells by dual annexin V/PI staining 3 h (a) and 24 h (b) after single (12 J. cm-2) or 
fractionated (1 + 11 J.cm-2) light dose. Cells were harvested and evaluated 3 or 24 h after 
PDT. The results are the means ± SD of three independent experiments presented as 
percentages of control values. Statistical significance is expressed as follows: experimental 
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groups versus untreated control (); fractionated light delivery versus single light delivery 
(+); fractionated light delivery with a 6 h versus 1 h dark pause () on the significance level 
p<0.05 ( or + or ); p<0.01 ( or ++); p<0.001 (). (C) control cells, (D) hypericin 
under dark conditions, (S) single light dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with 
a 1 h (FR1) or 6 h (FR6) dark pause between the two light doses. 
 
Figure 3. The effect of a sub-lethal dose 1 J.cm-2 on ROS production in HT-29 cells. Cells 
were harvested and evaluated 0.25, 0.5, 1 and 6 h after hypericin photoactivation. The results 
are the means ± SD of three independent experiments presented as ratios to untreated control 
values. Statistical significance is expressed as follows: photoactivated (1 J.cm-2) versus not 
photoactivated hypericin (D) (+) on the significance level p<0.01 (++); p<0.001 (+++). (D) 
hypericin under dark conditions. 
 
Figure 4. The effect of a single (12 J. cm-2) and fractionated (1 + 11 J.cm-2) light delivery on 
ROS production in HT-29 cells. Cells were harvested and evaluated 0.5, 3 and 24 h after 
hypericin-mediated photodynamic treatment.  The results are the means ± SD of three 
independent experiments presented as ratios to control values. Statistical significance is 
expressed as follows: experimental groups versus untreated control (+); fractionated light 
delivery versus single light delivery (); fractionated light delivery with a 6 h versus 1 h dark 
pause (	) on the significance level p<0.05 (); p<0.01 (++); p<0.001 (+++ or  or 			). 
(D) hypericin under dark conditions, (S) single light dose 12 J.cm-2, fractionated light dose 
1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) dark pause between the two light doses. 
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Figure 5. Determination of hypericin intracellular levels in HT-29 cells during the dark pause 
after first sub-lethal dose 1 J.cm-2. Cells were harvested and evaluated 0.25, 0.5, 1 and 6 h 
after hypericin photoactivation. The results are the means ± SD of three independent 
experiments presented as ratios to control values. Statistical significance is expressed as 
follows: photoactivated (1 J.cm-2) or not photoactivated (D) hypericin (0.5, 1 and 6 h) versus 
(0.25 h) (+); (6 h) versus (1 h) () on the significance level p<0.01 (); p<0.001 (+++). (D) 
hypericin under dark conditions. 
 
Figure 6. Determination of hypericin intracellular levels in HT-29 cells illuminated with a 
single (12 J. cm-2) and fractionated (1 + 11 J.cm-2) light delivery. Cells were harvested and 
evaluated 0.5, 3 and 24 h after PDT. The results are the means ± SD of three independent 
experiments presented as ratios to control values. Statistical significance is expressed as 
follows: single or fractionated light delivery versus not photoactivated (D) hypericin (+); not 
photoactivated hypericin (3 h or 24 h) versus ( 0.5 h) (	) on the significance level p<0.05 (+); 
p<0.01 (++); p<0.001 (			). (PDT) photodynamic treatment, (D) hypericin under dark 
conditions, (S) single light dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h 
(FR1) or 6 h (FR6) dark pause between the two light doses. 
 
Figure 7. NF-B binding activity (expressed as relative luciferase activity) of two HT-29 
clones #3 (a) and #93 (b) with pBIIX-LUC construct after treatment with  sub-lethal dose 1 
J.cm-2. Cells were lysed 0, 0.25, 0.5, 1, 3 and 6 h after PDT. The results are the means ± SD of 
three independent experiments presented as ratios to untreated control values. Statistical 
significance is expressed as follows: sub-lethal light dose versus untreated control (+) on the 
significance level p<0.01 (++). (C) control cells. 
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Figure 8.  Western blot analysis of Mcl-1, NF-B p65, p50 and p105, IB-, HSP70, GRP94, 
clusterin- and -actin proteins 1 or 6 h after hypericin photoactivation with a sub-lethal dose 
(1 J.cm-2) or 24 h after single (12 J. cm-2) and fractionated (1 + 11 J.cm-2) light delivery. The 
results are presented as a representative photo of three independent experiments. (C) control 
cells, (D) hypericin under dark conditions, (SLD) sub-lethal light dose 1 J.cm-2 (S) single light 
dose 12 J.cm-2, fractionated light dose 1+11 J.cm-2 with a 1 h (FR1) or 6 h (FR6) dark pause 
between the two light doses. 
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The role of p53 in the efﬁciency of photodynamic therapy with hypericin and
subsequent long-term survival of colon cancer cells
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Photodynamic therapy with hypericin (HY-PDT) is known as an efﬁcient modality for treatment of
various cancerous and non-cancerous diseases. Although the role of p53 protein in cell death signaling
is well established, relatively little is known of its impact on the efﬁciency of HY-PDT. Comparison of
sensitivity and long-term survival of p53-null versus wt-p53-expressing HCT-116 cells is reported here.
The lack of p53 function did not affect cell proliferation or attenuate the initial phases of programmed
cell death. However, analyses of apoptosis in the ﬁnal stages revealed suppression of its incidence and
delayed activation of caspase-3 in p53-null cells. Signiﬁcantly higher clonogenic ability, especially in
hypoxia, was identiﬁed in the case of p53-null cells. Induction of Mcl-1 and Bax levels were more
prominent in wt-pt53 cells. Interestingly, the level of Bcl-2 did not react to HY-PDT at all, in both cell
lines. Bringing the evidence together, we prove that despite insigniﬁcant impact on overall toxicity,
expression of p53 affects the clonogenic efﬁciency of HCT-116 cells. Since destruction of tumor tissue
and its vascular system by PDT tends to lead to hypoxia, superior survival of p53-deﬁcient tumor cells
under given conditions might result in recurrence of cancer diseases.
Introduction
Photodynamic therapy (PDT) represents a ﬂexible and versatile
therapeutic approach depending on the nature of the photosen-
sitive compound, its concentration and incubation time, on the
wavelength of light radiation, ﬂuency rate and light dose, as well
as on the histological origin of tissue andoxygenpressure in it.1 For
all these reasons, the type of cell death induced by PDT depends
upon many factors and their combinations.
Hypericin (HY), a naturally-occurring photosensitive com-
pound synthesized by Hypericum sp. (St. John’s Wort), has
properties suitable for PDT.1 The peculiar attributes of this
photosensitizer are high efﬁciency in production of singlet oxygen2
and superoxide anions after irradiation with light wavelength
around 600 nm, and low or no toxicity in the dark.3,4 Although
HY is localized in the endoplasmic reticulum andGolgi apparatus
and not inmitochondria1 (so it should induce apoptosis with lower
efﬁciency),5 rapid loss of mitochondrial membrane potential, sub-
sequent cytochrome c release, caspase-3 activation and apoptosis
occur as a result of the photodynamic action of activated HY.
The photosensitizing effects of HY are generally considered as
oxygen-dependent.6,7
TP53, a tumor suppressor gene encoding a tumor protein
53 (p53), plays a central role in cellular responses and defence
against DNA damage.8 Mutations in the p53 pathway are found
in nearly all types of cancers9 and more than 50% of all cancers
are reported to carry a mutant gene for p53, which is often
linked to altered cellular sensitivity towards chemotherapy and
radiation therapy.10,11 In response to the stress stimuli, p53 (which
Institute of Biology and Ecology, Faculty of Science, P.J. Sˇafa´rik Uni-
versity in Kosˇice, Moyzesova 11, 040 01, Kosˇice, Slovakia. E-mail: peter.
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normally has a low expression level) accumulates within cells
due to an increase in the protein stability.12,13 p53 integrates
signals from various pathways that become activated as a result of
different stimuli such as DNA damage, radiation, oxidative stress,
hypoxia and oncogene activation.14–16 Responses to the stimuli
are regulated through different mechanisms but most of them are
carried out via the ability of p53 to function as transcription factor.
In the ﬁeld of PDT the dependence of cell-killing on p53 is still
much debated, since papers proposing reliance17,18 as well as no
correlation19 have been published. There is also evidence to show
that induction of apoptosis (but not necrosis) may be inﬂuenced
by p53 and ATM (ataxia telangiectasia mutation) even if total cell
death is similar between the wild type and mutant phenotype.20
These studies have largely been limited because the cancer cell
lines employed by various researchers not only differ in their p53
status but are also likely to carry some other genetic differences in
part because theywere derived fromdifferent cell types or different
carcinoma samples.21
Since one of our previous works evaluated cell death incidence
evoked by HY-PDT in mut-p53 colon adenocarcinoma cells HT-
29,22 we continue here with a closer study of the effect of p53 on
the sensitivity of HY-PDT, consequent cell death incidence and its
role in the immediate and long-term survival of cells after PDT. In
order to understand these issues, p53-null and wt-p53-expressing
colon adenocarcinoma cell lines HCT-116 were chosen for the
experiments presented here.
Experimental
Cell culture conditions
For the present experiments, wild type p53- (wt-p53) expressing
HCT-116 cells (HCT-116 p53+/+) were compared to the p53-null
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HCT-116 subline (HCT-116 p53-/-), whichwas created by targeted
homologous recombination23 and was a gift from Professor Bert
Vogelstein (both kindly provided byDrAloisKozubı´k, Institute of
Biophysics, Brno, Czech Republic). Both cell lines were cultured
in McCoy’s 5A medium (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 10% fetal calf serum, antibiotics (penicillin
100Uml-1, streptomycin 100 mgml-1 and amphotericin 25 mgml-1;
Gibco Invitrogen Corp., Carlsbad, CA, USA) and gentamycin
(50 mg ml-1; Sigma-Aldrich).
The cultures were maintained at 37 ◦C in 5% CO2 and 95%
humidity. For the experiments, cells were seeded in 96 well (1 ¥
104 cells per well), 6 well (1.5 ¥ 105 cells per well) tissue culture
plates or 100 mm diameter Petri dish (1 ¥ 106 cells per dish)
(TPP, Trasadingen, Switzerland). 24 h after seeding, hypericin
(HPLC grade from Applichem, Darmstadt, Germany) was added
into the medium for another 16 h. For the irradiation procedure,
experimental groups as well as untreated controls were placed on
the diffuser glass of the irradiating device (L18W/30 ﬂuorescent
tubes (Osram, Berlin, Germany)) in sequence and exposed to
irradiation for speciﬁc time periods corresponding to the light dose
3.15 J cm-2. Afterwards cells were cultured in the stated conditions
and subsequently analyzed 8 h, 24 h or 48 h after irradiation. For
hypoxic cultivation, cells were maintained at 37 ◦C in 5% CO2,
1%O2 (controlled by ProoxModel 110, BioSpherix, Lacona, New
York, USA) and 95% humidity.
Clonogenic assay
For clonogenic assay, cells were harvested (8 h, 24 h and 48 h
after PDT treatment), counted and 500 viable cells were seeded
in 6 well plates (TPP). Cells were simultaneously maintained
under standard cultivation conditions as well as under the above-
mentioned hypoxic conditions. Ten days later, the plates were
stained with methylene blue dye (0.08% w/v) and scanned, and
colonies were counted using Clono-Counter software.24 Results
were evaluated as percentages of the untreated control.
Quantiﬁcation of total cell number and percentage of ﬂoating cells
Absolute numbers of cells within individual groups were evaluated
by counting in a Bu¨rker chamber or by Coulter Counter (Model
ZF, Coulter Electronics Ltd, Luton, Beds., UK). Total cell number
was expressed as a percentage of the untreated control. Floating
cells were expressed as a percentage of the total cell number.
Morphological analysis of cell death
Morphological analysis of cell death was carried out using viable
double staining with Hoechst 33342/propidium iodide or stain-
ing of ﬁxed cells with 2-(4-amidinophenyl)-6-indolecarbamidine
dihydrochloride (DAPI). At the scheduled time of analysis
(24 h or 48 h after HY-PDT), total cell population was harvested
(by trypsinisation of adherent and collection of medium with
ﬂoating cells), centrifuged and washed once in Hank’s balanced
salt solution (HBSS) (Sigma-Aldrich). Subsequently, 1 ¥ 106 cells
were either ﬁxed in cold 70% ethanol and kept at -20 ◦C overnight
or viably stained with Hoechst 33342 (2 mg ml-1) for 25 min and
propidium iodide (PI) (25 mg ml-1) for an additional 5 min (both
Sigma-Aldrich) in darkness at RT. Viable staining was followed
by washing in HBSS. Cells were then resuspended in 100 ml of
HBSS, prepared as fresh specimen slides and immediately eval-
uated with a ﬂuorescent microscope (Nikon Eclipse 400, Nikon
Instech Co. Ltd., Kawasaki, Japan). Representative photographs
of actual stainings are presented below. Ethanol ﬁxed samples
were processed as follows. The samples were stained in ﬁxative
solution by addition of DAPI (2 mg ml-1) and incubated for 30 min
at RT. Subsequently, cells were washed twice by centrifugation
and ﬁnally resuspended in PBS. The cells were then mounted into
MOWIOL 4-88 (Sigma-Aldrich) and allowed to harden for at
least 24 h at 4 ◦C. The slides were analyzed using a Nikon Eclipse
400 ﬂuorescentmicroscope and evaluated as the percentage of cells
with fragmented nuclei from a total number of minimum 300 cells.
Metabolic activity of cells analyzed by MTT assay
At scheduled timepoints (8 h, 24hor 48h) afterHY-PDT,MTT(3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) was
added to the cells in a 96 well plate (ﬁnal concentration 0.5 mg
ml-1). Cells were incubated for another 4 h at 37 ◦C. Reaction
was stopped and violet-blue crystals of insoluble formazan were
dissolved by addition of sodium dodecyl sulfate (SDS) at a ﬁnal
concentration of 3.3%.Cellswere incubated overnight at 37 ◦Cand
the absorbance (l = 584 nm)wasmeasured usingBMGFLUOstar
Optima (BMG Labtechnologies GmbH, Offenburg, Germany).
Results were evaluated as percentages of the absorbance of the
untreated control.
Analysis of hypericin incorporation
For analysis of HY incorporation, cells were seeded in 6 well plates
and left to settle for 24 h, then incubatedwithHY for another 16 h.
Subsequently, cells were harvested by trypsinization and the HY
ﬂuorescence was immediately analyzed using a BD FACSCalibur
ﬂow cytometer (Becton Dickinson, San Jose, CA, USA) with a
488 nm argon-ion excitation laser. The incorporation was quan-
tiﬁed as the ratio of each experimental group to the untreated
control.
Cell cycle analysis
Adherent and ﬂoating cells (5 ¥ 105) were harvested together 24 h
or 48 h after activation of HY, ﬁxed in cold 70% ethanol and kept
at -20 ◦C overnight. Prior to analysis, cells were washed in PBS.
RNA was degraded with ribonuclease A and nuclear DNA was
stained with propidium iodide (Sigma) (20 mg ml-1) in Vindelov’s
solution at RT for 30 min. DNA content was analyzed using a BD
FACSCalibur ﬂow cytometer. The ModFit 3.0 (Verity Software
House, Topsham,ME, USA) software was used to generate DNA
content frequency histograms and to quantify the number of cells
in the individual cell cycle phases.
Mitochondrial membrane depolarization
Adherent and ﬂoating cells (5 ¥ 105) were harvested together 24 h
after PDT,washedwithHBSS, stainedwith 100 nmol dm-3 tetram-
ethylrhodamine ethyl ester perchlorate (TMRE; Sigma-Aldrich)
for at least 10 min and than analyzed using a BD FACSCalibur
ﬂow cytometer. The results are presented as means ± SD of three
independent experiments together with one representative set of
data. Graphical output was generated using WinMDI software.
This journal is © The Royal Society of Chemistry and Owner Societies 2009 Photochem. Photobiol. Sci., 2009, 8, 1558–1567 | 1559
Phosphatidylserine externalization analysis
For phosphatidylserine externalization analysis, an Annexin
V-FITC/PI double-staining kit (Bender MedSystems, Vienna,
Austria) was used according to the manufacturer’s instructions.
Adherent and ﬂoating cells (1.5 ¥ 105) were harvested together
8 h or 24 h after PDT and stained with Annexin V-FITC in
binding buffer (Bender MedSystems) for 10 min, washed, stained
with PI for at least 10 min and thereafter analyzed using a
BD FACSCalibur ﬂow cytometer. Results were analyzed using
CellQuest Pro software. The results are presented asmeans ± SDof
three independent experiments togetherwith one representative set
of data. Graphical output was generated usingWinMDI software.
Cell membrane ﬂuidity analysis
For cell membrane ﬂuidity analysis, cells were maintained in
HBSS supplemented with 2% FCS during all steps of sample
preparation. Adherent and ﬂoating cells (5 ¥ 105) were harvested
together 24 h after PDT, washed, stained with MC540 (5 ng ml-1)
for 10 min (rotating), washed twice and than analyzed using a
BD FACSCalibur ﬂow cytometer. The results are presented as
means ± SD of three independent experiments together with one
representative set of data. Graphical output was generated using
WinMDI software.
Caspase-3 activation
Activation of caspase-3 was analyzed 8 h and 24 h after PDT
using a FITC Active Caspase-3 Apoptosis Kit (BD Pharmingen,
Franklin Lanes, NJ, USA, cat.# 550480) according to the man-
ufacturer’s instructions. Brieﬂy, adherent and ﬂoating cells were
harvested together, washed in cold PBS, permeabilized for 20 min
on ice, washed again twice, incubated with antibody for 30 min at
RT, washed and ﬁnally analyzed using a BD FACSCalibur ﬂow
cytometer. The results were evaluated as percentages of positively-
stained cells and are presented as means ± SD of four independent
experiments.
Western blot
ForWestern blot analysis, cells were scraped and lysed in Laemmli
sample buffer (100 mM Tris [pH 6.8], 2% SDS, 10% glycerol).
The extracts of total proteins were assayed with a DC protein
assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA)
and equal protein amounts (10 mg) with 0.01% bromphenol
blue and 1% mercaptoethanol were subjected to SDS-PAGE.
The gels were transferred electrophoretically to polyvinylidene
ﬂuoride membranes (Millipore, Bedford, MA, USA) in a buffer
containing 192 mM glycine, 25 mM Tris and 10% methanol.
The membranes were blocked for 1 h in 5% non-fat milk in
wash buffer (0.05% Tween-20 in 20 mM Tris [pH 7.6], 140 mM
NaCl). Primary antibodies (rabbit anti-Bax, 1 : 500, sc-493; mouse
anti-Bcl-2, 1 : 1000, sc-509; mouse anti-caspase-3, 1 : 500, sc-7272;
rabbit anti-PARP, 1 : 500, sc-7150; Santa Cruz Biotechnology,
Santa Cruz, CA, USA; mouse anti-b-actin, 1 : 6000, A5441,
Sigma-Aldrich; mouse anti-HSP70, 1 : 1000; MA3-006, Afﬁnity
BioReagents, Golden, CO, USA; rabbit anti-calpain I, 1 : 500,
#3189-100, BioVision, San Francisco Bay Area, CA, USA; mouse
monoclonal anti-p53 (DO-1) kindly provided by Dr. Vojtesˇek25)
were incubated with the blots for 2 h at RT or overnight at 4 ◦C.
After washing, secondary antibodies coupled with horseradish
peroxidase (anti-mouse IgG, 1 : 6000; anti-rabbit IgG, 1 : 6000;
both Amersham Biosciences, Buckinghamshire, UK) were added
for 2 h. The membranes were washed and antibody reactivity
was visualized with enhanced chemiluminescence (ECL) reagent
(Amersham Biosciences) against X-ray ﬁlm-CP (AGFA, Gevaert
N.V., Belgium). Loading was veriﬁed by detection of b-actin levels
and by non-speciﬁc amidoblack protein staining.
Statistical analysis
Data were analyzed using one-way ANOVAwith Tukey’s post test
or t-test and are expressed as mean ± standard deviation (S.D.).
Signiﬁcance levels are indicated in the legend to each particular
ﬁgure.
Results
For presented experiments focused on the implication of p53
in sensitivity of colon adenocarcinoma to HY-PDT, a p53-null
HCT-116 colon adenocarcinoma cell line (HCT-116 p53-/-) was
compared to HCT-116 cells expressing wild-type p53 (HCT-116
p53+/+).
Suitable concentrations for experiments were chosen based on
preliminary screening (MTT assay) with one light dose of 3.15 J
cm-2 and HY concentrations ranging 0–150 nmol dm-3 (data not
shown). Three concentrations (25, 50 and 75 nmol dm-3) were
used for all types of analyses, but in some cases only the results of
75 nmol dm-3 HYwere signiﬁcantwhen compared to the untreated
control, and accordingly only those are presented. Analyses were
performed 8, 24 or 48 h after PDT depending on the particular
method.
Total cell numbers were mostly insigniﬁcant, whereas the ﬂoat-
ing cells analysis showed higher accumulation in p53 deﬁcient cells
24 h after PDT. Analysis of total cell numbers (Fig. 1A) revealed
a dose-dependent reaction to HY-PDT, which was signiﬁcant in
almost all groups when compared to the untreated control and
therefore signiﬁcance is not presented. Differences between cell
lines were scarce and observed only at the lowest concentration.
In contrast, both cell lines showed signiﬁcantly elevated ﬂoating
cells not only when compared to the untreated control, but also
compared with each other, mainly 24 h after PDT (Fig. 1B).On
the other hand, analyses accomplished 48 h after PDT disclosed
that only 25 nmol dm-3 HYand untreated controls were signiﬁcant
and therefore appeared to be in good correlation with the total cell
number.
Cell cycle progression was signiﬁcantly affected by PDT; how-
ever, both cell lines underwent mostly similar changes. Changes in
cell cycle progression of both cell lines were signiﬁcantly affected
by HY-PDT (Table 1). The cells of both lines accumulated in the
G2/M-phase during the ﬁrst 24 h after HY-PDT. The percentage
of p53-null cells in the S-phase was signiﬁcantly higher at this
time point, but their untreated control had a similarly higher,
though insigniﬁcant percentage of S-phase cells as the untreated
control of wt-p53 cells. Later on, G2/M-phase arrest declined
but stayed signiﬁcant and both cell lines accumulated in the
S-phase. Although the trend seems to be similar, uneven distribu-
tion with signiﬁcantly higher percentage of cells in the G1-phase at
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Fig. 1 Total cell numbers (A) and ﬂoating cell percentage (B) of wt-p53
(HCT-116 p53+/+) or p53-null cells (HCT-116 p53-/-). Cells were untreated
or treated with 25, 50 and 75 nmol dm-3 hypericin, irradiated with
3.15 J cm-2 and harvested 24 or 48 h after PDT. The results (means ±
S.D.) of three independent experiments are shown as the percentages of an
untreated control. Statistical signiﬁcance is identiﬁed as follows: p < 0.05
(*), p < 0.01 (**) and p < 0.001 (***) HCT-116 p53+/+ versus HCT-116
p53-/-.
the expense of the S-phase was recorded in wt-p53 cells. However,
this might be the consequence of higher accumulation of p53
deﬁcient cells in the S-phase in general. Apart from these
differences, both cell lines responded to HY-PDT similarly.
Detection of phosphatidylserine externalization and cell vi-
ability by Annexin V/PI staining revealed that both cell
lines underwent signiﬁcant changes of cell membrane structure
(Table 2), as indicated by a signiﬁcant decrease in surviving
cells (Annexin V-/PI-) and an increase in cells dedicated to
programmed cell death (Annexin V+/PI-) in all comparisons
of the untreated control to the particular experimental group.
Differences between the cell lines were conﬁned to the percentage
of surviving cells (Annexin V-/PI-) 8 h after PDT only. Although
there were some differences in the percentage of Annexin V+/PI-
cells 24 h after PDT, these were insigniﬁcant. Apart from these
differences, the percentages of Annexin V+ cells as well as
surviving cells seem to be similar, and therefore there are no
differences between p53 deﬁcient versus p53 wild-type HCT-116
cells when considering this parameter 24 h after PDT. There
was a difference in time-dependent decrease in the surviving cells
percentage as there was transient resistance of HCT-116 p53+/+
cells 8 h after PDT. From this point of view, p53 deﬁcient cells
seemed to proceed to cell death faster during the ﬁrst hours after
HY-PDT.
p53-deﬁcient HCT-116 cells underwent mitochondrial mem-
brane depolarization and membrane structure loosening more
intensively 24 h after HY-PDT. Analysis of mitochondrial mem-
brane potential (DWm) 24 h after PDT revealed a signiﬁcant
decrease as a consequence of HY-PDT in both cell lines, but
signiﬁcantly superior DWm dissipation in p53-deﬁcient cells was
detected (Fig. 2A). Similarly, analysis of cell membrane loosening
by MC540 24 h after irradiation revealed alterations of cell
membrane structure in a signiﬁcantly higher percentage of cells
in both cell lines, and again the changes were more intensive in
p53-deﬁcient cells (Fig. 2B).
The percentage of cells in the ﬁnal apoptotic phase was
signiﬁcantly lower in the p53-deﬁcient cells. In spite of previous
data indicating an insigniﬁcant or higher preference for cell death
processes in the p53-null cells, the percentages of apoptotic cells
in the ﬁnal stages of programmed cell death, indicated as nuclear
Table 1 Cell cycle progression of wt-p53 (HCT-116 p53+/+) or p53-null cells (HCT-116 p53-/-). The cells were untreated or treated with 75 nmol dm-3
hypericin (Hyp 75), irradiated with 3.15 J cm-2 and harvested 24 h or 48 h after PDT. The results (means ± S.D.) of three independent experiments are
shown as percentages of cells in the particular phases of the cell cycle. Statistical signiﬁcance (S S.) is identiﬁed as follows: p < 0.05 (*) hypericin versus
untreated control; p < 0.05 (d) HCT-116 p53+/+ versus HCT-116 p53-/- and p < 0.05 (¥) 24 h versus 48 h interval
HCT-116 p53+/+ HCT-116 p53-/-
Time/h Group CC phase G0/G1 S G2/M G0/G1 S G2/M
24 Control Average [%] 67.09 22.16 10.75 53.48 29.41 17.11
S.D. ±1.46 ±1.6 ±0.15 ±9.25 ±5.65 ±3.58
S S.
24 Hyp 75 Average [%] 53.49 17.70 28.82 42.71 27.35 29.94
S.D. ±5.58 ±1.57 ±4.02 ±3.03 ±1.99 ±1.05
S S. d * d *
48 Control Average [%] 70.98 21.17 7.85 60.70 28.33 10.98
S.D. ±2.97 ±4.81 ±1.85 ±4.66 ±4.03 ±0.64
S S.
48 Hyp 75 Average [%] 47.87 33.78 18.36 40.03 37.85 22.12
S.D. ±0.96 ±1.96 ±2.92 ±0.45 ±0.72 ±1.18
S S. */d */¥ * */d */¥ */¥
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Table 2 Externalization of phosphatidylserine and viability of wt-p53 (HCT-116 p53+/+) or p53-null cells (HCT-116 p53-/-). The cells were untreated
or treated with 75 nmol dm-3 hypericin (Hyp 75), irradiated with 3.15 J cm-2 and harvested 8 h or 24 h after PDT. The results (means ± S.D.) of three
independent experiments are shown as percentages of cells in particular quadrants. Statistical signiﬁcance (S S.) is identiﬁed as follows: p < 0.05 (*), p <
0.01 (**) or p < 0.001 (***) hypericin versus untreated control; p < 0.05 (d) or p < 0.01 (dd) HCT-116 p53+/+ versus HCT-116 p53-/- and p < 0.05 (¥)
8 h versus 24 h interval
HCT-116 p53+/+ HCT-116 p53-/-
Annexin V + + - - + + - -
Time/h Group PI - + - + - + - +
8 Control Average [%] 3.0 4.3 87.4 5.3 1.2 2.2 91.9 4.7
S.D. ±1.4 ±2.8 ±1.2 ±3.1 ±0.9 ±1.5 ±1.6 ±2.2
S S. ** ***/d * ***/d
8 Hyp 75 Average [%] 26.9 9.9 57.8 5.4 30.0 22.3 39.6 8.1
S.D. ±4.3 ±4.9 ±2.0 ±2.6 ±7.2 ±9.8 ±2.9 ±4.9
S S. ** ***/dd/¥ * ***/dd
24 Control Average [%] 1.7 4.5 90.0 3.8 2.1 2.8 91.6 3.5
S.D. ±1.4 ±1.8 ±2.2 ±2.5 ±0.8 ±1.6 ±2.8 ±2.6
S S. * ** * **
24 Hyp 75 Average [%] 32.0 32.1 31.2 4.7 45.1 24.2 28.3 2.4
S.D. ±6.5 ±11.0 ±8.8 ±2.3 ±11.4 ±12.0 ±7.4 ±1.2
S S. * ** * **
fragmentation,were signiﬁcantly lower both 24 and 48 h after PDT
(Fig. 3). Concentration-dependent accumulation of apoptotic cells
was convincingly noticeable at the highest 75 nmol dm-3 HY,
although the trend was obvious in both cell lines also at lower
concentrations.
Analysis of nuclear morphology and cellular viability reveals
different tendencies for apoptotic cell death. Corresponding with
the differences between cell lines determined by morphological
analysis of nuclear morphology (DAPI staining; Fig. 3), ﬂoating
cells (Fig. 1B) and concurrence of total cell number (Fig. 1A),
the mutual analysis of nuclear morphology and cellular viability
using viable staining with Hoechst 33342 and propidium iodide
(Fig. 4) revealed different tendencies of cells to die by apoptosis or
necrosis. Whereas in HCT-116 p53+/+ cells prevalence of apoptotic
processes with characteristic nuclear morphology is evident when
detected 24 h after PDT, p53 deﬁcient cells tended to be shifted
towards necrosis.
Clonogenic assay revealed differences in survival of both cell
lines either under normoxic or hypoxic conditions. For clonogenic
assay, cells were harvested 8, 24 and 48 h after PDT, and
subsequently 500 viable cells were seeded. The results (Fig. 5)
reveal signiﬁcantly higher clonogenic potential (especially under
hypoxia) of p53-deﬁcient cells harvested and seeded 8 h after
HY-PDT (Fig. 5). Later on (24 and 48 h after HY-PDT), the
differences between hypoxia and normoxia became insigniﬁcant,
the clonogenic potential of both cell lines increased signiﬁcantly
with time and the differences between cell lines vanished.
Analyses of protein expression levels disclosed some interesting
events in the regulation of programmed cell death (Fig. 6). We
conﬁrmed an undetectable level of protein p53-null cells, but at the
same time we found its level responsive to HY-PDT in p53 wild-
type-expressing cells. The photocytotoxic effect of HY stabilized
p53 8 h after PDT, and led to the accumulation. Regression of
p53 at 75 nmol dm-3 HY 24 h after PDT might indicate intensive
degradation of p53 as a consequence of high dose PDT.
Cleavage of PARP was evident at 75 nmol dm-3 HY in both
cell lines and became even more markedly pronounced in p53-
deﬁcient cells 24 h after PDT even at lower (25 and 50 nmol dm-3)
HY concentrations.
Interestingly, neither p53 wild-type-expressing cells nor p53-
deﬁcient cells showed any impressive caspase-3 cleavage (except
p53-deﬁcient cells 8 h, 75 nmol dm-3 HY-PDT). An expression
of calpain did not indicate any signiﬁcant changes in either cell
line, too. Moreover, levels of anti-apoptotic Bcl-2 protein did not
respond to HY-PDT. On the other hand, the expression of Mcl-1
was markedly induced in HCT-116 p53+/+ cells already 8 h, and
endured even 24 h after PDT. The level of Mcl-1 in p53-deﬁcient
cells was less responsive and mild as compared to wt-p53 cells.
An expression of Bax, a protein involved in DWm depolarization,
responded to HY-PDT in cells expressing wild-type p53 but was
not responsive to PDT and generally minor in p53-deﬁcient cells.
Analysis ofHSP-70 level conﬁrmed the involvement of oxidative
stress in the photocytotoxic action of HY, since it responded to
PDT in both lines and both analysis time-points.
Percentage of cells with activated caspase-3 detected by FCM
analysis revealed time-delay of activation onset in p53-deﬁcient
cells. Percentages of cells with activated caspase-3 were detected
by FCM analysis 8 and 24 h after HY-PDT (Table 3). We found
differences between cell lines insigniﬁcant 24 h afterHYactivation,
but the earlier analysis (8 h) showed us lower incidence of caspase-
3pos events inHCT-116 cells deﬁcient in p53when treatedwith PDT
after incubation with either 50 or 75 nmol dm-3 HY. Although the
differences were not very striking when compared to untreated
control 8 h after activation, there was a signiﬁcant increase in
percentage of positives after treatment with 50 and 75 nmol dm-3
HY, though not with the 25 nmol dm-3 dose. Later on, when
analyzed 24 h after PDT, only the PDT treatment with 75 nmol
dm-3 HY showed signiﬁcant accumulation of cells with activated
caspase-3 (over 20% positive events) in comparison to untreated
control as well as to previous analysis. Since a total lysate of the
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Fig. 2 Mitochondrial membrane depolarization (A) and cell membrane
loosening (B) of wt-p53 (HCT-116 p53+/+) or p53-null cells (HCT-116
p53-/-) cells measured by TMRE and merocyanine (MC540) incorpora-
tion, respectively. The cells were untreated or treated with 75 nmol dm-3
hypericin (Hyp 75), irradiated with 3.15 J cm-2 and harvested 24 h after
PDT. The results (means ± S.D.) of three independent experiments are
shown as percentages of cells in particular quadrants together with one
representative set of results. Statistical signiﬁcance is identiﬁed as follows:
p < 0.01 (**) or p < 0.001 (***) hypericin versus untreated control;
p < 0.01 (dd) HCT-116 p53+/+ versus HCT-116 p53-/-.
whole cell population (Fig. 6) did not facilitate sufﬁciently detailed
analyses, activation of caspase-3 analyzed by FCM was used for
further evaluation of activation of programmed cell death.
Discussion
In our previous study, we found necrosis to be the principal formof
cell death in adenocarcinoma colon cancer cells HT-29,22 despite
Fig. 3 Percentage of apoptotic cells analyzed via DAPI staining and
morphological analysis of nuclear fragmentation in wt-p53 (HCT-116
p53+/+) or p53-null cells (HCT-116 p53-/-). Cells were untreated or treated
with 25, 50 and 75 nmol dm-3 hypericin, irradiated with 3.15 J cm-2 and
harvested 24 and 48 h after PDT. The results (means ± S.D.) of three
independent experiments are shown as a percentage of cells with apoptotic
morphology within the minimum of 300 cells. Statistical signiﬁcance is
identiﬁed as follows: p < 0.05 (*) HCT-116 p53+/+ versusHCT-116 p53-/-.
Fig. 4 Hoechst 33342/Propidium iodide staining of wt-p53 (HCT-116
p53+/+) or p53-null cells (HCT-116 p53-/-) 24 h after PDT. Cells were
untreated or treated with 50 nmol dm-3 hypericin (Hyp 50), irradiated with
3.15 J cm-2, harvested and stained 24 h after PDT.Cells could be recognized
as vital (blue stained compact nuclei), apoptotic (blue stained fragmented
nuclei), necrotic (red stained compact nuclei) and secondary necrotic
(red stained fragmented nuclei). One of three independent experiments
is presented herein (magniﬁed 200¥).
the extensive range of HY-PDT doses evoked by variations in
two variables: hypericin concentration and light dose. We also
suggested that the mutation of TP53 in HT-29 cells leading to the
stabilization of p53 protein and its consequent accumulation may
play a key role in cell death signaling of these cells subjected to
PDT.Our investigationof p53 as the factor possibly responsible for
the drift in cell death incidence induced by PDT led to the present
experiments employing a model of HCT-116 cells expressing wild-
type p53 compared to the same cell line with p53 knock-out.
Summarizing our data, we can presume that proliferation of
HCT-116 after HY-PDT was not dependent on status of p53.
Though earlier analysis revealed a tendency of p53 null cells to
detach and undergo cell death faster, later on (48 h after PDT)
ﬂoating cells aligned (Fig. 1). This tendency was also indicated
by intensive phosphatidyl serine externalization already 8 h after
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Fig. 5 Clonogenic assay of wt-p53 (HCT-116 p53+/+) or p53-null cells (HCT-116 p53-/-) under hypoxic (A) or normoxic (B) conditions. Cells were
harvested 8, 24 or 48 h after PDT with 50 and 75 nmol dm-3 hypericin (Hyp 50 and Hyp 75). Representative results of cells harvested 8 h after PDT (C) is
presented. The results (means ± S.D.) of three independent experiments are shown as a ratio to untreated control. Statistical signiﬁcance is identiﬁed as
follows: p < 0.05 (*) and p < 0.01 (**) HCT-116 p53+/+ versusHCT-116 p53-/-; p < 0.05 (¥) hypoxia versus normoxia; p < 0.05 (s) and p < 0.01 (ss)
24 h/48 h versus 8 h time of seeding post PDT.
Fig. 6 Western blot analysis of PARP and caspase-3 (a procaspase)
cleavage or calpain, HSP-70, p53,Mcl-1, Bcl-2, Bax and b-actin expression
in wt-p53 (HCT-116 p53+/+) or p53-null cells (HCT-116 p53-/-). Cells were
untreated or treated with 25, 50 and 75 nmol dm-3 hypericin, irradiated
with 3.15 J cm-2 and harvested 8 and 24 h after PDT. One representative
experiment of two is presented.
Table 3 Percentage of cells without activated caspase-3. Cells were
harvested 8 h and 24 h after PDT with 25, 50 and 75 nmol dm-3
hypericin. Percentage of cells positive for active caspase-3 is a result of
four independent experiments (mean ± S.D.). Statistical signiﬁcance (S
S.) is identiﬁed as follows: p < 0.05 (*), p < 0.01 (**), p < 0.001 (***)
hypericin versus untreated control; p < 0.05 (d), p < 0.01(dd) HCT-116
p53+/+ versus HCT-116 p53-/-; p < 0.01(¥¥), p < 0.001(¥¥¥) 8 h versus
24 h analysis
Time/h
HCT-
116 Hyp [nmol dm-3] Average ± S.D. S S.
8 p53+/+ 0 97.91% ± 0.32
8 p53+/+ 25 97.13% ± 0.44
8 p53+/+ 50 94.38% ± 1.23 */d
8 p53+/+ 75 87.65% ± 1.66 ***/dd/¥¥
8 p53-/- 0 98.72% ± 0.15
8 p53-/- 25 98.25% ± 0.24
8 p53-/- 50 96.83% ± 0.69 */d
8 p53-/- 75 93.90% ± 1.99 */dd/¥¥¥
24 p53+/+ 0 95.11% ± 0.68
24 p53+/+ 25 93.75% ± 3.17
24 p53+/+ 50 95.42% ± 2.39
24 p53+/+ 75 79.87% ± 2.63 ***/—/¥¥
24 p53-/- 0 96.95% ± 1.27
24 p53-/- 25 94.19% ± 2.16
24 p53-/- 50 92.71% ± 3.61
24 p53-/- 75 72.02% ± 6.73 **/—/¥¥¥
PDT (Table 2) and further supported by a higher percentage
of cells with lowered DWm and increased cell membrane ﬂuidity
(both in goodmutual correlation, indicating close interconnection
of the processes) (Fig. 2) detected 24 h after HY-PDT. However,
morphological analyses (Fig. 3 and 4) revealed a prevalence
of apoptotic processes with characteristic nuclear morphology
in HCT-116 p53+/+ cells and shifting towards necrosis in
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p53-deﬁcient cells. Yet, the hallmarks of oxidative stress (HSP70)
and programmed cell death (PARP cleavage) were detectable
in both cell lines (Fig. 6), as was the activation of caspase 3
(Table 3). Therefore it is likely that termination of the apoptotic
process in HCT-116 cells is linked with the functional version
of p53. Long term surival detected by clonogenic assay (Fig. 5)
indicated differences between populations of viable cells harvested
especially 8 h after HY-PDT. Cells deﬁcient in p53 achieved a
higher recovery rate even in spite of evidence of higher toxicity.
Therefore it is possible that p53 status affects processes leading to
survival of tumour cells exposed to HY-PDT.
It is well known that the p53 protein can promote apoptosis via
transcription-independent mechanisms as well as transcriptional
activation of pro-apoptotic (Bax)26 or repression of anti-apoptotic
genes.27 Still, there is a lot of confusion about the role of p53 and
its status in the efﬁcacy of PDT. This is mostly due to the fact
that PDT is generally considered as non-genotoxic, because the
photosensitizers employed in PDT do not localize to the nucleus.28
There are several studies linking induced p53 expression to higher
incidence of apoptosis after ALA-PDT29 or claiming either p53-
dependent17 or p53-independent19 toxicity of Photofrin-PDT. The
possibly hazy and scrambled nature of the results suggests that
the question of the role of p53 in PDT might not have an easy
and straightforward answer. Not only does p53 play a crucial
role in numerous cellular processes, but moreover the phenotype
of different sorts of cancer and distinct molecular and cellular
mechanisms of phototoxicity induced by various photosensitizers
under various conditions certainly signiﬁcantly affect the overall
efﬁcacy of PDT.
The role of protein p53 in the photocytotoxicity of PDT has
already been studied by several authors. Lee and colleagues30
even studied HY-PDT in osteosarcoma cells with low versus
high expression of p53 induced by stabilization of the protein,
and they found the comparison of sensitivity between cell lines
established by MTT and clonogenic assay insigniﬁcant. Likewise,
phosphatidylserine externalization and mitochondrial potential
dissipation exhibited similar trends in the onset and progression of
programmed cell death. However, they did not present a quantita-
tive analysis of the ﬁnal stages of apoptosis. In another experiment,
the dependence of the efﬁciency of PDTwithm-THPCon atm and
TP53 gene expression20 demonstrated that p53 and ATM are not
required for necrosis but might be required for apoptosis. In this
case, genomicDNA fragmentation detected by TUNEL assay was
used to analyze the ﬁnal stage of the apoptotic process.
In concert with the results of Lee and colleagues,30 we also
concluded that p53 does not affect HY accumulation (data not
shown) or the ability of photoactivatedHY to kill tumour cells, i.e.
its overall toxicity. We also found results of phosphatidylserine ex-
ternalization 24 h after PDT insigniﬁcant, though earlier analysis
(8 h) revealed some signiﬁcant results in our experiment. However,
since these authors did not present any quantitative analysis of
the ﬁnal stage of apoptosis, we could not compare our results
indicating different incidence of apoptosis in our in vitromodel of
colon adenocarcinoma cells (Fig. 3). But the lower percentage of
ﬁnal stage apoptotic cells in p53-deﬁcient cells correlates with m-
THPC-mediated PDT in the work of Heinzelmann-Schwarz and
colleagues.20
To bring more light to bear on the mechanism of passage
along the apoptotic pathway inﬂuenced by p53 status, activation
of caspase-3 was analyzed using Western blot as well as on a
cellular basis using FCM (Fig. 6 and Table 3). The percentage
of cells with activated caspase-3 (caspase-3pos) analyzed 8 h after
PDT (Table 3) was signiﬁcantly enhanced in cells expressing wt-
p53 when compared to control as well as to p53-deﬁcient cells.
However, considerable induction of caspase-3pos cells by PDT
with 75 nmol dm-3 HY, but no difference between cell lines 24
h after PDT, indicated that the apoptotic program was executed
irrespective of p53 status, although some deceleration in p53-
deﬁcient cells was detected at the early stage (8 h). Since PARP is a
substrate of caspase-3,31 its cleavage, similar in both cell lines, is in
accordance with caspase-3 activation. Though PARP cleavage did
not correlate with differences in percentages of cells with apoptotic
morphology of the nucleus. Therefore we consider it more as a
qualitative/semiquantitative, but not a fully quantitative, indicator
of the apoptotic process. And since there is some evidence of
caspase-332 or even caspase-3, -6 and -7 independent cleavage of
PARP33 as well as a caspase- and PARP-cleavage-independent
apoptotic pathway,34,35 we might consider PARP cleavage more as
a qualitative hallmark of programmed cell death.
Since PDT action is limited to a short period during photosensi-
tizer activation by light, and subsequent cell death is a consequence
of damage induced byROS produced during activation, those cells
that handle the impact of PDT may undergo a series of different
changes, even those inducing resistance.36 The signiﬁcantly higher
clonogenic potential of p53-deﬁcient cells harvested 8 h and
24 h after PDT and the elapsed-time ascending trend (Fig. 5)
in both cell lines indicate that the pools of viable cells seeded
at those mentioned time points differed in their physiological
status. Especially the 8 h harvest indicates that the population
of p53-deﬁcient cells, even though showing a lower survival rate
(Annexin V/PI), contained a pool of surviving cells in different
physiological condition and evenwhen seeded in the samenumbers
they expressed a higher clonogenic potential. It is liable, that this
population of surviving cells might be coincident with cancer stem
cell subpopulations of HCT-116 cells described by Botchkina
and colleagues,37 which proved to possess higher clonogenic
potential and in vivo tumorigenicity than the bulk population
they originated from. In accordance with this presumption, cancer
stem cells deﬁned as CD133+ are known to be highly resistant to
chemotherapy38 and their higher percentage correlates with tumor
aggressiveness and clinical outcome.39 When populations of both
cell lines were harvested and seeded 48 h after PDT, the differences
between them diminished.
Interestingly, harvesting and seeding cells 8 h after PDT
revealed signiﬁcantly higher clonogenic potential of both cell
lines also under hypoxic conditions (1% O2). These ﬁndings
underline the impact of early response mechanisms (e.g. HIF-
140) on the therapeutic outcome and suggest that low-dose PDT
might stimulate cell survival and induce resistant phenotype.36
Regarding these results, it is also likely that the mechanisms linked
to higher clonogenic potential under hypoxia are independent of
p53 status. All told, together with analyses of phosphatidylserine
externalization, DWm dissipation, cell membrane ﬂuidity, total cell
number and ﬂoating cells, we suggest that the programmed cell
death pathway is decelerated in cells expressing wt-p53, whereas
cells deﬁcient in p53 proceeded faster to their demise. Although
activation of caspase-3 seems to be an exception negating the
above stated premise, as a matter of fact only a fraction of cells
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with higher cell membrane ﬂuidity, dissipatedDWm or externalized
phophatidylserine proceeded to caspase-3 activation. A higher
percentage of Annexin V+ cells compared to cells with dissipated
DWm might also signify either preferential onset of phosphatidyl
serine externalization41 or reversibility of the process.42,43
As already reported by us and others, HY-PDT induces cell
cycle arrest with preference at the G2/M transition point.
22,44–46
Moreover, the protein p53 is known to affect cell cycle progression
at the G1/S transition
47 as well as the G2/M transition point.
48 In
our experiment, both cell lines underwent G2/M arrest, however
signiﬁcantly higher accumulation of p53-deﬁcient cells in the
S-phase at the expense of the G1-phase was detected 48 h after
PDT. Based on these results, we suggest that accumulation of cells
in the G2/M phase of the cell cycle is not affected by p53 status, in
accordancewith the results of Lee and colleagues.30 But in addition
we might claim that HY-PDT induced minor accumulation at the
G1/S transition point, which was abrogated in p53-deﬁcient cells.
However justiﬁcation of this event might require further study.
The crucial role in the onset of the apoptotic process is played
by a wide group of anti- and pro-apoptotic proteins from the Bcl-2
family. Interestingly, an expression of Bcl-2 was not affected at all,
either by p53 status or PDT (Fig. 6). On the other hand, induction
of Mcl-1, another anti-apoptotic member of the Bcl-2 family, was
in apparent correlation with PDT dose in the wt-p53 expressing
cells. Bax, a representative of the pro-apoptotic group of the Bcl-
2 family, responded to HY-PDT in the HCT-116 p53+/+ but not
p53-/- cells (Fig. 6). Since Mcl-1 does not inhibit Bax-mediated
apoptosis,49 induction of Bax, in spite of higher levels of Mcl-1,
might be responsible for onset of apoptosis in wt-p53 cells. In
contrast, the low expression of Bcl-2 together with Bax and only
weaker responsiveness of Mcl-1 to increasing HY concentration
were characteristic for apoptotic signaling in p53-deﬁcient cells.
Thismight indicate an impact of p53 status onBcl-2 protein family
signaling.
Based on the data presented here, we can predicate that our
results correlate with other studies discussing this issue when
considering the direct overall phototoxicity ofHY-PDT.Although
the lack of p53 function did not attenuate the initial phases of
programmed cell death, analysis of apoptosis in the ﬁnal stage
revealed suppression of its incidence in p53 knock-out cells.
Analyses of the apoptotic pathway in the execution phase revealed
delayed stimulation of caspase-3 in p53-deﬁcient cells 8 h after
PDT, however we found it similar together with PARP cleavage in
both cell lines at the same time (24 h after PDT) when differences
in nuclear fragmentation were detected. Clonogenic assay revealed
differences in ability to repopulate, especially high under hypoxic
conditions, when harvested and seeded 8 h after PDT. Stimulation
of programmed cell death onset in wt-p53 expressing cells was
documented by induction in protein levels of anti-apoptotic Mcl-
1 and pro-apoptotic Bax, whereas induction of Mcl-1 in p53-
deﬁcient cells was less prominent, and the level of Bax did not
respond to PDT treatment. Interestingly, the level of Bcl-2 did not
react to HY-PDT at all, in either cell line.
Conclusions
Bringing the evidence together, we demonstrate that despite its
insigniﬁcant impact on overall toxicity, expression of the p53
protein affects the clonogenic efﬁciency of HCT-116 cells. Since
destruction of tumor tissue and its vascular system as a conse-
quence of PDT tends to lead to hypoxia, superior survival of
tumour cells under these conditionsmight cause recurrence of can-
cer disease. Unfortunately, there is so far no literature discussing
in detail the p53-dependent mechanisms of apoptosis regulation
after PDT. Further studies will therefore be required to identify
key molecular targets which might in future be treated pharmaco-
logically in order to overcome the risk of disease recurrence.
Acknowledgements
This work was supported by the Slovak Research and Develop-
ment Agency under the contracts No. VVCE-0001-07 and No.
APVV0321-07, andby the ScientiﬁcGrantAgency of theMinistry
of Education of the Slovak Republic No. VEGA 1/0240/08. The
authors are grateful toViera Bala´zˇova´ for assistancewith technical
procedures. Thanks also toAndrew J. Billingham for proofreading
the manuscript.
Notes and references
1 P.Agostinis,A.Vantieghem,W.Merlevede andP.A. deWitte,Hypericin
in cancer treatment: more light on the way, Int. J. Biochem. Cell Biol.,
2002, 34, 221–241.
2 R.W.Redmond and J.N.Gamlin,A compilation of singlet oxygen yields
from biologically relevant molecules, Photochem. Photobiol., 1999, 70,
391–475.
3 E. Fox, R.F. Murphy, C.L. McCully and P.C. Adamson, Plasma
pharmacokinetics and cerebrospinal ﬂuid penetration of hypericin in
nonhuman primates, Cancer Chemother. Pharmacol., 2001, 47, 41–44.
4 J.M. Jacobson, L. Feinman, L. Liebes, N. Ostrow, V. Koslowski, A.
Tobia, B.E. Cabana, D. Lee, J. Spritzler and A.M. Prince, Pharma-
cokinetics, safety, and antiviral effects of hypericin, a derivative of St.
John’s wort plant, in patients with chronic hepatitis C virus infection,
Antimicrob. Agents Chemother., 2001, 45, 517–524.
5 S. Marchal, A. Fadloun, E. Maugain, M.A. D’Hallewin, F. Guillemin
and L. Bezdetnaya, Necrotic and apoptotic features of cell death
in response to Foscan photosensitization of HT29 monolayer and
multicell spheroids, Biochem. Pharmacol., 2005, 69, 1167–1176.
6 E. Delaey, A. Vandenbogaerde, W. Merlevede and P. de Witte,
Photocytotoxicity of hypericin in normoxic and hypoxic conditions,
J. Photochem. Photobiol., B, 2000, 56, 19–24.
7 T. Utsumi, M. Okuma, T. Kanno, Y. Takehara, T. Yoshioka, Y. Fujita,
A.A.Horton andK.Utsumi, Effect of the antiretroviral agent hypericin
on rat liver mitochondria, Biochem. Pharmacol., 1995, 50, 655–662.
8 T. Enoch and C. Norbury, Cellular responses to DNA damage: cell-
cycle checkpoints, apoptosis and the roles of p53 and ATM, Trends
Biochem. Sci., 1995, 20, 426–430.
9 T. Soussi, p53 alterations in human cancer: more questions than
answers, Oncogene, 2007, 26, 2145–2156.
10 S. Bladt and H. Wagner, Inhibition of MAO by fractions and
constituents of hypericum extract, J. Geriatr. Psychiatr. Neurol., 1994,
7, S57–S59.
11 S. Fan, M.L. Smith, D.J. Rivet, D. Duba, Q. Zhan, K.W. Kohn, A.J.
Fornace and P.M. O’Connor, Disruption of p53 function sensitizes
breast cancer MCF-7 cells to cisplatin and pentoxifylline, Cancer Res.,
1995, 55, 1649–1654.
12 J.K. Hsieh, D. Yap, D.J. O’Connor, V. Fogal, L. Fallis, F. Chan, S.
Zhong and X. Lu, Novel function of the cyclin A binding site of E2F
in regulating p53-induced apoptosis in response to DNA damage,Mol.
Cell. Biol., 2002, 22, 78–93.
13 S. Hansen, T.R. Hupp and D.P. Lane, Allosteric regulation of the
thermostability and DNA binding activity of human p53 by speciﬁc
interacting proteins. CRC Cell Transformation Group, J. Biol. Chem.,
1996, 271, 3917–3924.
14 B. Vogelstein, D. Lane and A.J. Levine, Surﬁng the p53 network,
Nature, 2000, 408, 307–310.
1566 | Photochem. Photobiol. Sci., 2009, 8, 1558–1567 This journal is © The Royal Society of Chemistry and Owner Societies 2009
15 M. Oren, Decision making by p53: life, death and cancer, Cell Death
Differ., 2003, 10, 431–442.
16 K.H. Vousden andD.P. Lane, p53 in health and disease,Nat. Rev.Mol.
Cell Biol., 2007, 8, 275–283.
17 A.M. Fisher, N. Rucker, S. Wong and C.J. Gomer, Differential
photosensitivity in wild-type and mutant p53 human colon carcinoma
cell lines, J. Photochem. Photobiol., B, 1998, 42, 104–107.
18 W.G. Zhang, X.W. Li, L.P.Ma, S.W.Wang, H.Y. Yang and Z.Y. Zhang,
Wild-type p53 protein potentiates phototoxicity of 2-BA-2-DMHA in
HT29 cells expressing endogenousmutant p53,Cancer Lett., 1999, 138,
189–195.
19 A.M. Fisher, A. Ferrario, N. Rucker, S. Zhang and C.J. Gomer,
Photodynamic therapy sensitivity is not altered in human tumor cells
after abrogation of p53 function, Cancer Res., 1999, 59, 331–335.
20 V. Heinzelmann-Schwarz, A. Fedier, R. Hornung, H. Walt, U. Haller
and D. Fink, Role of p53 and ATM in photodynamic therapy-induced
apoptosis, Lasers Surg. Med., 2003, 33, 182–189.
21 A.A. Eshraghi, D.J. Castro,M.B. Paiva, I.P. Graeber, N. Jongewaard, S.
Arshadnia, G. Lamas, J. Soudant and R.E. Saxton, Laser chemother-
apy of human carcinoma cells with three new anticancer drugs, J. Clin.
Laser Med. Surg., 1997, 15, 15–21.
22 J. Mikesˇ, J. Kleban, V. Sacˇkova´, V. Horva´th, E. Jamborova´, A.
Vaculova´, A. Kozubı´k, J. Hofmanova´ and P. Fedorocˇko, Necrosis
predominates in the cell death of human colon adenocarcinomaHT-29
cells treated under variable conditions of photodynamic therapy with
hypericin, Photochem. Photobiol. Sci., 2007, 6, 758–766.
23 F. Bunz, A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J.P. Brown,
J.M. Sedivy, K.W. Kinzler and B. Vogelstein, Requirement for p53 and
p21 to sustain G2 arrest after DNA damage, Science, 1998, 282, 1497–
1501.
24 M. Niyazi, I. Niyazi and C. Belka, Counting colonies of clono-
genic assays by using densitometric software, Radiat. Oncol., 2007,
2, 4.
25 B. Vojtesˇek, J. Bartek, C.A. Midgley and D.P. Lane, An immuno-
chemical analysis of the human nuclear phosphoprotein p53. New
monoclonal antibodies and epitope mapping using recombinant p53,
J. Immunol. Methods, 1992, 151, 237–244.
26 N. Zacal, M. Espiritu, G. Singh and A.J. Rainbow, Increased BNip3
and decreased mutant p53 in cisplatin-sensitive PDT-resistant HT29
cells, Biochem. Biophys. Res. Commun., 2005, 331, 648–657.
27 M.Weller, Predicting response to cancer chemotherapy: the role of p53,
Cell Tissue Res., 1998, 292, 435–445.
28 T.J. Dougherty, C.J. Gomer, B.W. Henderson, G. Jori, D. Kessel, M.
Korbelik, J.Moan andQ. Peng, Photodynamic therapy, J. Natl. Cancer
Inst., 1998, 90, 889–905.
29 C.M.N. Yow, C.K. Wong, Z. Huang and R.J. Ho, Study of the efﬁcacy
and mechanism of ALA-mediated photodynamic therapy on human
hepatocellular carcinoma cell, Liver Int., 2007, 27, 201–208.
30 H.B. Lee, A.S. Ho and S.H. Teo, p53 Status does not affect photody-
namic cell killing induced by hypericin,Cancer Chemother. Pharmacol.,
2006, 58, 91–98.
31 Y.A. Lazebnik, S.H. Kaufmann, S. Desnoyers, G.G. Poirier and W.C.
Earnshaw, Cleavage of poly(ADP-ribose) polymerase by a proteinase
with properties like ICE, Nature, 1994, 371, 346–347.
32 R.U. Janicke, P. Ng, M.L. Sprengart and A.G. Porter, Caspase-3
is required for alpha-fodrin cleavage but dispensable for cleavage of
other death substrates in apoptosis, J. Biol. Chem., 1998, 273, 15540–
15545.
33 E.A. Slee, C. Adrain and S.J. Martin, Executioner caspase-3, -6, and -7
perform distinct, non-redundant roles during the demolition phase of
apoptosis, J. Biol. Chem., 2001, 276, 7320–7326.
34 A. Coutant, J. Lebeau, N. Bidon-Wagner, C. Levalois, B. Lectard
and S. Chevillard, Cadmium-induced apoptosis in lymphoblastoid cell
line: involvement of caspase-dependent and -independent pathways,
Biochimie, 2006, 88, 1815–1822.
35 Z.Q. Wu, R. Zhang, C. Chao, J.F. Zhang and Y.Q. Zhang, Histone
deacetylase inhibitor trichostatin A induced caspase-independent
apoptosis in human gastric cancer cell, Chin. Med. J., 2007, 120, 2112–
2118.
36 V. Sacˇkova´, L. Kulikova´, J. Mikesˇ, J. Kleban and P. Fedorocˇko,
Hypericin-mediated photocytotoxic effect on HT-29 adenocarcinoma
cells is reduced by light fractionation with longer dark pause between
two unequal light doses, Photochem. Photobiol., 2005, 81, 1411–1416.
37 I.L. Botchkina, R.A. Rowehl, D.E. Rivadeneira, M.S. Karpeh jr., H.
Crawford, A. Dufour, J. Ju, Y. Wang, Y. Leyfman and G.I. Botchkina,
Phenotypic subpopulations of metastatic colon cancer stem cells:
Genomic Analysis, Cancer Genomics Proteomics, 2009, 6, 19–30.
38 N.Y. Frank, A. Margaryan, Y. Huang, T. Schatton, A.M. Waaga-
Gasser, M. Gasser, M.H. Sayegh, W. Sadee and M.H. Frank, ABCB5-
mediated doxorubicin transport and chemoresistance in human malig-
nant melanoma, Cancer Res., 2005, 65, 4320–4333.
39 F. Zeppernick, R. Ahmadi, B. Campos, C. Dictus, B.M. Helmke, N.
Becker, P. Lichter, A. Unterberg, B. Radlwimmer and C.C. Herold-
Mende, Stem cell marker CD133 affects clinical outcome in glioma
patients, Clin. Cancer Res., 2008, 14, 123–129.
40 M.I. Koukourakis, A. Giatromanolaki, J. Skarlatos, L. Corti, S. Blan-
damura, M. Piazza, K.C. Gatter and A.L. Harris, Hypoxia inducible
factor (HIF-1a and HIF-2a) expression in early esophageal cancer
and response to photodynamic therapy and radiotherapy, Cancer Res.,
2001, 61, 1830–1832.
41 G. Denecker, H. Dooms, G. Van Loo, D. Vercammen, J. Grooten, W.
Fiers, W. Declercq and P. Vandenabeele, Phosphatidyl serine exposure
during apoptosis precedes release of cytochrome c and decrease in
mitochondrial transmembrane potential, FEBS Lett., 2000, 465, 47–
52.
42 S.R. Stowell, S. Karmakar, C.M. Arthur, T. Ju, L.C. Rodrigues,
T.B. Riul, M. Dias-Barufﬁ, J. Miner, R.P. McEver and R.D. Cum-
mings, Galectin-1 induces reversible phosphatidylserine exposure at
the plasma membrane,Mol. Biol. Cell, 2009, 20, 1408–1418.
43 G. Kroemer, L. Galluzzi, P. Vandenabeele, J. Abrams, E.S. Alnemri,
E.H. Baehrecke, M.V. Blagosklonny, W.S. El-Deiry, P. Golstein, D.R.
Green, M. Hengartner, R.A. Knight, S. Kumar, S.A. Lipton, W.
Malorni, G. Nun˜ez, M.E. Peter, J. Tschopp, J. Yuan, M. Piacentini,
B. Zhivotovsky and G. Melino, Classiﬁcation of cell death: recom-
mendations of the Nomenclature Committee on Cell Death 2009, Cell
Death Differ., 2009, 16, 3–11.
44 P. Agostinis, A. Donella-Deana, J. Cuveele, A. Vandenbogaerde, S.
Sarno, W. Merlevede and P. de Witte, A comparative analysis of the
photosensitized inhibition of growth-factor regulated protein kinases
by hypericin-derivatives, Biochem. Biophys. Res. Commun., 1996, 220,
613–617.
45 J. Kleban, J.Mikesˇ, V. Horva´th, V. Sacˇkova´, J. Hofmanova´, A. Kozubı´k
and P. Fedorocˇko, Mechanisms involved in the cell cycle and apoptosis
ofHT-29 cells pre-treatedwithMK-886 prior to photodynamic therapy
with hypericin, J. Photochem. Photobiol., B, 2008, 93, 108–118.
46 V. Sacˇkova´, P. Fedorocˇko, B. Szila´rdiova´, J. Mikesˇ and J. Kleban,
Hypericin-induced photocytotoxicity is connectedwithG2/Marrest in
HT-29 and S-phase arrest in U937 cells, Photochem. Photobiol., 2006,
82, 1285–1291.
47 S. Maddika, S.R. Ande, S. Panigrahi, T. Paranjothy, K.Weglarczyk, A.
Zuse,M. Eshraghi, K.D.Manda, E.Wiechec andM. Los, Cell survival,
cell death and cell cycle pathways are interconnected: implications for
cancer therapy, Drug Resist. Updates, 2007, 10, 13–29.
48 G. Micali, F. Lanuzza and P. Curro`, High-performance liquid chro-
matographic determination of the biologically active principle hyper-
icin in phytotherapeutic vegetable extracts and alcoholic beverages, J.
Chromatogr., A, 1996, 731, 336–339.
49 D. Zhai, C. Jin, Z.Huang, A.C. Satterthwait and J.C. Reed,Differential
regulation ofBax andBakby anti-apoptotic Bcl-2 family proteinsBcl-B
and Mcl-1, J. Biol. Chem., 2008, 283, 9580–9586.
This journal is © The Royal Society of Chemistry and Owner Societies 2009 Photochem. Photobiol. Sci., 2009, 8, 1558–1567 | 1567
